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1 Introduction 
Endogenous synthesis of long-chain polyunsaturated fatty acids. The two 
essential fatty acids (EFA) linoleic acid (LA, Figure  1.1) and alpha-linolenic acid 
(ALA) and their further desaturated, longer-chain derivatives, the long-chain 
polyunsaturated fatty acids (LCPUFA), are indispensable for human development 
and optimal health.  
 
 
Figure  1.1. Chemical structure of linoleic acid and alpha-linolenic acid. 
 
Arachidonic acid (AA), dihomo-gamma-linolenic acid (DGLA), and eicosapentaenoic 
acid (EPA) all serve as precursors for eicosanoids, while docosahexaenoic acid 
(DHA) is an important structural component of the gray matter of the brain and the 
retina of the eye. Although they can be synthesised in the body from LA or ALA 
through a series of elongation and desaturation (and additionally β-oxidation for DHA 
synthesis), this synthesis is restricted by the activity of the rate-limiting enzyme ∆6-
desaturase (Figure  1.2). Conversion of ALA to EPA and DHA is not very efficient and 
depends on the level of ALA and its ratio to LA in the diet, because n-6 and n-3 fatty 
acids compete for the same enzymes responsible for their conversion [1]. Previous 
studies with stable isotopically labelled ALA have shown conversion of ALA to EPA 
C 
O 
OH 
n - 3 
Linoleic acid  
(18:2n-6) 
α-Linolenic acid 
(18:3n-3) 
C
O
OH
n-6
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varying from 6-21% [2-4] to much lower values (0.1-0.2%; [5-7]). Reports on the 
conversion of ALA to DHA range from 4-9% [2,4] to 0.04% [8] or undetectable DHA 
synthesis [3]. Thus, endogenous formation of EPA and especially DHA is thought 
insufficient under certain circumstances [9], and additional dietary intake of 
preformed n-3 LCPUFA is needed to cover metabolic requirements. 
 
 
 
Figure  1.2. Synthesis of polyunsaturated fatty acids (modified from [10]). 
 
Dietary intake and sources of n-3 LCPUFA in the Western diet. The vast majority 
of dietary EPA and DHA in a typical Western diet is consumed in the form of fish and 
seafood (68%) with much smaller contributions coming from eggs (12%), poultry 
(7%), meat and sausages (7%) [11]. Plant foods and vegetable oils are devoid of 
EPA and DHA, but contain varying amounts of ALA. Major sources of ALA are 
vegetable oils and selected nuts and seeds (e.g. soybean and canola oil, flaxseed, 
Linoleic acid (18:2n-6; LA) 
γ-Linolenic acid (18:3n-6; GLA) 
Dihomo-γ-linolenic acid (20:3n-6; DGLA) 
Arachidonic acid (20:4n-6; AA) 
α-Linolenic acid (18:3n-3; ALA) 
Stearidonic acid (18:4n-3) 
Eicosatetraenoic acid (20:4n-3) 
Eicosapentaenoic acid (20:5n-3; EPA) 
Docosapentaenoic acid (22:5n-3) 
Docosahexaenoic acid (22:6n-3; DHA) 
∆ 6-desaturase 
Elongase 
∆ 5-desaturase 
Elongase 
Elongase 
∆ 6-desaturase 
β-oxidation 
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English walnuts) [12,13]. The typical Western diet provides ∼1-2 g ALA per day but 
only 0.1-0.2 g/d EPA and DHA combined [12,14,15]. For German adults, a recent 
study reported the median dietary intake of EPA and DHA combined to be 141 mg/d 
among women and 186 mg/d among men [11]. The lowest median intake was 
observed among women aged 18-24 years (84 mg/d, Figure  1.3). 
 
 
Figure  1.3. Distribution of EPA + DHA intake in German adults stratified by sex and age (bottom and 
top edges of the box are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median and whiskers mark the data points that are nearest to the 1.5 interquartile ranges, outliers are 
not shown). The average daily DHA and EPA intake corresponding to two servings of fatty fish per 
week (150-300 g fish, containing 1 g EPA/DHA per 100 g) is marked by a horizontal line. 
* Figure from Bauch et al. [11]. 
 
The high intake of n-6 fatty acid LA (5-7% of daily energy or 11-16 g/day) yields a 
mean overall n-6:n-3 dietary ratio of about 9.8:1 in the United States [12] and 7.2:1 - 
8.6:1 in Germany [16]. The German Society of Nutrition has recommended [17] that 
this ratio should be lowered < 5:1 to reduce the competitive influence of high LA 
intakes on ALA conversion to EPA and DHA. Attaining the proposed recommended 
combined EPA and DHA intake ≥ 650 mg/d for healthy adults [18] will require an 
approximately 4-fold increase in fish consumption in the United States and other 
Western countries. Such a change in dietary habits is not realistic for all persons (e.g. 
Introduction 4 
vegetarians, fish allergic persons) or might not be adequate for persons with 
increased n-3 LCPUFA requirements (patients with coronary heart diseases, 
pregnant women). Additionally, individual gustatory preferences may also limit 
additional fish consumption. Furthermore, an increase in fish consumption is 
ecologically (overfishing) and regarding heavy metal contamination problematic. 
Alternative strategies, such as n-3 fatty acid supplements, food enrichment and use 
of biotechnology will become increasingly important in raising n-3 fatty acid intake in 
the Western diet over the long term. 
N-3 LCPUFA intake and status of vegetarians. Total n-3 fatty acid intakes are 
similar for vegans, vegetarians, and omnivores (< 1-3 g/d, with the current average 
being ∼1.1-1.6 g/d) [19]. However, the intakes of n-3 LCPUFA vary appreciably: 
ovolacto vegetarians consume minimal amounts of EPA and varying amounts of DHA 
from eggs, milk and dairy products (average intakes < 33 mg/d) [20]. Vegans 
consume negligible amounts of n-3 LCPUFA and rely entirely on in vivo biosynthesis 
of n-3 LCPUFA from the precursor ALA. N-6 fatty acid intakes are significantly higher 
in vegan and vegetarian populations than in omnivorous populations, ranging from 5-
7% of energy in omnivores to about 10-12% of energy in vegans. As a result, the n-
6:n-3 ratio is generally considered to be elevated in vegans (14:1 – 20:1) and 
ovolacto vegetarians (10:1 – 16:1) compared with omnivores (< 10:1) [19]. 
Lack of EPA and DHA in vegetarian and especially vegan diets is reflected in 
reduced amounts of these fatty acids in platelets, red blood cells (RBC) and plasma 
[21-26]. 
N-3 LCPUFA and coronary heart diseases. The risk for many chronic diseases, 
including coronary heart diseases (CHD), is influenced by dietary fatty acid intake 
[27-29]. A higher degree of incorporation of n-3 LCPUFA into myocardial membranes 
reduces deaths following myocardial ischemia [30]. In a nested case-control study 
(94 men with incident CHD and 94 men without incident CHD), levels of DHA in 
plasma phospholipids were inversely correlated with CHD risk in a multivariate model 
that controlled for the effects of HDL:LDL cholesterol ratio (standardized odds ratio = 
0.57; 95% confidence interval 0.36-0.90) [31]. Harris et al. [32] showed that n-3 
LCPUFA content in RBC membranes reflects that of cardiac membranes. The 
percentage content of EPA + DHA in RBC membranes (hereafter called omega-3 
index) has recently been identified as a risk indicator for death from CHD [33]. The 
relationship between the omega-3 index and the risk for CHD death, especially 
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sudden cardiac death (SCD), was evaluated using the data from several published 
primary and secondary prevention studies. An omega-3 index ≥ 8 wt% was 
associated with the greatest cardioprotection, whereas an index ≤ 4 wt% was 
associated with the least. Harris & von Schacky [33] observed significant increases of 
the omega-3 index after EPA and DHA supplementation (1 g/d) for 5 months, ranging 
after intervention from 5 wt% to 13 wt%. These different levels in people consuming 
the same amount of EPA + DHA for several months might be caused by individual 
differences in baseline values of the omega-3 index or differences in digestion, 
absorption, transport, uptake in target tissues, metabolism from storage sites and in 
vivo conversion of ALA to LCPUFA derivatives. Consequently, a subject with low 
baseline omega-3 index may require a larger dose than a person with a higher 
baseline value. Further studies investigating the dose-response relationship between 
EPA + DHA intake and the omega-3 index in subjects with different background diets 
are needed. For clinical studies it is in addition of interest to know whether RBC total 
lipid fatty acids (especially omega-3 index) correspond to values found in other lipid 
classes (plasma phospholipids, RBC phosphatidylcholine, RBC phosphatidyl-
ethanolamine) in subjects with a stable background diet. 
Circulating triacylglycerol (TG) levels in the fasting and postprandial states are 
associated with the severity and progression of atherosclerosis [34] and are 
recognised as independent risk factors for CHD [35]. According to Assmann [36], the 
need to include factors other than LDL cholesterol in risk assessment of myocardial 
infarction (MI) is indicated by multivariate analysis of data from the Prospective 
Cardiovascular Münster (PROCAM) study in which HDL cholesterol, LDL cholesterol, 
TG level, age, systolic blood pressure, family history of MI, cigarette smoking, and 
diabetes were each identified as independent risk variables for MI. From Assmann’s 
point of view, the impact of curvilinear relation between LDL cholesterol level and risk 
of MI, as shown in Figure  1.4 and demonstrated in other epidemiological studies [37-
41], is frequently underestimated and it goes unrecognised that curves of different 
steepness are generated depending on global risk of the individuals. A change in one 
of the 7 identified risk factors beside LDL cholesterol (e.g. TG decrease) could result 
in the transfer of an individual to a lower-risk group without necessarily modifying LDL 
cholesterol level (Figure  1.4 and Figure  1.5). 
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Figure  1.4. Myocardial infarction (MI) risk within multiple logistic function (MLF) quintiles according to 
LDL cholesterol (LDL-C) level in the Prospective Cardiovascular Münster study population.*  
*  Figure from Assmann [36]. 
 
 
 
 
 
Figure  1.5. Incidence of myocardial infarction (MI) in 10 years according to baseline triglyceride level 
and LDL cholesterol (LDL-C) level in the Prospective Cardiovascular Münster study.* 
*  Figure from Assmann [36]. 
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A meta-analysis by Austin et al. [42] suggested that after adjustment for HDL 
cholesterol and other risk factors, each 1 mM increase in TG is associated with a 
14% increase in CHD in men and a 37% increase in women. According to Griffin [43] 
there is convincing evidence to show that even moderately raised plasma TG (> 1.5 
mM), which has a predicted frequency of between 25-30% in middle-aged men and 
postmenopausal women, confer increased cardiovascular risk in otherwise normal, 
healthy individuals. 
N-3 LCPUFA have TG-lowering effects in humans [44-49]. In a meta-analysis of 65 
studies, Harris [50] concluded that an average dose of 4 g EPA and DHA per day 
results in a 25-30% decrease of fasting TG in both normolipidaemic and 
hypertriacylglycerolaemic subjects. It has been assumed that the hypotriglyceri-
daemic effect of n-3 LCPUFA is mediated by several mechanisms such as increased 
hepatic fatty acid oxidation, inhibition of fatty acid and TG synthesis and reduced 
assembly and secretion of VLDL triacylglycerol [51]. Most studies of n-3 LCPUFA 
have generally used oils containing mixtures of EPA and DHA in the range of 1-5 g/d, 
but studies investigating specifically the effects of individual n-3 LCPUFA on TG and 
lipoproteins in humans are rare. Few studies have compared the effects of purified 
EPA and DHA (as ethyl esters) showing inconsistent results: in a study by Rambjor et 
al. [52] supplementing normolipidaemic subjects with 3 g EPA or DHA/d for 3 weeks, 
EPA, but not DHA had a TG-lowering effect. Other studies show that both EPA and 
DHA lower serum TG concentrations at intakes of 3.0-4.9 g/d [47,48,53,54], whereas 
HDL cholesterol concentrations tend to increase only with DHA supplementation 
[47,52,53]. 
Studies applying single-cell oil as DHA source, which contain only trace amounts of 
EPA and other n-3 fatty acids, reported a significant reduction in TG concentrations 
and an increase in HDL cholesterol levels at DHA intakes in the range of 1.25-2.5 g/d 
in normo- or hyperlipidaemic volunteers [44,46,49,55], whereas other studies with 
DHA intakes of 0.7 g/d [56] and 0.75-1.5 g/d [57] did not find any significant effects 
on plasma TG and lipoproteins in normolipidaemic subjects. Future trials will be 
needed to determine minimum effective dosages of EPA and DHA over lengthy 
periods and to show reduction of CHD by intervention. 
Introduction 8 
N-3 LCPUFA and infantile development. DHA and AA are found in high 
concentrations in structural lipids of the central nervous system and have been 
shown to be important for brain development and function [58-60]. Adequate 
accretion of both DHA and AA in brain and retina is particularly important during the 
rapid brain growth, which takes place in the perinatal period [60]. However, since 
pregnancy is associated with a decrease in the biochemical and functional LCPUFA 
status of the mother, the foetal and neonatal LCPUFA status may not be optimal [9]. 
Numerous studies have been conducted over recent years to evaluate the functional 
effects of dietary DHA supplementation on visual and cognitive development of 
preterm and term infants. It is now generally accepted that postnatal DHA 
administration promotes, at least temporarily, cognitive and visual development of 
infants born preterm [61-66]. Developmental benefit of postnatal DHA 
supplementation has been observed in term infants also, but the results are less 
consistent [67-69]: Some studies have shown improved development of visual acuity 
and cognitive functions in term infants [70-76], whereas others have shown no 
significant effects [77-80].  
Two studies were performed in children with hyperphenylalaninaemia or 
phenylketonuria (mean subject age: 6 years and 11 years respectively [81,82]), 
whose habitual diets contain nearly no n-3 LCPUFA. These investigators observed 
significant improvements in visual evoked potential latencies after supplementation 
with LCPUFA / fish oil, suggesting that n-3 LCPUFA are essential substrates for the 
nervous system function even beyond infancy. 
Dietary supplementation with DHA not only improves the DHA status in the recipient, 
but at the same time it reduces the availability of AA [83]. AA is the second-most 
abundant LCPUFA in the brain, and AA-derived eicosanoids are important functional 
mediators [84]. AA is involved in cell signalling [85] and is one of the major fatty acid 
moieties of anandamides, which serve important functions as ligands of the 
cannabinoid receptor in the brain [86]. Information on the importance of AA for 
development and function of the central nervous system is less clear than for DHA. 
Only limited evidence points to a positive effect of this fatty acid on brain 
development and function, when given in combination with DHA to term infants 
[71,87]. But cerebral AA may be required for the prevention of neuromental disorders 
like schizophrenia [87]. Whether or not the AA reduction associated with DHA 
supplementation diminishes DHA-induced functional improvements is not known. 
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Because of this lack of knowledge, any supplementation of mothers or infants 
intended to improve their DHA availability should not compromise maternal and 
neonatal AA status.  
A potentially simple way to achieve this may be the administration of gamma-linolenic 
acid (GLA). This fatty acid is the ∆6-desaturated derivative of LA (see Figure  1.2) and 
has been suggested to be more readily converted to AA than LA [88]. Since the 
EFA/LCPUFA status of neonates is positively correlated with that of their mothers, a 
higher maternal GLA status can be expected to increase the neonatal GLA status. 
This may be of importance for the prevention of obesity, insulin resistance and 
hypertriglyceridaemia in later life, since at seven years of age these have been 
shown to be inversely related to GLA status at birth [89,90]. In addition, a significant, 
positive relationship has been observed between the DGLA status of the neonate 
and its birth weight [91]. According to the Barker hypothesis [92,93], a higher birth 
weight may be associated with a lower risk for certain chronic diseases in later life. In 
addition, GLA may serve essential functions in the transcription of genes involved in 
glucose and lipid metabolism [94,95] and is thought to play a role in atopy [96,97]. 
Dietary intake of GLA is very low and endogenously synthesised GLA may be 
expected to be converted to DGLA and possibly AA. Therefore, supplementation with 
GLA to pregnant women may increase the GLA and DGLA status of mothers and 
their neonates and, thereby, promote infantile development and support disease 
prevention.  
Most formulas for preterm infants and some term formulas already contain a 
combination of DHA and AA and some formulas are enriched with GLA as well. 
However, infants should preferably be fed with breast milk and, consequently, the 
EFA and LCPUFA content of mother’s milk should also be adequate for optimal 
postnatal development. Because the LCPUFA content of breast milk can be very low, 
it may be desirable to “fortify” mother’s milk with LCPUFA. This can be achieved i.e. 
by supplementing lactating mothers with these fatty acids or their precursors. Cant et 
al. [98] were the first to show that GLA supplementation results in GLA enrichment of 
breast milk lipids. This was confirmed by Thijs and co-workers, who demonstrated 
that supplementation of lactating atopic mothers with 230 or 460 mg per day of GLA 
from borage oil caused a dose dependent increase in milk lipid concentrations of 
GLA and DGLA [99]. AA concentrations, however, were not significantly affected. 
ALA supplementation increases ALA, EPA and DPA, but not DHA concentration in 
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breast milk lipids [100]. Supplementation with DHA-rich single cell oil in doses up to 
1.3 g DHA per day for 3 months increased the breast milk DHA concentration more 
than 5-fold (from 0.21 to 1.13 % of total fatty acids), whereas the AA content 
decreased slightly, but significantly [101]. Infant DHA levels in plasma and RBC 
phospholipids after 12 weeks of lactation were significantly and positively related to 
the DHA dose their mothers were supplemented with, and reached values up to 9.1 
and 9.8% for plasma and erythrocyte phospholipids respectively [102]. Infant plasma 
and erythrocyte AA contents reduced significantly in the supplemented groups and in 
proportion to the maternal DHA supplementation doses. Therefore, there is need to 
design a fatty acid supplement for pregnant women and lactating mothers which 
enhances GLA, DGLA, and DHA status in the neonates and later on in the breastfed 
infants while not compromising their AA status. 
Mothers may also functionally benefit from postnatal LCPUFA supplementation 
themselves, since their postnatal DHA status is lower than that of non-lactating 
mothers [103] and they may need to recover from possible cognitive impairments 
during pregnancy [104,105]. In addition, a low maternal DHA status has been 
suggested to increase the risk of post partum depression [106,107]. This hypothesis 
is supported by recent findings that a higher DHA status at delivery [107] and a better 
improvement of the maternal DHA status after delivery [108] are associated with less 
depressive symptoms in the post partum period. In a longitudinal study it appeared 
that post partum depression is often preceded by depression during the 32nd week of 
pregnancy already [109], which may also be DHA-related. Therefore, a higher DHA 
status during early pregnancy may be beneficial in the prevention of depressive 
symptoms during pregnancy and after delivery. 
Objectives of this work. This work is intended to evaluate two supplementation 
strategies to improve n-3 LCPUFA status in healthy adults. Two randomised, double 
blind, placebo-controlled intervention studies with parallel design were performed. In 
the first study (DHAVEG study), healthy adult vegetarians with low basal n-3 
LCPUFA status consumed a vegetarian, DHA-rich oil (delivering 1.05 g DHA and < 7 
mg of each GLA, AA, and EPA as triglycerides per day) or a placebo for 8 weeks.  
In the second study (FO/EPO study), healthy non-pregnant women were 
supplemented with a fish oil/evening primrose oil mixture (FO/EPO, providing not 
only 419 mg DHA and 72 mg EPA but also 14 mg AA and 337 mg GLA as 
triglycerides per day) or a placebo.  
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The objectives of this work are as follows: 
 
• Evaluation of a method for the analysis of fatty acids in RBC total lipids. 
• Validation of RBC total fatty acid analyses as a marker of essential fatty acid 
status. 
• Evaluation of a method for the analysis of vitamin A and E in plasma. 
• Effects of a supplementation with DHA alone or combined with GLA on fatty acid 
composition (RBC and/or plasma lipids). 
• Effects of DHA supplementation on plasma triglycerides and lipoproteins. 
• Tolerance and safety assessment of the two used fatty acid supplements 
(microalgae oil and fish oil/evening primrose oil respectively). 
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2 Subjects and Methods 
2.1 DHAVEG study 
2.1.1 Subjects and study design 
Ethical permission of the study was obtained from the Bavarian Board of Physicians. 
All volunteers completed a health and lifestyle questionnaire before entering the 
study. Eligible for the study were persons, who fulfil the following inclusion criteria: 
 
• Adherence to a vegetarian diet since at least one year (no meat, less than one 
fish meal per month) 
• Age ≥ 18 years 
• Body mass index (BMI) between 18 and 25 kg/m2 
• No presence of metabolic, cardiovascular, renal or neurological diseases 
• No intake of medication with known influence on the lipid metabolism during 
the last 3 months 
• No use of n-3 fatty acid supplements 
• No pregnancy or lactation 
• No participation in another scientific study 
 
Written informed consent was obtained from all subjects. Participants received 
financial compensation for their participation in the study. The study was conducted 
between June and November 2003 as a randomised double blind, placebo-controlled 
intervention study with two parallel groups. The subjects consumed 2.3 g daily of 
either a vegetarian, DHA-rich oil from microalgae Ulkenia sp. (providing 1.05 g DHA 
as triglyceride per day) or the same amount of olive oil (as placebo) for 8 weeks. 
Subjects were randomly assigned to one of the intervention groups with stratification 
for gender on the basis of a computer-generated random table.  
At baseline (day 0) and after 56 to 60 days of intervention, fasted blood samples 
were collected and body weight, height, blood pressure (BP), and heart rate were 
measured (Figure  2.1).  
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Figure  2.1. Study design, DHAVEG study. 
RBC, red blood cells. 
 
Before the first investigation (day 0), the subjects recorded their diet for 3 consecutive 
days (two weekdays and one weekend day). During the intervention, the subjects 
noted side effects, signs of illness, intake of medication and the number of capsules 
not consumed. At the end of the intervention period, they recorded their diet again for 
3 consecutive days. Telephone interviews were performed every two weeks of the 
intervention period to monitor study compliance and side effects. Compliance was 
assessed by counting leftover capsules and by the plausibility of the DHA increase in 
RBC phosphatidylethanolamine (PE). 
 
2.1.2 Study oils 
Each DHA capsule contained on average 571 mg oil derived from microalgae Ulkenia 
sp. (Nutrinova® DHA, Nutrinova GmbH, Frankfurt/Main, Germany). Nutrinova®DHA is 
a highly concentrated, triglyceride-based oil, containing at least 43 g DHA/100 g total 
fatty acids (wt%) and almost no EPA. Matching placebo capsules contained on 
average 562 mg olive oil, which is free of n-3 LCPUFA. The fatty acid composition of 
the two study oils as determined during intervention period is given in Table  2.1.  
 
3-day dietary 
record 
                    0                       2                     4                       6                       8                 weeks 
height, weight, 
 blood pressure, 
 plasma fatty acids,  
RBC fatty acids, 
safety parameters 
 
weight, 
 blood pressure, 
 plasma fatty acids,  
RBC fatty acids, 
safety parameters 
 
Microalgae oil (4 capsules/day) 
Placebo (4 capsules/day) 
 
3-day dietary 
record 
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Table  2.1. Major fatty acids of microalgae and placebo oils, DHAVEG study (wt%). 
 Microalgae oil (n = 12)               Placebo oil (n = 12)                
 Mean SD  Mean SD 
SFA 39.99 0.25  14.62 0.98 
18:1n-9 0.52 0.03  75.86 0.76 
18:1n-7 0.08 0.01  2.37 0.04 
18:2n-6 1.21 0.08  5.32 0.14 
18:3n-6 0.22 0.01  n.d.  
20:4n-6 0.09 0.01  n.d.  
22:5n-6 9.70 0.14  n.d.  
18:3n-3 0.11 0.01  0.68 0.02 
20:5n-3 0.29 0.01  n.d.  
22:5n-3 0.09 0.01  n.d.  
22:6n-3 46.13 0.20  n.d.  
n.d., not detected; SFA, saturated fatty acids. 
 
 
One thousand ppm mixed natural tocopherols (equals 2.2-2.3 mg mixed natural 
tocopherols per day) were added for stabilisation of the capsule content. The 
volunteers were required to take one capsule each during breakfast and dinner and 
two capsules during lunch (a total of four capsules per day). Capsules were stored 
refrigerated or at room temperature in a dry, dark place. 
 
2.1.3 Measurements, blood sampling and storage 
All anthropometrical measurements followed standardised procedures. Subjects were 
weighed without shoes and outdoor clothing on a digital scale at week 0 and week 8; 
height was measured only at study entry. A lump sum of 1 kg was subtracted for the 
weight of the clothes. The BMI was calculated as body weight (kg) divided by the 
square of body height (m). Seated blood pressure was determined using a 
stethoscope and a standard sphygmomanometer. Heart rate was counted for 15 sec 
at the wrist. 
Venous blood samples were collected from an antecubital vein of the forearm into 
EDTA, citrate, and lithium heparin containing tubes (Sarstedt, Nümbrecht, Germany) 
as well as special tubes for platelet function analysis (containing sodium citrate, 1:10) 
after an overnight fast. For factor VII, von Willebrand factor, and PAI-1 analyses, 
citrated blood, and for vitamin A/E and fatty acid analyses, EDTA blood was 
centrifuged at 1300 g for 7 minutes at room temperature within 2 hours. The obtained 
plasma was divided into aliquots, and stored at -80°C until analyses.  
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Blood cells from EDTA blood were washed 3 times with 0.9% sodium chloride (NaCl) 
solution. After lysis with distilled water (at least 200 µl/0.5 ml RBC) for 5 min, 8 ml 
isopropanol with BHT (50 mg/l) was added under constant shaking in 100 µl steps, 
and the tubes were frozen at -80°C.  The analyses of fatty acids, vitamin A and E, 
factor VII, von Willebrand factor, and PAI-1 of a given subject were performed during 
12 months of storage within the same analytical run. The other biochemical 
parameters were analysed at the day of blood drawing using established routine 
methods in the clinical chemistry laboratories of the University of Munich hospital. 
 
2.1.4 Analytical methods 
2.1.4.1 Chemicals, consumables and equipment  
 
Table  2.2. Chemical list (fatty acid analysis). 
Chemicals Source Quality 
2.7 Dichlorfluorescein Merck, Darmstadt for analysis 
2-Propanol Merck, Darmstadt for analysis 
Acetic acid Merck, Darmstadt for analysis 
Ammonia solution 25%  Merck, Darmstadt for analysis 
Butylated hydroxytoluene (BHT) Fluka, Neu-Ulm ≥ 99% GC 
Chloroform Merck, Darmstadt extra pure 
Diisopropyl ether Merck, Darmstadt for analysis 
Distilled water Braun, Melsungen ad iniectabilia 
Ethanol  Baker, Deventer, Holland absolute 
Methanol Merck, Darmstadt for analysis 
Methanolic HCl (3N) Supelco, Bellefonte, USA for analysis 
n-Heptane Merck, Darmstadt for analysis 
n-Hexane Merck, Darmstadt for analysis 
Sodium carbonate Merck, Darmstadt anhydrous for analysis 
Sodium chloride Merck, Darmstadt for analysis 
Sodium chloride solution (0.9%) Braun, Melsungen ad iniectabilia 
Sodium hydrogen carbonate Merck, Darmstadt for analysis 
Sodium sulfate Merck, Darmstadt for analysis 
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 Table  2.3. Chemical list (vitamin A and E analysis). 
Chemicals Source Quality 
Acetonitrile  Merck, Darmstadt LiChrosolv 
Ammonium acetate  Merck, Darmstadt Fractopur 
Butylated hydroxytoluene (BHT) Fluka, Neu-Ulm ≥ 99% GC 
Chloroform Merck, Darmstadt LiChrosolv 
Distilled water Braun, Melsungen ad iniectabilia 
Ethanol  Baker, Deventer, Holland absolute 
Methanol  Merck, Darmstadt LiChrosolv 
n-Hexane Merck, Darmstadt LiChrosolv 
Precipitation reagent Immundiagnostik, Bensheim 
Tetrahydrofuran  Merck, Darmstadt LiChrosolv 
 
Table  2.4. List for consumables (fatty acid analysis). 
Consumables Source 
Brown glass bottle R1, G4 CS-Chromatographie Service, Langerwehe 
Crimp cap R11-1.0 CS-Chromatographie Service, Langerwehe 
Filter paper grade 388 Sartorius, Göttingen 
Micro inlay G30/6 CS-Chromatographie Service, Langerwehe 
Pasteur pipette VWR International, Darmstadt 
Pipette tip CP100 Gilson, Villiers-le-Bel, France 
Pipette tip 50-1000 µl, 500-2500 µl Eppendorf, Hamburg 
Pipette tip 10-100 µl, 100-1000 µl Greiner bio-one, Frickenhausen 
Screw cap G13 CS-Chromatographie Service, Langerwehe 
Sealing disc G13 CS-Chromatographie Service, Langerwehe 
Test-tube 55.459 PS Sarstedt, Nümbrecht 
TLC plate, silica gel 60 Merck, Darmstadt (DHAVEG study) 
TLC plate, silica gel 60 Macherey-Nagel, Düren (FO/EPO study) 
 
Table  2.5. List for consumables (vitamin A and E analysis). 
Consumables Source 
Brown glass bottle G1, G4 CS-Chromatographie Service, Langerwehe 
Micro inlay G30/5 CS-Chromatographie Service, Langerwehe 
Pipette tip CP100, CP250, CP1000 Gilson, Villiers-le-Bel, France 
Pipette tip 50-1000 µl Eppendorf, Hamburg 
Pipette tip 10-100 µl, 100-1000 µl Greiner bio-one, Frickenhausen 
Screw cap G8-L, G13 CS-Chromatographie Service, Langerwehe 
Sealing disc G13 CS-Chromatographie Service, Langerwehe 
Silicone-PTFE septum Merck, Darmstadt 
Silicone-PTFE septum, slitted Merck, Darmstadt 
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Table  2.6. Equipment list (fatty acid analysis). 
Equipment Source 
Analytical balance type 1801 Sartorius, Göttingen 
Centrifuge Beckman GPR Beckman, Bucks, UK 
Centrifuge Hettich Universal 1200 Hettich, Tuttlingen 
Centrifuge Universal 30 F Hettich, Tuttlingen 
Centrifuge glass tube, conical angle 30° (12 ml) Sc hott Duran, Mainz 
Centifuge glass tube (25 ml) Schmitz, Munich 
Funnel D35m, D55mm Duran Schott, Mainz 
Membrane vacuum pump MZ 2c Vacuubrand, Wertheim 
Metal block thermostat type 2102 Bachofer, Reutlingen 
Nitrogen evaporation system type 5000 6101 Bachofer, Reutlingen 
Pear-shape glass flask, single-neck (50 ml) Lenz, Wertheim 
Pipette 10-100 µl, 100-1000 µl (Transferpette) Brand, Wertheim 
Pipette 50-250 µl, 500-2500 µl Eppendorf, Hamburg 
Pipette Microman M100 Gilson, Villiers-le-Bel, France 
Rotary evaporator Rotavapor R-114 Büchi Labortechnik, Flawil, Switzerland 
Solvent chamber for thin layer chromatography Desaga, Heidelberg 
Ultraviolet lamp Benda, Wiesloch 
Vortexer VF2 IKA-Labortechnik, Heitersheim 
Waterbath B-480 Büchi-Labortechnik, Flawil, Switzerland 
  
Gas chromatography:  
Autosampler A200S Carlo Erba Instruments, Milan, Italy              
(FO/EPO study) 
Autosampler HP 7673 Hewlett Packard, Böblingen (DHAVEG study) 
Capillary column, BPX-70 (60 m x 0.32 mm)  SGE, Weiterstadt 
Controller HP 7673 Hewlett Packard, Böblingen 
Gas chromatograph HP 5890 Series II Hewlett Packard, Böblingen 
Integrator HP 3396 Series II Hewlett Packard, Böblingen 
Software EZChromEliteV2.61 Scientific Software, Pleasanton, USA 
 
Table  2.7. Equipment list (vitamin A and E analysis). 
Equipment Source 
Analytical balance type 1801 Sartorius, Göttingen 
Brown glass bottle (25 ml) Schott Duran, Mainz 
Centrifuge Universal 30 F Hettich, Tuttlingen 
Nitrogen evaporation system type 5000 6101 Bachofer, Reutlingen 
Pipette 10-100 µl, 100-1000µl  (Transferpette) Brand, Wertheim 
Pipette 50-250µl Eppendorf, Hamburg 
Pipette Microman M100, M250, M1000 Gilson, Villiers-le-Bel, France 
Quartz cuvette SUPRASIL Hellma, Müllheim 
Ultrasonic bath Sonorex Super RK 102 H Bandelein, Berlin 
UV/Vis Spectrophotometer Cary 1E Varian, Darmstadt 
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Equipment (continuation) Source 
Volumetric flask 10 ml, 25 ml Schott Duran, Mainz 
Vortexer VF2 IKA-Labortechnik, Heitersheim 
  
HPLC:  
Autosampler AS-4000A Intelligent Merck Hitachi, Darmstadt 
Column, LiChroCART 250-3, LiChrospher 100, RP18 
(5 µm) 
Merck, Darmstadt 
Column oven STH 585 Gynkotek, Germering 
Pump L-6200 Intelligent Pump Merck Hitachi, Darmstadt 
Software EZChromEliteV2.61 Scientific Software, Pleasanton, USA 
UV/Vis detector L-4250 Merck Hitachi, Darmstadt 
 
 
Table  2.8. List for the used standard substances (fatty acid analysis). 
Standard substance Source 
Internal standard:  
Cholesteryl pentadecanoic acid Sigma, Deisenhofen 
Dipentadecanoyl phosphatidylcholine Sigma, Deisenhofen 
Pentadecanoic acid Sigma, Deisenhofen 
Tripentadecanoin Sigma, Deisenhofen 
  
Standards for peak identification:  
GLC-85 (reference standards) Nu-Chek, Elysian, MN, USA 
14:1t Sigma, Deisenhofen 
16:1t Sigma, Deisenhofen 
18:1n-7 Sigma, Deisenhofen 
18:2tt Sigma, Deisenhofen 
18:4n-3 Sigma, Deisenhofen 
20:3n-9 Sigma, Deisenhofen 
20:5n-3 Sigma, Deisenhofen 
22:1t Sigma, Deisenhofen 
22:4n-6 Sigma, Deisenhofen 
22:5n-3 Sigma, Deisenhofen 
22:5n-6 OmegaTech, CO, USA 
24:0 Sigma, Deisenhofen 
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Table  2.9. List of the used standards and control sera (vitamin A and E analysis). 
Standards/Control sera Source Quality 
Internal standard   
Retinyl acetate Hoffmann-La Roche, Basel, Switzerland Purity 99.7% 
Tocol  Eisai, Tokyo, Japan for HPLC 
   
Standards for peak identification   
alpha-Tocopherol Supelco, Bellefonte, PA, USA Purity 99.3% 
Retinol Merck, Darmstadt Purity >98% 
   
Control serum   
NIST Standard Reference Material 968c Gaithersburg, USA  
 
 
2.1.4.2 Fatty acid analysis in study oils 
Methyl esters of fatty acids (FAME) from study oil triglycerides were obtained by 
reaction with 3M methanolic hydrochloric acid (HCl), methanol and hexane (1+1+0.5, 
by vol) at 90°C for 60 min in closed glass tubes. A fter adding distilled water and 
hexane with BHT (2 g/l), the samples were vortexed and centrifuged. The upper 
hexane phase containing the FAME was stored until GC analysis at -80°C. 
 
2.1.4.3 Fatty acid analysis in plasma phospholipids 
Preparation of the internal standard. For quantification of fatty acids in plasma lipid 
fractions, defined concentrations of dipentadecanoyl phosphatidylcholine, 
pentadecanoic acid, tripentadecanoin, and cholesteryl pentadecanoic acid (equalled 
10 µg 15:0/100 µl for each lipid fraction) were used.  
 
Table  2.10. Composition of the internal standard for fatty acid analysis. 
 
Molecular weight 
(g/mol) 
Correction factor for 
non-15:0 residue 
Weighted sample              
(g per 200 ml 
methanol/chloroform) 
Cholesteryl pentadecanoic acid 611.0 x 2.52 50.47 
Dipentadecanoyl 
phosphatidylcholine 706.0 x 1.46 29.22 
Pentadecanoic acid 242.4 x 1.00 20.05 
Tripentadecanoin 765.3 x 1.05 21.06 
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The in Table  2.10 presented amounts were dissolved in 200 ml methanol/chloroform 
(35+15, by vol, with 2 g/l BHT), aliquoted in 4 ml brown glass bottles and stored at 
−80°C until usage. To get a high reliability, the sa me internal standard mixture was 
used for all analyses. 
Lipid extraction. Plasma lipids were extracted according to a modified method of 
Kolarovic & Fourier [110]. For this, 100 µl internal standard and 2 ml hexane/ 
isopropanol (3+2, by vol) were added to 250 µl plasma and the tube was vortexed for 
30 sec. After centrifugation at 1000 g for 7 min the hexane phase was transferred 
into a 4 ml brown glass vial. Thereafter, two extractions with 2 ml hexane were 
performed and the combined extracts were taken to dryness under a gentle stream of 
nitrogen.  
Separation of lipid fractions. The lipid residue was dissolved in 400 µl chloroform/ 
methanol (1+1, by vol) and deposited on a thin layer chromatography (TLC) plate. 
Phospholipids (PL), free cholesterol, non-esterified fatty acids (NEFA), TG and 
cholesterol esters (CE) were separated using heptane, diisopropyl ether and acetic 
acid (60+40+3, by vol) as mobile phase [111]. After visualisation of the lipids with 2.7-
dichlorofluorescein (1% in ethanol) and UV-light, the band with the phospholipid 
fraction was scraped from the TLC plate and transferred into a 4 ml brown glass 
bottle (Figure  2.2). 
 
 
 
 
Figure  2.2. Separation of plasma lipid fractions using thin layer chromatography. 
NEFA, non-esterified fatty acids. 
Phospholipids 
NEFA 
Cholesterol 
Cholesterol 
esters 
Triglycerides 
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Transesterification and extraction of FAME. FAME were obtained by reaction with 
3M methanolic HCl at 85°C for 45 min. After neutral isation with sodium 
carbonate/sodium hydrogen carbonate/sodium sulphate buffer (1+2+2, by weight), 
1 ml hexane was added. After centrifugation at 1000 g for 4 min the hexane layer 
was transferred into a 2 ml brown glass bottle. The hexane extraction was repeated 
and the combined extracts were taken to dryness under a gentle stream of nitrogen. 
For storage until GC analysis at -80°C, the samples  were dissolved in 50 µl hexane + 
2g/l BHT.   
 
2.1.4.4 Fatty acid analysis in RBC total lipids and phospholipids 
Lipid extraction. The RBC/isopropanol mixture (see  2.1.3) was completely 
transferred into a 25 ml centrifuge tube; 6 ml isopropanol and 4 ml chloroform were 
added in little steps under constant shaking. Thereafter, the tubes were vortexed for 
10 minutes and centrifuged at 1400 g for 10 min. The supernatant was filtrated into a 
pear-shaped glass flask and a second extraction with 4 ml chloroform was 
performed. After shaking for 10 min, the whole sample was filtrated into the same 
flask and the filter was washed two times with chloroform. Four ml of the obtained 
lipid extract were transferred into a 4 ml brown glass bottle and frozen at -80°C until 
the analysis of RBC total lipids; 3 ml RBC extract was transferred into a second glass 
flask and taken to dryness under reduced pressure at 37°C.   
Separation of lipid fractions. The lipid residue was dissolved in 400 µl of 
chloroform/methanol (1+1, by vol) and deposited on a TLC plate. RBC 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) were separated using 
chloroform, methanol, 25% ammonia solution, and distilled water (73+27+2.2+2.8, by 
vol) as mobile phase. After visualisation of the lipids with 2.7-dichlorofluorescein (1% 
in ethanol) and UV-light, the bands containing PE and PC were scraped separately 
from the TLC plate and transferred into 4 ml glass tubes.  
For the analysis of RBC total lipids, 2 ml of the defrosted lipid extract was directly 
transferred into a brown glass tube and taken to dryness under nitrogen.  
Transesterification and extraction of FAME. Transesterification of RBC PE, PC, 
and total lipids, extraction of FAME and storage were performed as described for 
plasma fatty acids (see  2.1.4.3). 
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2.1.4.5 Gas chromatography conditions 
FAME were separated using capillary gas liquid chromatography. For this, 3 µl 
sample was injected into the gas chromatograph. The GC program is described in 
Table  2.11 and Figure  2.3. 
 
 
Table  2.11. GC programme for fatty acid analysis. 
Oven  
Initial temperature 130°C 
Initial time 0.50 min 
Rate 3.0°C/min  
Final temperature 150°C  
Final time 0.00 min 
Rate A 1.5°C/min  
Final temperature 180°C  
Final time 0.00 min 
Rate B 3.0°C/min  
Final temperature 210°C  
Final time 23.00 min (plasma PL and TG, RBC PE and PC), 
33.00 min (plasma CE and total lipids, RBC total lipids) 
Pressure  
Initial pressure 1.10 bar 
Rate 0.025 bar/min 
Final time 40.00 min 
Injector / Detector  
Injector temperature 250°C 
Detector temperature 300°C 
CE, cholesterol esters; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PL, phospholipids; 
RBC, red blood cells. 
 
 
Flame ionisation detector signals were evaluated with the software EZ-Chrom Elite, 
version 2.61 (Scientific Software, Pleasanton, USA) and identified by comparison 
with the retention times of a standard mixture run previously (Figure  3.1). The 
instrument was calibrated regularly by using a quantitative standards mixture (GLC-
85, Nu-Chek, Elysian, MN, USA). 
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Individual fatty acid (mg/l)* 100 
Sum of all identified C14 - C24 fatty acids (mg/l) 
 
Figure  2.3. GC temperature programme for fatty acid analysis. 
 
2.1.4.6 Calculation of fatty acid contents 
Absolute fatty acid concentration (mg/l) of all identified fatty acids with 14 – 24 carbon 
atoms was determined via comparison with the peak area of the internal standard 
(15:0) and correction with the accordant response factor. In plasma lipid fractions 
(PL, CE, TG), the area of the internal standard equalled 10 µg 15:0/250 µl plasma = 
40 mg 15:0/l plasma.  
Additionally, fatty acid weight percentages (wt%) were calculated as follows: 
 
 
Individual fatty acid (wt%) = 
 
 
Absolute fatty acid concentrations in RBC lipids cannot be determined, because no 
internal standard was added and the used RBC volume is not exactly known. For 
RBC, fatty acid weight percentages (wt%) were calculated by dividing the peak area 
of each individual peak by the peak area of all C14 – C24 fatty acids (each peak area 
was corrected by the accordant response factor) and multiplying the result with 100. 
In addition to the fatty acid profile, the following fatty acid sums and ratios were 
calculated for each sample: sum of EPA and DHA (EPA + DHA), sum of all n-6 fatty 
acids (Σ-6 FA), sum of all n-3 fatty acids (Σn-3 FA), sum of all long-chain n-6 fatty 
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acids (Σ-6 LCPUFA), sum of all long-chain n-3 fatty acids (Σ-3 LCPUFA), the ratio of 
n-6 to n-3 fatty acids (Σn-6/Σn-3 FA), and the ratio of n-6 LCPUFA to n-3 LCPUFA 
(Σn-6/Σn-3 LCPUFA).  
 
2.1.4.7 Examination of reproducibility (fatty acid analysis) 
Prior to analyses of the study samples, RBC and plasma were obtained from a large 
blood sample as described in  2.1.3, aliquoted and stored at -80°C. Intra-assay 
reproducibility was assessed by analysing 8 pool samples in the same analytical run. 
Inter-assay reproducibilities of the used methods were assessed by analysing pool 
samples 11x during 6 weeks (plasma phospholipids), 14x during 9 weeks (RBC PC 
and PE), and 19x during 3 weeks (RBC total lipids). 
 
2.1.4.8 Analysis of vitamin A and E in plasma 
The analysis of vitamin A and E was performed according to a modified method of 
Schaffer [112] and Göbel et al. [113]. 
Preparation of the mobile phase. An isocratic mobile phase consisting of 
acetonitrile, tetrahydrofuran, methanol and 1% ammonium acetate (684+220+68+28, 
by vol) was used [114]. To avoid the formation of explosive peroxides from 
tetrahydrofuran, the mobile phase was prepared prior to use and degassed 
ultrasonically. 
Preparation of the internal standard. To consider losses during the extraction 
process as well as unsteady injection amounts into the HPLC system, retinyl acetate 
was added as internal standard to plasma and standard samples at the beginning of 
the analysis. To prepare the internal standard, 250 mg retinyl acetate was dissolved 
in 100 ml ethanol/BHT (0.0625%). In a second step, this concentrate was diluted 
1:1000 to a concentration of 2.5 mg/l to get an adequate peak height in the 
chromatogram. The internal standard was frozen at -80°C until usage. To get a high 
reliability, the same internal standard mixture was used for analyses of all study 
samples. 
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Preparation of standard concentrates and dilutions. For preparation of the 
standard concentrates, the following amounts of retinol and alpha-tocopherol (Table 
 2.12) were dissolved in 10 ml ethanol each, aliquoted in 4 ml brown glass bottles and 
stored at -80°C. From these standard concentrates, dilutions were prepared as 
described in Table  2.12 and stored in 25 ml brown glass bottles at -80°C until usage. 
 
Table  2.12. Preparation of retinol and alpha-tocopherol standard concentrates and dilutions, DHAVEG 
study. 
Substance Standard concentrate Standard dilution 
Retinol 10 mg/10 ml ethanol 200 µl concentrate/10 ml ethanol ⇒ 0.02 g/l 
alpha-Tocopherol 50 mg/10 ml ethanol 1000 µl concentrate/10 ml ethanol ⇒ 0.5 g/l 
 
 
Preparation of the stock standard. For a new standard curve, standard dilutions 
were defrosted and their absorbance was measured on a spectrophotometer at 325 
nm for retinol and at 292 nm for alpha-tocopherol (Table  2.13). Lambert-Beer Law 
was used to determine the exact concentration of the standard dilutions (c) from 
absorbance (A) (A1%1cm, extinction coefficient of a compound at a certain wave 
length; d, thickness of cuvette).  
 
The formula is: 
 
A = A1%1cm * c (g/dl) * d (cm) 
 
Thus, concentration can be calculated by: 
  
c (g/dl) = A /[A1%1cm * d (cm)] 
 
 
Table  2.13. Extinction coefficients for retinol and alpha-tocopherol, DHAVEG study. 
Substance 
Molecular weight 
(g/mol) 
Wave length 
(nm) 
Extinction 
coefficient (A1%1cm) 
Source 
Retinol 286.5 325 1780 [112] 
alpha-Tocopherol 430.7 292 75.8 [112] 
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On the basis of the photometrically determined concentrations, the composition of the 
stock standard mixture was defined: the stock standard mixture corresponds to the 
highest standard of the standard curve (Std. 7) and its concentration should be 
higher than all expected concentrations in the plasma samples. For preparation of the 
stock standard mixture, certain amounts of the standard dilutions were pipetted into a 
10 ml volumetric flask, dried under a gentle stream of nitrogen and redissolved in 10 
ml hexane (Table  2.14).  
 
 
Table  2.14. Preparation of the stock standard mixture for vitamin A/E analysis (example), DHAVEG 
study. 
Substance Concentration of 
standard dilution (µg/µl)* 
Pipetted amount 
(µl) 
Concentration of stock 
standard mixture (mg/l) 
Retinol 0.0134 760 1.018 
alpha-Tocopherol 0.3861 585 22.59 
* Calculated by Lambert-Beer-Law. 
 
 
For the calibration curve, various amounts of the stock standard mixture were 
evaporated after addition of 0.5% hexane/BHT and redissolved in 1 ml hexane (Table 
 2.15).  
 
 
Table  2.15. Preparation of the 7 standard dilutions for vitamin A/E analysis, DHAVEG study. 
 Std. 7 Std. 6 Std. 5 Std. 4 Std. 3 Std. 2 Std.1 
1)  Stock standard 1000 µl 844 µl 688 µl 532 µl 376 µl 220 µl 100 µl 
2)  Add 0.5%     
     hexane/BHT    100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
3)  Dry under  
     nitrogen 
       
4)  Add hexane 1000 µl 1000 µl 1000 µl 1000 µl 1000 µl 1000 µl 1000 µl 
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The concentrations of standards 1 – 7 were calculated according to their dilution 
factors (Table  2.16): 
 
Table  2.16. Calculated concentrations of the 7 standard dilutions for retinol and tocopherol calibration 
curves (mg/l), DHAVEG study. 
 Std. 7  Std. 6  Std. 5  Std. 4  Std. 3  Std. 2  Std.1  
Dilution factor x1 x0.84 x0.69 x0.53 x0.36 x0.22 x0.1 
Retinol 1.018 0.856 0.700 0.541 0.383 0.224 0.102 
alpha-Tocopherol 22.59 19.07 15.54 12.02 8.49 4.97 2.26 
 
 
Extraction of the standards. The extraction method of the 7 standards was similar 
to the extraction of the plasma samples (see below): 250 µl distilled water (instead of 
plasma), 50 µl internal standard and 500 µl precipitation reagent were pipetted into a 
4 ml brown glass tube to minimize light-induced degradation of vitamins and vortexed 
for 15 sec. Thereafter, 250 µl standard (standard 1 – 7 respectively) and 750 µl 
hexane (instead of 1 ml hexane in case of plasma samples) were added and the 
samples were mixed for another 30 sec. After centrifugation at 1100 g for 5 min, the 
upper phase was transferred into a 1.5 ml brown glass vial. Thereafter, a second 
extraction with 1 ml hexane was performed and the combined extracts were taken to 
dryness under a gentle stream of nitrogen. The dried extract was redissolved in 100 
µl mobile phase, shaken mechanically for 10 min and transferred into microvials 
before injecting into a HPLC system with UV-Vis detection. The HPLC conditions are 
shown in  2.1.4.9. Detector signals were evaluated with the software EZ-Chrom Elite, 
version 2.61. Figure  2.4 exemplifies the separation of fat-soluble vitamins and 
carotenes with HPLC. 
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Figure  2.4. Chromatogram of a standard mixture using UV-Vis detection, DHAVEG study. 
IS, internal standard (retinyl acetate); d-Tocopherol, delta-tocopherol; b-Tocopherol, beta/gamma-
tocopherol, a-Tocopherol, alpha-tocopherol; a-Carotin, alpha-carotene; b-Carotin, beta-carotene. 
 
 
Standard curve construction. A 7-point standard curve was constructed for retinol 
and alpha-tocopherol with the software Microsoft Excel 97 SR-2 (Microsoft GmbH, 
Unterschleißheim) by plotting the vitamin concentrations (Table  2.16, y-axis) against 
the peak-area ratios (vitamin/internal standard, x-axis) (see Figure  8.1). 
Subsequently, the equation of the regression line and the coefficient of determination 
(r2) were calculated. 
Extraction of plasma samples. 250 µl plasma, 50 µl internal standard and 500 µl 
precipitation reagent were pipetted into a 4 ml brown glass bottle and vortexed for 15 
sec to precipitate the proteins. Subsequently, two extractions with 1 ml hexane were 
performed. The upper phases were transferred into a 1.5 ml brown glass bottle and 
taken to dryness under a gentle stream of nitrogen. The dried extract was redissolved 
in 100 µl mobile phase, shaken mechanically for 10 min and transferred into 
microvials. 50 µl were injected into a HPLC system with UV-Vis detection. The HPLC 
conditions are shown in  2.1.4.9. Detector signals were evaluated with the software 
EZ-Chrom Elite, version 2.61 and identified by comparison with the retention times of 
a standard mixture run previously (Figure  2.4).  
Calculation of vitamin A and E concentrations. The peak-area ratios (vitamin / 
internal standard) were computed for retinol and alpha-tocopherol and the 
appropriate concentrations were calculated using the equations of the standard 
curves (Figure  8.1). 
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2.1.4.9 HPLC conditions 
The column temperature was held constant at 30°C. T he programs of pump and 
UV/Vis detector were as follows: 
 
Table  2.17. Programme of the HPLC pump, DHAVEG study. 
Time (min) Flow (ml/min) 
0 0.65 
8 0.65 
9 1.30 
13 1.30 
15 0.65 
 
 
Table  2.18. Programme of the UV-Vis detector, DHAVEG study. 
Time 
(min) 
Wave length 
(nm) 
Detection of 
0 325 Retinol 
4 292 Tocopherols 
9 450 Carotenes 
15 325  
 
 
2.1.4.10 Examination of reproducibility, recovery, and accuracy (vitamin A and 
E analysis) 
Before analysing the study samples, plasma was obtained from a large blood sample 
as described in  2.1.3, aliquoted and stored at -80°C. Intra-assay r eproducibility was 
assessed by analysing 8 pool samples in the same analytical run. Inter-assay 
reproducibility of the used method was assessed by analysing pool samples 11x 
during 2 weeks. 
Recovery of the vitamin A and E measurements was assessed by performing the 
described method for plasma samples ( 2.1.4.8), but using for the first extraction 
instead of 1 ml hexane 50 µl stock standard and 950 µl hexane (n = 4). Recovery 
was calculated by dividing the mean measured concentration by the expected 
concentration and multiplying the result with 100%. 
The accuracy of the vitamin A and E measurements was verified with lyophilised 
standard reference material 968c obtained from the US National Institute of 
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Standards and Technology (NIST), which contains the vitamins in low and high 
concentrations. Three samples of each concentration level were analysed and 
compared with the approved values. A bias between 0 and 5% is regarded as 
excellent, while a bias between 5 and 10% is considered acceptable by the NIST. 
 
2.1.4.11 Plasma triglycerides and lipoproteins 
TG, total and HDL cholesterol concentrations were determined in lithium heparin 
plasma by standard enzymatic methods on an automated sample processor with the 
appropriate reagent systems (Table  2.19). LDL cholesterol concentrations were 
calculated using the Friedewald formula [115]: 
 
LDL cholesterol = Total cholesterol – HDL cholesterol – VLDL cholesterol 
(in which VLDL cholesterol = Triglycerides / 5). 
 
The reproducibility of the used test kits as declared from the manufacturer is shown 
in Table  8.1. 
 
 
Table  2.19. Analyses of plasma triglycerides, total and HDL cholesterol, DHAVEG study. 
Parameter Test kit Analytical equipment 
Triglycerides Cobas Integra TRIGL                            
(Roche Diagnostics GmbH, Mannheim)  
Total cholesterol Cobas Integra CHOLL                                   
(Roche Diagnostics GmbH, Mannheim) 
HDL cholesterol 
 
Cobas Integra HDL_C                                  
(Roche Diagnostics GmbH, Mannheim) 
      
 
      Cobas Integra 800                                               
     (Roche Diagnostics GmbH, Mannheim) 
 
 
 
2.1.4.12 Blood cell count, biochemical and haemostatic parameters 
Full blood cell count and biochemical parameters. Full blood cell counts were 
performed in EDTA blood on an automatic analyser (Table  2.20). Bilirubin, creatinine, 
gamma-glutamyl transpeptidase (Gamma-GT), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), cholinesterase (CHE), creatinekinase (CK), 
lactate dehydrogenase (LDH), uric acid, total protein, C-reactive protein (CRP) and 
glucose were measured in lithium heparin plasma on an automated sample 
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processor with the appropriate reagent systems. The reproducibility of the used test 
kits as declared from the manufacturer is shown in Table  8.2. 
 
Table  2.20. Analyses of full blood cell count and biochemical parameters, DHAVEG study. 
Parameter Test kit Analytical equipment 
Full blood cell count  Coulter Micro Diff II                                      
(Beckmann Coulter, Krefeld) 
 All test kits from Roche 
Diagnostics GmbH, Mannheim  
Bilirubin  BIL-T DPD 
Creatinine CREA Jaffe  
Gamma-GT  GGT flüssig 
ALT  ALT/GPT IFCC 
AST  AST/GOT IFCC 
CHE  CHE 
CK  CK NAC 
LDH LDH IFCC 
Uric acid UA plus 
Total protein TP 
CRP  CRP TINA-QUANT 
Glucose  GLU HK 
  
 
 
 
 
     Roche/Hitachi 912                                                    
     (Roche Diagnostics GmbH, Mannheim) 
Gamma-GT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CHE, cholinesterase; CK, creatinekinase; LDH, lactate dehydrogenase;  
CRP, C-reactive protein. 
 
 
Haemostatic parameters. Platelet function analysis was performed within 2 hours of 
blood collection in citrated whole blood using a platelet function analyser (Table 
 2.21). Membranes pre-coated with collagen/epinephrine or collagen/adenosine 
diphosphate were used to stimulate platelet aggregation. Quick’s time, partial 
thromboplastin time (PTT), fibrinogen, and d-dimers were measured in citrated 
plasma using automated analysers with commercially available kits. PAI-1 activities 
were measured using an ELISA assay. Factor VII and von Willebrand factor analyses 
were performed on automated sample processors with commercial test kits. The 
reproducibility of the used test kits as declared from the manufacturer is shown in 
Table  8.3. 
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Table  2.21. Analyses of haemostatic parameters, DHAVEG study. 
Parameter Test kit Analytical equipment 
Quick’s time Thromborel S                                                     
(Dade Behring, Marburg) 
PTT Pathromtin**SL                                                        
(Dade Behring, Marburg) 
Fibrinogen Multifibren U                                                        
(Dade Behring, Marburg) 
 
 
      Amelung Amax CS                                 
      (Trinity Biotech, Darmstadt) 
D-dimers TINA-QUANT a D-Dimer                                 
(Roche Diagnostics GmbH, Mannheim) 
Roche/Hitachi 912                                                  
(Roche Diagnostics GmbH, Mannheim) 
Factor VII HemosIL, Factor VII deficient plasma,          
(Instrumentation Laboratory, Milan, Italy) 
ACL 9000                                                   
(Instrumentation Laboratory, Milan, Italy) 
Von Willebrand 
factor 
IL TestTM Von Willebrand Faktor                 
(Instrumentation Laboratory, Milan, Italy) 
BCS                                                            
(Dade Behring, Marburg) 
PAI-1 Coatest PAI                                        
(Chromogenix-Instrumentation 
Laboratory, Milan, Italy) 
SPECTRA thermo                                            
(Tecan, Crailsheim) 
PFA-ADP PFA-100 reagents                                                
(Dade Behring, Marburg) 
PFA-EPI PFA-100 reagents                                              
(Dade Behring, Marburg) 
      Platelet Function Analyzer PFA-100    
   (Dade Behring, Marburg) 
PTT, partial thromboplastin time; PAI-1, plasminogen activator inhibitor-1 activity; PFA-ADP, platelet 
function analysis with adenosine diphosphate; PFA-EPI, platelet function analysis with epinephrine. 
 
 
2.1.4.13 Dietary evaluation 
Food consumption of the subjects was determined before and during the intervention 
period using a self-reported three-day estimated dietary record (see Attachment, 
pages A54 – A57). We applied a modified form of the “Freiburger Ernährungs-
protokoll”, which is contained as protocol template in the used nutrition software Prodi 
(Nutri-Science GmbH, Freiburg, Germany). Vegetarian foods were added to the 
original protocol and foods of animal origin were excluded with the exception of eggs, 
butter, milk, and dairy products.  
In the used tally sheet protocol, the subjects estimated the quantities of the foods and 
beverages consumed using household measures (teaspoon, tablespoon, cup, slice, 
piece, etc.) according to the provided instructions. The diet was recorded over three 
consecutive days covering two weekdays and one weekend day (Thursday to 
Saturday or Sunday to Tuesday).  
Recorded dietary intakes were entered into the software Prodi version 4.5 LE 2003, 
which calculated the nutrient intake based on the German Nutrient Data Base BLS, 
version II.3 (BgVV, Berlin, Germany). 
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2.1.5 Data management and statistical analyses 
Statistical evaluation was carried out with SPSS 12.0 for Windows (SPSS Inc., 
Chicago, USA). Data are presented as mean ± SD for normally distributed data or as 
median with interquartile range (IQR, 25th – 75th percentiles) in case of non-normality.  
Test for normality. Data were checked for normality by visual inspection and by 
Kolmogorov-Smirnov-test (with Lilliefors correction). Parametric tests were used for 
normally distributed variables and nonparametric tests for variables that are not 
normally distributed. Exact significances were calculated for all nonparametric tests.  
Between-group differences. Any differences between the groups (active treatment 
vs. placebo) at each time point or the impact of treatment on absolute changes (week 
8 minus week 0) were tested for significance using Student’s unpaired t-test for 
normally distributed variables or the Mann-Whitney U test for variables not normally 
distributed.  
Within-group differences. Differences between week 0 and week 8 were 
determined within each treatment group using Student’s t-test for dependent samples 
and Wilcoxon nonparametric test respectively.  
Correlations and bivariate tabular analysis. Correlations between parameters 
were estimated by computing Pearson’s correlation coefficient in the case of normally 
distributed values and the Spearman-Rho correlation coefficient in the case of other 
distributions respectively. For bivariate tabular analysis the chi-square test (exact 
calculation) was used. In cases of expected values smaller than 5, a Fisher exact test 
was used instead.  
Level of significance. P values below 5% were considered significant. 
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2.2 FO/EPO study 
2.2.1 Subjects and study design 
Ethical permission of the study was obtained from the Bavarian Board of Physicians. 
All volunteers completed a health and lifestyle questionnaire before entering the 
study. Eligible for the study were persons, who fulfil the following inclusion criteria: 
 
• Female gender 
• Age between 18 and 40 years 
• BMI between 18 and 25 kg/m2 
• No hypertension (defined as a systolic blood pressure > 140 mm Hg or a 
diastolic blood pressure > 90 mm Hg [116]) 
• No presence of metabolic, cardiovascular, renal or neurological diseases 
• No long-term use of medication (contraceptives excluded) 
• No use of EFA or LCPUFA supplements 
• No drug abuse 
• No vegetarian lifestyle during the last 3 months 
• Smoking of ≤ 5 cigarettes per day 
• Consumption of ≤ 7 glasses alcohol per week 
• Consumption of fish ≤ 2 times a week 
• No pregnancy or lactation 
• No participation in another scientific study 
 
All subjects gave their written informed consent and received financial compensation 
for their participation. The study was conducted between June and August 2005 as a 
randomised double blind, placebo-controlled intervention study with two parallel 
groups. The subjects consumed 3.4 g daily of either a fish oil/evening primrose oil 
mixture (FO/EPO, delivering 419 mg DHA, 72 mg EPA, 14 mg AA, 337 mg GLA as 
triglycerides per day) or the same amount of a placebo (mixture of palm oil, rapeseed 
oil, and sunflower seed oil) for 8 weeks. Subjects were randomly assigned to one of 
the intervention groups on the basis of a computer-generated random table.  
Fasted blood samples were collected at weeks 0 (baseline), 4, 6 and 8 (Figure  2.5). 
Body weight, blood pressure, and heart rate were measured at study entry and after 
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8 weeks of intervention; height was measured at baseline only. During the 
intervention, the subjects noted side effects, signs of illness, intake of medication and 
the number of capsules not consumed. Compliance was assessed by counting 
leftover capsules and calculated as the percentage of the prescribed capsules taken. 
To check the success of blinding, the subjects were asked at the end of the study 
about their assumed group assignment. 
 
 
 
Figure  2.5. Study design, FO/EPO study. 
 
 
2.2.2 Study oils 
Each FO/EPO capsule contained 438 mg evening primrose oil (EFAMOL Ltd, 
Brackenholme, Selby, North Yorkshire, UK) and 129 mg fish oil (Incromega DHA 500 
TG SR, Croda Chemicals Europe Ltd, Cowick Hall, East Yorkshire, UK) (Table  2.22). 
Matching placebo capsules consisted of palm oil, rapeseed oil, and sunflower seed 
oil. The study capsules contained 1% synthetic vitamin E acetate for stabilisation of 
the capsule content. The fatty acid composition of the two study oils as declared from 
the manufacturer and as determined after the intervention period in our laboratory 
(January 2006) is given in Table  2.23. The volunteers were required to take daily 2 x 
3 capsules or 3 x 2 capsules with the meals (a total of six capsules per day). 
Capsules were stored refrigerated or at room temperature in a dry, dark place. 
 
 
Fish oil + evening primrose oil (6 capsules/day) 
Placebo (6 capsules/day) 
                 0                                                 4                        6                      8        weeks 
weight, 
 blood pressure, 
 plasma fatty acids,  
full blood cell count, 
liver enzymes 
 
 plasma fatty acids  
 
height, weight, 
 blood pressure, 
 plasma fatty acids,  
full blood cell count, 
liver enzymes 
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Table  2.22. Ingredients of placebo and FO/EPO capsules, FO/EPO study. 
 Component Percent (%) 
Palm oil 59.4 
Rapeseed oil 19.8 
Sunflower seed oil 19.8 
Placebo capsule (567.2 mg) 
Synthetic vitamin E acetate 1.0 
 
Efamol Evening primrose oil  76.5 
Croda Incromega DHA 500 TG SR 22.5 
FO/EPO capsule (572.7 mg) 
Synthetic vitamin E acetate 1.0 
FO/EPO, fish oil and evening primrose oil mixture. 
 
 
Table  2.23. Major fatty acids of FO/EPO and placebo oils (wt%), FO/EPO study. 
 FO/EPO* FO/EPO
†              
(n = 4) Placebo* 
Placebo†                   
(n = 4) 
16:0 5.1 4.93 ± 0.03  27.8 28.46 ± 0.03 
18:0 1.9 1.84 ± 0.01  3.8 3.63 ± 0.01 
18:1n-9 + 18:1n-7 6.3 5.98 ± 0.06  42.4 42.01 ± 0.07 
18:2n-6 56.4 56.64 ± 0.04  21.1 21.37 ± 0.02 
18:3n-6 9.8 10.28 ± 0.03  - - 
20:4n-6 0.4 0.41 ± 0.00  - - 
18:3n-3 0.2 0.17 ± 0.01  2.0 2.06 ± 0.03 
20:5n-3 2.1 2.13 ± 0.02  - - 
22:6n-3 12.2 13.28 ± 0.06  - - 
FO/EPO, fish oil and evening primrose oil mixture. 
*  Values are reported as means (according to manufacturer’s declaration). 
†  As determined in our laboratory in January 2006 (mean ± SD). 
 
 
2.2.3 Measurements, blood sampling and storage 
All anthropometrical measurements at baseline followed standardised procedures. 
Height without shoes was measured to the nearest 5 millimetres and body weight 
without shoes and outdoor clothing to the nearest 100 g using a digital scale. A lump 
sum of 1 kg was subtracted for the weight of the clothes. Blood pressure and heart 
rate were determined in sitting position using a digital sphygmomanometer.  
Venous blood samples (5 ml) were collected from the antecubital vein of the forearm 
into an EDTA containing tube (Sarstedt, Nümbrecht, Germany) in sitting or lying 
position of the subject. Blood was centrifuged at 4°C (1500 g for 5 minutes) within 2 
hours and the obtained plasma was aliquoted into two plastic storage vials, which 
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were closed tightly under a stream of nitrogen, and stored at -80°C until analysis of 
total lipid (TL), phospholipid (PL), triglyceride (TG) and cholesterol ester (CE) fatty 
acids. At baseline and after 8 weeks of supplementation, two additional blood 
samples (1 ml each) were collected into a lithium heparin tube and into an EDTA tube 
(both Sarstedt, Nümbrecht, Germany) for liver enzyme measurements and a full 
blood count respectively. Fatty acid analyses of a given subject (weeks 0, 4, 6, and 8) 
were performed during 4 months of storage within the same analytical run. Full blood 
cell count and liver enzymes were analysed at the day of blood drawing using 
established routine methods in the clinical chemistry laboratories of the University of 
Munich hospital. 
 
2.2.4 Analytical methods 
2.2.4.1 Chemicals, consumables and equipment 
Chemicals, consumables and equipment for fatty acid analyses as well as the 
preparation of the internal standard and the GC conditions are described in  2.1.4.1 
and  2.1.4.5. 
 
2.2.4.2 Fatty acid analysis in study oils 
Fatty acid composition of the study oils was analysed as described in  2.1.4.2.  
 
2.2.4.3 Fatty acid analysis in plasma lipids 
Lipid extraction. Plasma lipids were extracted according to a modified Folch method 
[117]. One hundred µl of the internal standard solution (see  2.1.4.3), 10 ml 
chloroform/methanol (2+1, by vol, containing 50 mg BHT/l) and 2.5 ml distilled water 
were added to 250 µl plasma for total lipids, PL, TG and CE analysis. The tubes were 
vortexed for 15 minutes and centrifuged at 1000 g for 6 min. The aqueous phase was 
discarded and the remaining organic phase replenished with methanol up to a total 
volume of 10 ml. Subsequently, two extractions with 2.5 ml 2% NaCl solution were 
performed. The aqueous phases were discarded and the remaining organic phase 
containing the lipids was taken to dryness under reduced pressure.  
Separation of lipid fractions. The lipid residue was dissolved in 600 µl of 
chloroform/methanol (1+1, by vol), of which 150 µl were directly transferred into the 
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reaction vial and taken to dryness under nitrogen for analyses of fatty acids in plasma 
total lipids. The remaining 450 µl were deposited on a TLC plate for separation of PL, 
free cholesterol, NEFA, TG and CE using heptane, diisopropyl ether and acetic acid 
(60+40+3, by vol) as mobile phase [111]. After visualisation of the lipids with 2.7-
dichlorofluorescein (1% in ethanol) and UV-light, the bands with the lipid fractions of 
interest (PL, TG, and CE) were scraped separately from the TLC plate and 
transferred into 4 ml glass tubes (Figure  2.2).  
Transesterification and extraction of FAME. Transesterification of plasma total 
lipids and lipid fractions, extraction of FAME and storage were performed as 
described for plasma fatty acids in the DHAVEG study (see  2.1.4.3). 
 
2.2.4.4 GC conditions and calculation of fatty acid concentrations 
For gas chromatography conditions see  2.1.4.5. The calculation of fatty acid 
concentrations (mg/l) in plasma lipid fractions (PL, CE, TG) is described in  2.1.4.6. In 
plasma total lipids, the area of the internal standard equalled 40 µg 15:0/250 µl 
plasma = 160 mg 15:0/l plasma. Fatty acid percentages (wt%) were calculated 
dividing the absolute concentration of an individual fatty acid by the concentration of 
all C14 – C24 fatty acids and multiplying the result with 100. 
In addition to the fatty acid profile, the following fatty acid sums and ratios were 
calculated for each sample: sum of GLA and DGLA (GLA + DGLA), sum of all n-6 
fatty acids (Σ-6 FA), sum of all n-3 fatty acids (Σn-3 FA), sum of all long-chain n-6 
fatty acids (Σ-6 LCPUFA), sum of all long-chain n-3 fatty acids (Σ-3 LCPUFA), the 
ratio of n-6 to n-3 fatty acids (Σn-6/Σn-3 FA), and the ratio of n-6 LCPUFA to n-3 
LCPUFA (Σn-6/Σn-3 LCPUFA).  
 
2.2.4.5 Examination of reproducibility 
Pool plasma samples were provided by the sponsor of the study and stored at -80°C. 
Intra-assay reproducibility was assessed by analysing 8 pool samples in the same 
analytical run. When analysing the study samples, inter-assay reproducibility of the 
used method was assessed by analysing pool plasma samples 10/11x during 7 
weeks.  
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2.2.4.6 Blood cell count and liver enzymes 
Full blood cell counts were performed in EDTA blood on an automatic analyser. 
Gamma-glutamyl transpeptidase, alanine aminotransferase, aspartate amino-
transferase, and cholinesterase were measured in lithium heparin plasma on an 
automated sample processor with the appropriate reagent systems (see  2.1.4.12).  
 
2.2.5 Data management and statistical analyses 
Statistical evaluation was carried out with SPSS 12.0 for Windows (SPSS Inc., 
Chicago, USA). Data are presented as mean ± SD for normally distributed data (raw 
or transformed data) or as median with IQR in case of non-normality. For transformed 
data, the back-transformed mean is shown additionally. 
Test for normality. Data were checked for normality by visual inspection and by 
Kolmogorov-Smirnov-test (with Lilliefors correction). In case of non-normality, 
transformation of the fatty acid data was performed to obtain a normal distribution. 
Parametric tests were used for normally distributed variables and nonparametric tests 
for variables that are not normally distributed. Exact significances were calculated for 
all nonparametric tests.  
Between-group differences. Any differences between the groups (active treatment 
vs. placebo) at each time point or the impact of treatment on absolute changes (i.e. 
week 8 minus week 0) or relative changes from baseline (i.e. [week 8-week 0]/week 
0) were tested for significance using Student’s unpaired t-test for normally distributed 
variables or the Mann-Whitney U test for variables not normally distributed.  
Within-group differences. Student’s t-test for dependent samples with Bonferroni-
Holm correction [118] for multiple comparisons was used to compare data from 
weeks 4, 6, and 8 with baseline data within each treatment group. In cases of non-
normally distributed data, which could not successfully be transformed, the Wilcoxon 
nonparametric test with Bonferroni-Holm correction for multiple comparisons was 
used to compare data from week 4, 6, and 8 with baseline data within each treatment 
group. 
General Linear Model. The overall effect of treatment on fatty acid composition was 
determined using the General Linear Model (GLM) for repeated measures corrected 
for fatty acid concentrations at baseline (week 0). The between-subjects factor had 
two levels (“placebo” versus “FO/EPO”), whereas the within-subjects factor “time” 
had three levels (weeks 4, 6, and 8).  
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Correlations and bivariate tabular analysis. Correlations between parameters 
were estimated by computing Pearson’s correlation coefficient in the case of normally 
distributed values and the Spearman-Rho correlation coefficient in the case of other 
distributions respectively. For bivariate tabular analysis the chi-square test (exact 
calculation) was used. In cases of expected values smaller than 5, a Fisher exact test 
was used instead.  
Level of significance. P values below 5% were considered significant with exception 
of multiple comparisons (week 4, 6 and 8 vs. week 0), in which the p values were 
corrected to < 1.67%, < 2.5%, and < 5% [118].  
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3 Results 
3.1 DHAVEG study 
3.1.1 Methods for fatty acid analysis 
The GC method ( 2.1.4.5) enabled the separation of the following C14 – C24 fatty 
acids, which were identified by comparison with the peaks of a standard mixture 
(Figure  3.1): 
Saturated fatty acids: 14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0; 
Trans fatty acids: 14:1t, 16:1t, 18:1t, 18:2tt, 22:1t; 
Monounsaturated fatty acids: 14:1n-5, 15:1n-5, 16:1n-7, 17:1n-7, 18:1n-9, 18:1n-7, 
20:1n-9, 22:1n-9, 24:1n-9; 
Polyunsaturated fatty acids: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6 (small amounts of 22:3n-3 
cannot be excluded), 22:5n-6, 22:5n-3, 22:6n-3. 
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Figure  3.1. Chromatogram of the fatty acid standard mixture. 
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Reproducibility. In biological assays, intra-assay coefficients of variation below 5% 
are considered desirable. Table  3.1 and Table  3.2 show the determined coefficients 
of variation for selected n-6 and n-3 fatty acids in plasma PL, RBC total lipids, PE, 
and PC (for complete intra-assay and inter-assay CV see Table  8.4 - Table  8.6). 
 
 
Table  3.1. Intra-assay CV (%) of fatty acid analyses, DHAVEG study. 
 Plasma PL                          
(n = 8) 
RBC TL               
(n = 8) 
RBC PE             
(n = 7) 
 RBC PC              
(n = 7) 
 mg/l* wt%†  wt%†  wt%†  wt%† 
n-6 fatty acids         
18:2n-6 1.52 0.64  0.65  2.68  0.92 
18:3n-6 8.16 8.12  2.74  3.49  n.d. 
20:3n-6 1.58 0.83  1.32  0.71  1.49 
20:4n-6 1.76 0.39  0.22  2.00  2.27 
22:4n-6 1.85 1.33  0.44  2.77  9.49 
22:5n-6 3.82 4.19  1.74  3.28  7.31 
n-3 fatty acids         
18:3n-3 2.15 1.76  2.51  5.38  6.18 
20:5n-3 3.02 2.29  0.93  1.85  2.07 
22:5n-3 2.93 2.74  0.48  3.15  4.14 
22:6n-3 4.31 4.11  0.54  3.32  3.71 
n.d., not detected; PL, phospholipids; RBC, red blood cell; TL, total lipids; PE, phosphatidylethanol-
amine; PC, phosphatidylcholine. 
*  CV absolute fatty acid concentration (mg/l). 
†  CV relative fatty acid composition (wt%). 
 
 
The performed intra- and inter-assay variation tests proved a good reproducibility of 
the used methods for most fatty acids. Intra-assay CV were < 5% for the described n-
3 and n-6 fatty acids (mg/l and wt%) with the exception of GLA in plasma PL (CV 
8%), 22:4n-6 in RBC PC (9%) and ALA in RBC PE and PC (5.4% and 6.2% 
respectively), but these fatty acids account for minor proportions of total fatty acids (< 
0.4 wt% each). Inter-assay CV for the described n-3 and n-6 fatty acids were < 8% in 
plasma PL and RBC total lipids, < 7% in RBC PE and < 10% in RBC PC. 
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Table  3.2. Inter-assay CV (%) of fatty acid analyses, DHAVEG study 
 Plasma PL                          
(n = 11) 
RBC TL               
(n = 19) 
RBC PE             
(n = 14) 
 RBC PC              
(n = 14) 
 mg/l* wt%†  wt%†  wt%†  wt%† 
n-6 fatty acids         
18:2n-6 4.70 1.79  1.17  1.30  0.94 
18:3n-6 7.97 5.17  7.96  5.64  5.30 
20:3n-6 5.12 2.10  0.86  1.26  2.14 
20:4n-6 7.19 5.47  0.82  1.25  3.28 
22:4n-6 6.22 3.82  1.04  1.80  6.11 
22:5n-6 6.15 3.72  2.31  2.44  8.82 
n-3 fatty acids         
18:3n-3 4.27 2.01  3.23  6.76  2.84 
20:5n-3 6.74 3.92  1.99  1.48  3.99 
22:5n-3 7.46 6.72  1.78  2.19  9.74 
22:6n-3 5.13 2.95  2.06  1.84  6.02 
PL, phospholipids; RBC, red blood cell; TL, total lipids; PE, phosphatidylethanolamine; PC, 
phosphatidylcholine. 
*  CV absolute fatty acid concentration (mg/l). 
†  CV relative fatty acid composition (wt%). 
 
 
3.1.2 Method for vitamin A and E analysis 
Linearity of calibration curves. The calculated coefficients of determination (r2) 
obtained with the described method using seven vitamin concentration levels in the 
stated concentration range were as follows: retinol 0.102 – 1.018 mg/l (r2 = 0.9995), 
alpha-tocopherol 2.26 – 22.59 mg/l (r2 = 0.9998) (Figure  8.1). 
Reproducibility. The performed intra- and inter-assay variation tests proved good 
reproducibilities of the used method. Table  3.3 shows the determined coefficients of 
variation for retinol and alpha-tocopherol: intra-assay CV were < 2% and inter-assay 
CV < 4% for both substances.  
 
Table  3.3. Reproducibility of vitamin A and E analysis in plasma, DHAVEG study. 
 Intra-assay (n = 8)  Inter-assay (n = 11) 
 Mean (mg/l) CV (%)  Mean (mg/l) CV (%) 
Retinol 0.50 1.89  0.49 3.79 
alpha-Tocopherol 7.31 1.80  9.06 3.67 
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Recovery from plasma. The mean recoveries of added retinol and alpha- tocopherol 
to plasma  (n = 4) were 100% and 97% respectively. 
 
Table  3.4. Recoveries of retinol and alpha-tocopherol from plasma, DHAVEG study. 
 Basal plasma                     
(n = 4)  
Plasma + standard 
mixture (n = 4) 
Expected 
concentration 
Recovery (%) 
Retinol 0.586 ± 0.007 0.756 ± 0.008 0.755 100 ± 1 
alpha-Tocopherol 9.54 ± 0.21 15.03 ± 0.21 15.46 97 ± 1 
 
 
Accuracy of the measurements. The results for retinol were in excellent agreement 
with the approved values of the NIST standard reference material (bias < 5%), 
whereas the results for the lower alpha-tocopherol level corresponded acceptably to 
the certified values. The results for the higher alpha-tocopherol level were almost 
13% lower than the certified values.   
 
Table  3.5. Accuracy of vitamin A and E measurements, DHAVEG study. 
  Certified value 
(mg/l)† 
Measured                    
(n = 3, mg/l)§ Bias (mean, %) 
Retinol    
    Level 1 0.841 ± 0.027 0.850 ± 0.019 0.5 
    Level 2 0.484 ± 0.012 0.475 ± 0.007 -1.8 
alpha-Tocopherol    
    Level 1 7.47 ± 0.47 6.79 ± 0.13 -9.1 
    Level 2 16.79 ± 0.76 14.67 ± 0.07 -12.8 
The bias from the assigned value was calculated as follows:  
(mean of the 3 measured samples – certified value) * 100% / certified value. 
†  The true concentration is expected, with 95% confidence, to be in the interval defined  
   by the certified value ± the expanded uncertainty. 
§  Mean ± SD. 
 
 
3.1.3 Subjects 
One hundred-fourteen free-living, apparently healthy vegetarians aged 18 to 43 years 
(87 female, 27 male) were included in the study and randomly assigned to one of the 
intervention groups. There was no difference between the groups with respect to 
age, BMI, blood pressure, heart rate, duration of vegetarian diet, proportion of non-
smokers and gender ratio at study entry (Table  3.6).  
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Table  3.6. Baseline characteristics of the subjects, DHAVEG study (mean ± SD or median with IQR). 
 DHA (n = 58 - 59)*  Placebo (n = 55)  P† 
Female (n) / male subjects (n) 44 / 15  43 / 12  0.667 
Age (years)§ 24 (22 – 27)  24 (22 – 29)  0.904 
BMI (kg/m2) 21.4 ± 1.8  21.2 ± 2.0  0.532 
Blood pressure (mm Hg) 
   Systolic§ 
   Diastolic§ 
 
98 (90 – 100) 
65 (60 – 70) 
  
95 (90 – 100) 
70 (60 – 70) 
  
0.574 
0.737 
Heart rate (beats/min)§ 68 (60 – 72)  68 (64 – 72)  0.872 
Years on a vegetarian diet§ 8.0 (6.0 – 13.0)  8.5 (5.0 – 10.0)  0.445 
Non-smokers (%) 75  80  0.512 
*  For one subject, blood pressure and heart rate values are missing. 
§  Median with IQR in parentheses. 
†  Analyses of group differences. 
 
 
Two of the 114 subjects recruited into the study dropped out during the intervention 
period. One subject in the placebo group came down with a renal colic, which was 
considered unrelated to the dietary supplement, and the contact to one subject of the 
DHA group was lost. Three individuals in the DHA group and one in the placebo 
group were excluded from all analyses. The reasons for exclusions were poor 
compliance with study protocol (n = 2) and diarrhoea/vomitus for more than 6 days of 
the intervention period (n = 2, one subject from each group). Thus, 108 subjects 
(94.7%) are included in the statistical analysis. Two subjects were additionally 
excluded from the statistical analyses of triglycerides and lipoproteins, because of 
suspected hypertriacylglycerolaemia (basal TG > 2.5 mmol/l), resulting in 106 
subjects (93.0%) for these parameters. 
 
3.1.4 Compliance and side effects 
The median number of days in the study was 56 days (range: 56 – 60 days) in both 
groups. Compliance as judged by capsule count was 98% (mean) in the DHA group 
and 99% in the placebo group, with no significant between-group difference (Table 
 3.7).  
Side effects were reported in the DHA group by 11% and in the placebo group by 8% 
of the subjects (Table  3.8) including gastrointestinal upsets (flatulence, pain, 
diarrhoea, belching) and minor skin reactions (acne). Side effects were evenly 
distributed between DHA and placebo groups.  
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Table  3.7. Compliance, DHAVEG study (% of prescribed capsules taken).* 
 DHA                                     
(n = 55) 
Placebo                              
(n = 53) 
Mean ± SD (%) 98 ± 2 99 ± 2 
Median with IQR (%) 100 (97 – 100) 100 (98 – 100) 
100% compliance (number and %) 28  (51%) 32  (60%) 
*  No difference in compliance was observed between DHA and placebo groups (p = 0.441). 
 
 
 Table  3.8. Reported side effects, DHAVEG study (number and %).* 
 DHA                         
(n = 55) 
Placebo                       
(n = 53) 
Total side effects 6  (11%) 4  (8%) 
     Skin reactions - 1  (2%) 
     Flatulence 3  (5%) 2  (4%) 
     Stomach ache 2  (4%) 1  (2%) 
     Diarrhoea - 2  (4%) 
     Belching 2  (4%) 1  (2%) 
*  Side effects were evenly distributed between DHA and  
 placebo groups (p > 0.05). 
 
 
3.1.5 BMI, blood pressure and heart rate 
Body weight, BMI, blood pressure and heart rate did not differ between DHA and 
placebo groups at week 0 and week 8 (Table  8.11). An examination of within-group 
changes demonstrated slight but significant increases in body weight and BMI after 8 
weeks of intervention in the placebo group, but no changes in the DHA group. 
Changes from baseline in body weight and BMI tended to be different between DHA 
and placebo groups (p = 0.072 and p = 0.056 respectively). In both groups, slight 
increases of systolic blood pressure were observed (not significant in the DHA group: 
p = 0.066); the change from baseline in systolic blood pressure was not different 
between the groups. Diastolic blood pressure and heart rate did not change during 
intervention. 
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3.1.6 Dietary intake 
The proportion of macronutrients and the intakes of energy, alcohol, cholesterol, and 
n-3 LCPUFA with the background diet (not including supplements for placebo and 
DHA group) were not different between the two groups before the intervention and 
did not change (with the exception of energy intake in the DHA group) in both groups 
during intervention (Table  3.9).  
Energy intake in the DHA group was significantly lower during intervention compared 
to baseline and tended to be reduced at this time point compared to placebo (p = 
0.079). Dietary fibre intake was comparably high between both groups before 
intervention; during intervention it was significantly lower in the DHA than in the 
placebo group. Baseline DHA intakes were 23 mg/d (median) in the DHA group and 
20 mg/d in the placebo group. Before intervention, DHA and placebo groups differed 
in dietary LA intake (% of energy) (medians: 3.3% vs. 5.0%) and LA:ALA ratios 
(median: 6.6:1 vs. 7.9:1). Dietary LA intake and LA:ALA ratio decreased in the 
placebo group during the study, resulting in values comparable to the DHA group at 
study end.  
 
Table  3.9. Dietary intake with the background diet before and during intervention, DHAVEG study 
(mean ± SD or median with IQR). 
 DHA group (n = 55)  Placebo group (n = 53) 
 Before intervention During intervention  Before intervention During intervention 
Energy (MJ)§ 8.8 (7.2 – 10.3) 7.7 (6.5 – 9.2) 1  8.8 (7.0 – 10.1) 8.1 (7.0 – 10.9) 
Protein                            
(% of energy)§  13.0 (10.9 – 15.2) 12.4 (11.1 – 15.2)  13.2 (10.8 – 14.7) 12.5 (11.0 – 14.2) 
Total fat                      
(% of energy)§ 28.9 (23.1 – 32.9) 28.5 (24.1 – 31.9)  31.0 (24.1 – 38.4) 29.8 (24.6 – 35.0) 
Carbohydrates                    
(% of energy) 54.2 ± 1.1 54.3 ± 1.0  51.6 ± 1.2 52.9 ± 1.1 
Fibre (g)§ 28.1 (21.1 – 35.9) 24.8 (19.5 – 35.9)a  30.5 (22.6 – 44.8) 30.1 (24.3 – 41.3) 
Alcohol (g)§ 2.0 (0.2 – 9.2) 1.3 (0.1 – 10.9)  2.0 (0.1 – 10.9) 5.1 (0.1 – 11.1) 
Cholesterol (mg)§ 150 (84 – 231) 137 (88 – 200)  146 (76 – 208) 143 (73 – 256) 
LA (% of energy)§ 3.3 (2.5 – 4.6)a 3.3 (2.6 – 5.2)  5.0 (3.3 – 7.3) 3.5 (2.5 – 6.2) 1 
ALA                         
(% of energy)§ 0.51 (0.42 – 0.79) 0.52 (0.42 – 0.72)  0.57 (0.42 – 0.87) 0.52 (0.42 – 0.81) 
LA:ALA ratio§ 6.6 (4.5 – 8.6)a 6.7 (4.7 – 9.1)  7.9 (6.1 – 10.4) 6.1 (5.2 – 9.0) 1 
EPA (mg)§ 0.0 (0.0 – 3.3) 0.0 (0.0 – 3.3)  0.0 (0.0 – 3.3) 0.0 (0.0 – 3.3) 
DHA (mg)§ 23.3 (6.7 – 53.3) 16.7 (6.7 – 36.7)  20.0 (3.3 – 40.0) 20.0 (5.0 – 45.0) 
ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid.  
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0;  
a  p < 0.05 vs. placebo at the same time point. 
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Spearman-Rho correlation coefficients between dietary LA intake (g/d) and LA (wt%) 
in RBC total lipids, RBC PE, RBC PC, and plasma PL at baseline were 0.454, 0.470, 
0.391 and 0.318 respectively (p always < 0.01). 
 
3.1.7 Plasma triglycerides and lipoproteins 
Measured lipid metabolism parameters were not different between the two groups at 
study entry and did not change in the placebo group (Figure  3.4, Table  8.12). A 
significant 20% decrease in plasma TG concentrations from 0.96 to 0.77 mmol/l 
(medians) was observed in the DHA group. Absolute TG changes from baseline were 
significantly different between DHA (-0.15 mmol/l, median) and placebo groups (-0.02 
mmol/l). After DHA supplementation, observed TG concentrations did not exceed 1.5 
mmol/l (Figure  3.2, •), whereas after placebo intervention, the values were distributed 
beyond 2.5 mmol/l (ο). The number of subjects with plasma TG levels > 1.5 mmol/l 
did not differ between DHA and placebo group at week 0 (17% vs. 15%), but after the 
intervention, the frequency was significantly lower in the DHA supplemented group 
compared to placebo (0% vs. 21%). 
 
 
Figure  3.2. Plasma triglycerides at week 0 and week 8, DHAVEG study (n = 53 in both groups). 
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Figure  3.3. Plasma triglyceride changes after DHA supplementation  
according to baseline triglyceride levels, DHAVEG study (n = 53). 
 
 
Figure  3.3 shows that in subjects with basal TG levels ≤ 1.2 mmol/l, DHA 
supplementation had no influence on TG levels (n = 40; mean TG levels 0.79 mmol/l 
at week 8 vs. 0.83 mmol/l at baseline; p = 0.161), but that in subjects with basal TG 
levels > 1.2 mmol/l, DHA decreased TG consistently (n = 13; mean TG levels 0.95 
mmol/l at week 8 vs. 1.83 mmol/l at baseline; p < 0.001). 
Plasma total, LDL and HDL cholesterol increased significantly in the DHA group; the 
changes from baseline in these parameters were significantly different between DHA 
and placebo groups (Figure  3.4, Table  8.12). We found a slight, negative correlation 
between absolute changes in TG and in HDL concentrations after DHA 
supplementation (r = -0.307, p = 0.025). In the DHA group, there were no correlations 
between individual DHA changes in plasma/RBC and changes in plasma TG, total, 
LDL or HDL cholesterol concentrations.  
The ratio of TG to HDL cholesterol was significantly reduced from 0.57 to 0.43 
(medians) in the DHA group and remained unchanged in the placebo group; these 
changes from baseline were significantly different between the two groups. Total 
cholesterol:HDL cholesterol and LDL cholesterol:HDL cholesterol ratios were not 
affected by intervention (Table  8.12).  
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Figure  3.4. Plasma triglycerides and lipoproteins at week 0 and week 8, DHAVEG study (n = 53 in 
both groups). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
1  p < 0.05 vs. week 0; a  p < 0.05 vs. placebo at the same time point. 
 
 
3.1.8 Vitamin A and E 
Absolute retinol and alpha-tocopherol levels as well as lipid-adjusted alpha-
tocopherol levels were not different between the two groups at study entry and did 
not change in both groups (Table  8.13). Retinol changes showed greater increases 
from baseline values with microalgae oil than with placebo; changes in absolute and 
lipid-adjusted alpha-tocopherol levels were not different between DHA and placebo 
groups. 
1,a 
1 
1 1 
↓ 
↑ 
↑ ↑ 
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3.1.9 Plasma haemostatic factors 
All measured haemostatic parameters were not different between the two groups at 
week 0 and week 8 (Table  8.14). Minor changes from baseline with no significant 
group differences were observed for fibrinogen, PTT, and PAI-1 as well as ADP-
induced platelet aggregation time. In the DHA group, a reduction of von Willebrand 
factor was observed and changes from baseline in this haemostatic factor were 
significantly different between the two intervention groups. 
With the exception of von Willebrand factor, incidence of haemostatic factors out of 
the laboratory’s reference range did not differ neither at baseline nor at week 8 
between DHA and placebo groups and within-group incidences did not differ between 
baseline and week 8 (Table  3.10). Concerning von Willebrand factor, we observed 
values out of reference range less often after DHA supplementation than at baseline 
(1 vs. 12 subjects), and incidence of such values was lower in the DHA group than in 
the placebo group at week 8 (1 vs. 11 subjects). 
 
 
Table  3.10. Haemostatic factors out of laboratory’s reference range, DHAVEG study (number). 
   DHA  Placebo 
 Reference 
range† 
 n* Week 0 Week 8  n* Week 0 Week 8 
Quick’s test (%) > 70  53 0 0  52 1 1 
PTT (sec) 25 - 42  53 0 0  52 2 0 
Fibrinogen (mg/dl) 160 - 400  54 3 4  52 8 7 
D-dimers (µg/ml) < 0.5  55 5 3  53 4 2 
Factor VII (%) 50 - 130  55 10 9  53 13 9 
Von Willebrand 
factor (%) 
50 - 130  55 12 11,a  53 11 11 
PAI-1 (AU/ml) < 15  55 6 3  53 2 2 
PFA-ADP < 110  43 8 9  40 8 9 
PFA-EPI < 160  42 4 4  34 3 6 
PTT, partial thromboplastin time; PAI-1, plasminogen activator inhibitor-1 activity; PFA-ADP, platelet 
function analysis with adenosine diphosphate; PFA-EPI, platelet function analysis with epinephrine. 
†  Reference range as specified from the clinical chemistry laboratories of the University of Munich   
   hospital. 
*  Some samples are missing because of technical problems during the measurements or coagulation    
   of the blood samples. 
1   p < 0.05 vs. week 0; a  p < 0.05 vs. placebo at the same time point. 
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3.1.10  Full blood cell count and biochemical parameters 
Parameters of haematology and blood chemistry were not different between the two 
groups at week 0 and week 8 with the exception of bilirubin levels at baseline, which 
were slightly, but significantly higher in the DHA than in the placebo group (0.7 vs. 
0.6 mg/dl, medians) (Table  8.15).  
Small changes from baseline within the normal ranges were observed in uric acid, 
total protein, leucocytes, haemoglobin and MCH with no significant group differences. 
ALT levels increased from 13.0 to 16.0 U/l (medians) and CHE levels decreased from 
7.5 to 7.2 kU/l (medians) with DHA supplementation; changes from baseline were 
significantly different between the two intervention groups. RBC count decreased in 
both groups compared to baseline, but reduction was significantly higher in the 
placebo group. The haematocrit value decreased with placebo treatment and 
changes from baseline were significantly different between the two groups. 
All observed changes in haematology and biochemical parameters were minor and 
within the normal ranges. Incidence of liver and cardiac enzymes out of the 
laboratory’s reference range did not differ neither at baseline nor at week 8 between 
DHA and placebo groups; within-group incidences did not differ between baseline 
and week 8 (Table  3.11).  
 
 
Table  3.11. Liver and cardiac enzymes out of laboratory’s reference range, DHAVEG study (number). 
   DHA  Placebo 
 Reference range†              
(male / female) 
n* Week 0 Week 8  n* Week 0 Week 8 
GGT (U/l) < 55 / < 38  55 2 2  53 1 0 
ALT (U/l)  < 45 / < 35  55 1 2  53 0 1 
AST (U/l)  < 40 / < 33  55 0 1  53 2 2 
CHE (kU/l) 5.00 – 13.30  54 2 3  51 4 5 
CK (U/l) < 180 / < 155  55 4 5  53 5 8 
LDH (U/l) < 250  54 0 0  53 0 0 
GGT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CHE, cholinesterase; CK, creatinekinase; LDH, lactate dehydrogenase. 
†  Reference range as specified from the clinical chemistry laboratories of the University of Munich   
   hospital. 
*  Some samples are missing because of technical problems during the measurements. 
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3.1.11   Fatty acids in plasma and RBC 
Fatty acid composition of RBC and plasma lipids was not different between groups at 
baseline (with the exception of Σn-3 LCPUFA in plasma PL) and changed negligibly 
in the placebo group (Table  8.16 - Table  8.19). After DHA supplementation, no 
changes or little increases were observed in saturated fatty acids 16:0 and 18:0. 
Microalgae oil supplementation resulted in significant increases of n-6 DPA, EPA, 
and DHA levels and significant decreases of 18:1n-9, 20:3n-9, 18:2n-6, 18:3n-6, 
20:3n-6, AA, 22:4n-6 and n-3 DPA levels in all measured fractions relative to baseline 
values (Figure  3.5).  
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Figure  3.5. Relative changes of selected fatty acids in RBC total lipids, RBC PE, RBC PC and plasma 
PL in the DHA group compared to baseline values, DHAVEG study (n = 52 in RBC total lipids, 
otherwise n = 55).  
Values were calculated as individual’s percent change in each lipid fraction and are reported as mean 
+/- SD. 
PA, 16:0; OA, 18:1n-9; LA, 18:2n-6; ALA, 18:3n-3; AA, 20:4n-6; DPA n-6, 22:5n-6; DPA n-3, 22:5n-3; 
EPA, 20:5n-3; DHA, 22:6n-3. 
 
 
Relative to placebo, DHA supplementation resulted in significantly higher contents of 
16:0 (not significant in RBC PC), n-6 DPA, EPA (not significant in RBC PE) and DHA, 
and lower contents of 18:1n-9 (not significant in RBC PE), 20:3n-9, 18:2n-6, 18:3n-6, 
20:3n-6, AA, 22:4n-6, 18:3n-3 (not significant in plasma PL and RBC PC) and n-3 
DPA. After DHA supplementation, the highest relative fatty acid changes were 
observed in DHA, n-6 DPA, and EPA in all measured lipid classes (Figure  3.5). The 
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degree of these changes was different in the various lipid classes with higher 
percentage changes in RBC PC and plasma PL than in RBC total lipids and RBC PE 
for DHA, n-6 DPA and EPA. 
The sums of n-6 FA and n-6 LCPUFA decreased and Σn-3 FA and Σn-3 LCPUFA 
increased significantly compared to baseline values in all measured plasma and RBC 
lipids after 8 weeks of DHA supplementation resulting in remarkable decreases of Σn-
6/Σn-3 FA and Σn-6/Σn-3 LCPUFA ratios. At week 8, Σn-6 FA, Σn-6 LCPUFA as well 
as the ratios of Σn-6/Σn-3 FA and Σn-6/Σn-3 LCPUFA were significantly lower and 
Σn-3 FA and Σn-3 LCPUFA were significantly higher in the DHA than in the placebo 
group. 
Statistically significant increases in EPA + DHA levels versus baseline values were 
observed after 8 weeks of microalgae oil supplementation in all investigated lipid 
fractions. The omega-3 index rose significantly from 4.8 ± 1.2 wt% to 8.4 ± 1.3 wt% 
(mean ± SD) in the DHA supplemented group, ranging after 8 weeks from 4.7 wt% to 
11.0 wt%. Relative to placebo application, supplementation with DHA-rich microalgae 
oil resulted in significantly higher contents of EPA + DHA in all tested lipid fractions. 
At baseline, 29% of the DHA group and 33% of the placebo group volunteers had an 
omega-3 index ≤ 4% and no one reached a desirable omega-3 index ≥ 8% (Figure 
 3.6). After 8 weeks of intervention, an omega-3 index ≤ 4% did not occur anymore in 
the DHA group but remained in 39% of the placebo group subjects (p < 0.001). 69% 
of the DHA supplemented subjects had an omega-3 index ≥ 8%, while no subject of 
the placebo group showed an omega-3 index above 8% (p < 0.001). 
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Figure  3.6. Omega-3 index (%) at week 0 and week 8, DHAVEG study 
(Placebo: n = 51; Microalgae oil: n = 52). 
 
 
 
3.1.12   Correlations between relative fatty acid concentrations 
Spearman-Rho correlation coefficients were computed between the relative fatty acid 
levels in RBC total lipids and fatty acid proportions in RBC PE, RBC PC, and plasma 
PL for all subjects (Table  8.20). Relative fatty acid content of selected fatty acids in 
RBC total lipids correlated significantly with the corresponding fatty acid content in 
the other lipid classes (plasma PL, RBC PC and RBC PE) (r always > 0.49). RBC 
total lipid DHA and RBC total lipid EPA + DHA consistently showed the strongest 
correlations with the other lipid fractions at both time points (r always ≥ 0.90). 
At baseline, correlation coefficients between omega-3 index and EPA + DHA from 
RBC PE, RBC PC and plasma PL were almost identical in DHA and placebo groups 
(Figure  8.2). After the intervention, correlation coefficients remained similar to 
baseline in the placebo group, but became lower in the DHA group.  
The correlations between EPA + DHA levels at week 0 and those at week 8 were 
lower in the DHA than in the placebo group in all tested lipid fractions (in the placebo 
group r = 0.841 - 0.970; in the DHA group r = 0.464 - 0.856, p always < 0.001). 
 
→ > 8% 
↑ > 8% 
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3.1.13 Correlations between percentage fatty acid changes 
In the DHA group, Spearman-Rho correlations were computed between relative fatty 
acid changes from baseline values in RBC total lipid / plasma PL and percentage 
changes in the other lipid fractions for LA, AA, n-6 DPA, ALA, EPA, n-3 DPA, DHA, 
and EPA + DHA (Table  8.21). Relative changes in RBC total lipid n-6 and n-3 fatty 
acids correlated significantly and positively with changes in the other lipid classes (r 
always > 0.48); here, the correlations were highest for n-6 DPA, EPA, DHA, and EPA 
+ DHA (r always > 0.75). Relative changes in RBC PE correlated better with RBC 
total lipid than with plasma PL changes for all tested fatty acids. Relative changes in 
plasma PL correlated best with changes in RBC PC for all tested n-6 and n-3 fatty 
acids with exception of ALA. 
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3.2 FO/EPO study 
3.2.1 Method for fatty acid analysis 
Reproducibility. The GC method ( 2.1.4.5) enabled the separation and identification 
of the in  3.1.1 described fatty acids. The used method for determination of fatty acids 
in plasma total lipids and lipid fractions showed good intra-assay and inter-assay 
reproducibilities. Table  3.12 and Table  3.13 describe the determined coefficients of 
variation for selected n-6 and n-3 fatty acids (for complete intra-assay and inter-assay 
CV see Table  8.7 - Table  8.10). 
 
 
Table  3.12. Intra-assay CV (%) of fatty acid analyses, FO/EPO study. 
 Plasma PL                          
(n = 8) 
Plasma CE              
(n = 8) 
Plasma TG          
(n = 8) 
Plasma TL            
(n = 8) 
 mg/l* wt%†  mg/l* wt%†  mg/l* wt%†  mg/l* wt%† 
n-6 fatty acids            
18:2n-6 0.70 0.35  1.22 0.08  1.38 0.28  1.31 0.98 
18:3n-6 2.46 2.78  1.17 0.33  1.88 1.24  1.85 1.55 
20:3n-6 0.74 0.69  1.49 0.41  1.37 0.74  2.06 1.76 
20:4n-6 1.21 1.12  1.37 0.38  1.35 0.22  1.43 0.90 
22:4n-6 0.88 1.15  n.d. n.d.  3.29 2.36  1.97 1.50 
22:5n-6 1.49 1.44  6.37 5.57  2.20 1.24  2.04 1.86 
n-3 fatty acids            
18:3n-3 0.96 1.15  1.54 0.58  1.76 1.16  1.17 0.98 
20:5n-3 1.27 1.71  1.56 0.62  3.16 2.90  1.71 1.09 
22:5n-3 1.39 1.76  n.d. n.d.  2.06 2.02  2.16 1.84 
22:6n-3 1.62 1.85  2.21 0.46  1.82 1.44  2.21 1.90 
n.d., not detected, PL, phospholipids; CE, cholesterol esters; TG, triglycerides; TL, total lipids. 
*  CV absolute fatty acid concentration (mg/l). 
†  CV relative fatty acid composition (wt%). 
 
 
Intra-assay CV were < 4% for the described n-3 and n-6 fatty acids (mg/l and wt%) 
with the exception of 22:5n-6 in plasma CE (CV < 7%), but this fatty acid accounted 
only for a minor proportion of total fatty acids in plasma CE (0.05 wt%, mean). Inter-
assay CV for the described n-3 and n-6 fatty acids were < 5% in plasma PL and <6% 
in plasma CE, TG and TL (exception: 22:5n-6 in plasma CE with an inter-assay CV 
<10%). 
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Table  3.13. Inter-assay CV (%) of fatty acid analyses, FO/EPO study. 
 Plasma PL                          
(n = 11) 
Plasma CE              
(n = 10) 
Plasma TG          
(n = 10) 
Plasma TL            
(n = 10) 
 mg/l* wt%†  mg/l* wt%†  mg/l* wt%†  mg/l* wt%† 
n-6 fatty acids            
18:2n-6 3.22 0.71  3.37 0.43  2.87 0.45  3.35 1.22 
18:3n-6 4.55 2.85  3.53 2.23  3.47 2.38  3.55 1.96 
20:3n-6 3.52 1.29  4.90 2.88  4.88 3.38  4.06 3.12 
20:4n-6 3.80 1.53  3.97 1.37  4.07 2.56  3.32 1.68 
22:4n-6 4.36 2.52  n.d. n.d.  5.30 4.44  4.48 3.06 
22:5n-6 3.39 2.26  9.26 7.58  5.37 4.01  5.23 4.67 
n-3 fatty acids            
18:3n-3 4.07 2.50  3.88 1.45  2.84 2.92  3.16 0.88 
20:5n-3 3.92 1.73  5.18 4.18  4.14 3.70  3.85 2.81 
22:5n-3 4.86 2.81  n.d. n.d.  5.23 4.06  4.24 3.29 
22:6n-3 4.91 2.97  5.66 4.42  5.13 3.91  3.81 2.57 
n.d., not detected, PL, phospholipids; CE, cholesterol esters; TG, triglycerides; TL, total lipids. 
*  CV absolute fatty acid concentration (mg/l). 
†  CV relative fatty acid composition (wt%). 
 
 
3.2.2 Subjects 
Forty free-living, apparently healthy, non-pregnant women aged 19 to 36 years were 
included in the study and randomly assigned to one of the intervention groups. There 
were no significant differences in subject characteristics between the two intervention 
groups at study entry (Table  3.14).  
 
 
Table  3.14. Baseline characteristics of the subjects, FO/EPO study (mean ± SD). 
 FO/EPO (n = 20)  Placebo (n = 20)  P† 
Age (years) 24.6 ± 4.2  24.8 ± 2.9  0.863 
BMI (kg/m2) 21.8 ± 1.9  21.9 ± 2.0  0.823 
Blood pressure (mm Hg) 
   Systolic 
   Diastolic 
 
118 ± 13 
74 ± 7 
  
119 ± 11 
73 ± 8 
  
0.743 
0.741 
Heart rate (beats/min) 76 ± 13  74 ± 14  0.767 
Non-smokers (%) 90  70  0.235 
Use of oral contraceptives (%) 60  60  1.000 
†  Analyses of group differences. 
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One subject from the FO/EPO group dropped out during the first 4 weeks of the 
intervention period, because she came down with an abdominal influenza and could 
not take the capsules for more than 7 days. Thus, 39 subjects (97.5%) were included 
in the statistical analysis. 
 
3.2.3 Compliance, side effects and success of blinding 
Compliance as judged by capsule count was 98% (mean) for both groups with no 
significant group difference (Table  3.15).  
 
Table  3.15. Compliance, FO/EPO study (% of prescribed capsules taken).* 
 FO/EPO                                     
(n = 19)  
Placebo                              
(n = 20)  
Mean ± SD (%) 98 ± 2 98 ± 3 
Median with IQR (%) 99 (98 – 100) 99 (97 – 99) 
100% compliance (number and %) 5 (26%) 3 (15%) 
IQR, interquartile range. 
*  No difference in compliance was observed between FO/EPO and placebo groups (p = 0.533). 
 
 
Three subjects from each group reported mild adverse effects including 
gastrointestinal upsets (indigestion, belching), minor skin reactions (acne) and 
prolonged bleeding time (Table  3.16). Side effects were evenly distributed between 
FO/EPO and placebo groups. Group assignment was guessed correctly in the 
FO/EPO group by 63% and in the placebo group by 50% of the subjects with no 
significant group difference (p = 0.523). 
 
Table  3.16. Reported side effects, FO/EPO study (number).* 
 FO/EPO                     
(n = 19) 
Placebo                  
(n = 20) 
Total side effects 3 3 
     Skin reactions 1 1 
     Prolonged bleeding  
     time 
- 1 
     Indigestion 1 - 
     Diarrhoea - 1 
     Belching 1 - 
*  Side effects were evenly distributed between FO/EPO and  
    placebo groups (p > 0.05). 
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3.2.4 BMI, blood pressure and heart rate 
Body weight, BMI, blood pressure and heart rate did not differ between FO/EPO and 
placebo groups at week 0 and week 8 and absolute changes from baseline after 8 
weeks of intervention were not significantly different between the two groups (Table 
 8.22). The diastolic blood pressure decreased slightly after 8 weeks of FO/EPO 
supplementation compared to baseline (p = 0.046), but changes from baseline were 
not significantly different between the groups. 
 
3.2.5 Full blood cell count and liver enzymes 
Liver enzymes and haematological parameters did not differ between FO/EPO and 
placebo groups at week 0 and week 8 with the exception of platelet counts at both 
time points (p < 0.05) and cholinesterase (CHE) levels at baseline (trend: p = 0.053, 
Table  8.23). Small changes from baseline within the normal ranges were observed in 
MCV and MCHC with no significant group differences. CHE levels were significantly 
increased after 8 weeks of placebo intervention and changes from baseline were 
significantly different between the two groups. The haematocrit value decreased with 
FO/EPO supplementation compared to baseline and changes from baseline were 
significantly different between FO/EPO and placebo groups. Changes from baseline 
in haemoglobin levels showed a greater reduction with FO/EPO treatment compared 
to placebo.  
All observed changes in haematology and liver enzymes were minor and within the 
normal ranges. Incidence of liver enzymes and haematological parameters out of the 
laboratory’s reference range did not differ neither at baseline nor at week 8 between 
FO/EPO and placebo groups; within-group incidences did not differ between baseline 
and week 8 (Table  3.17). 
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Table  3.17. Liver enzymes and haematological parameters out of reference range, FO/EPO study 
(number). 
   FO/EPO (n = 19)  Placebo (n = 20) 
 Reference range*  Week 0 Week 8  Week 0 Week 8 
GGT (U/l) < 38  0 0  0 0 
ALT (U/l) < 35  2 1  1 0 
AST (U/l) < 33  0 1  2 0 
CHE (kU/l) 5.0 - 13.3  3 3  7 5 
Blood cell count        
     Leucocytes (G/l) 4.0 - 11.0  0 0  0 0 
     Erythrocytes (T/l) 4.1 - 5.1  1 2  1 1 
     Haemoglobin (g/dl) 12.0 - 15.5  1 0  0 1 
     Haematocrit (%) 36.0 - 46.0  1 0  0 1 
     MCV (fl) 80.0 - 96.0  1 3  2 2 
     MCH (pg) 28.0 - 33.0  2 3  0 1 
     MCHC (%) 32.0 - 36.0  3 0  1 2 
     Platelets (G/l) 150 - 400  0 1  0 1 
GGT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; CHE, cholinesterase; MCV, mean cellular volume; MCH, mean cellular haemoglobin; MCHC, 
mean cellular haemoglobin concentration; G = Giga, 109; T = Tera, 1012. 
*  Reference range as specified from the clinical chemistry laboratories of the University of Munich   
   hospital. 
 
 
3.2.6 Relative fatty acid composition 
The GLM could not be performed for the following fatty acids, sums and ratios, 
because the data could not successfully be transformed into a normal distribution: 
EPA in TL and PL, DHA in PL and TG, Σn-6 FA in PL, Σn-3 FA in CE, Σn-6 LCPUFA 
in PL, and Σn-6/Σn-3 LCPUFA in TL (Table  3.18). 
The GLM for repeated measures (weeks 4, 6, and 8) corrected for fatty acid 
percentages at baseline (week 0) revealed significant increasing effects of FO/EPO 
treatment compared to placebo on the following fatty acids, sums and ratios: GLA, 
DGLA, AA (in plasma TG), adrenic acid (in plasma TG), EPA, DHA, GLA + DGLA, 
Σn-3 FA, Σn-6 LCPUFA, and Σn-3 LCPUFA (Table  3.18, ↑). 
The GLM for repeated measures corrected for fatty acid percentages at baseline 
indicated significant decreasing effects of FO/EPO treatment compared to placebo on 
the following fatty acids, sums and ratios: Mead acid (MA), LA (in plasma PL), 
adrenic acid (in plasma PL), n-6 DPA (in plasma TL, PL, and CE), ALA, n-3 DPA (in 
plasma PL), Σn-6/Σn-3 FA, and Σn-6/Σn-3 LCPUFA (↓). 
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The GLM for repeated measures indicated no different effects of FO/EPO and 
placebo treatment on LA (in plasma TL, CE, and TG), AA (in plasma TL, PL, and 
CE), adrenic acid (plasma TL), n-6 DPA (in plasma TG), n-3 DPA (in plasma TL and 
TG), and Σn-6 FA. 
 
Table  3.18. Effects of treatment on fatty acid proportions, sums, and ratios, FO/EPO study.* 
 Total lipids Phospholipids Cholesterol esters Triglycerides 
20:3n-9  ↓ ↓ ↓ ↓ 
18:2n-6 = ↓ = = 
18:3n-6  ↑ ↑ ↑ ↑ 
20:3n-6 ↑ ↑ ↑ ↑ 
20:4n-6  = = = ↑ 
22:4n-6 = ↓ n.d. ↑ 
22:5n-6 ↓ ↓ ↓ = 
18:3n-3 ↓ ↓ ↓ ↓ 
20:5n-3 NN NN ↑ ↑ 
22:5n-3 = ↓ n.d. = 
22:6n-3 ↑ NN ↑ NN 
GLA + DGLA ↑ ↑ ↑ ↑ 
∑n-6 FA = NN = = 
∑n-3 FA ↑ ↑ NN ↑ 
∑n-6 LCPUFA ↑ NN ↑ ↑ 
∑n-3 LCPUFA ↑ ↑ ↑ ↑ 
∑n-6/∑n-3 FA ↓ ↓ ↓ ↓ 
∑n-6/∑n-3 LCPUFA NN ↓ ↓ ↓ 
GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; ∑n-6 FA, sum of n-6 fatty acids; ∑n-
3 FA, sum of n-3 fatty acids; ∑n-6 LCPUFA, sum of all long-chain n-6 fatty acids; ∑n-3 LCPUFA, sum 
of all long-chain n-3 LCPUFA; ∑n-6/∑n-3 FA, ratio of n-6 to n-3 fatty acids; ∑n-6/∑n-3 LCPUFA, ratio 
of n-6 to n-3 long-chain polyunsaturated fatty acids; n.d., not detected; NN, non-normally distributed 
(no GLM could be performed); ↓, decrease compared to placebo; ↑, increase compared to placebo; =, 
same effect as placebo. 
*  Indicated by GLM. 
 
 
The effects of treatment were further described by comparing data from weeks 4, 6, 
and 8 with baseline data within each group and by determining differences among 
treatment groups at each time point (Table  8.24 - Table  8.31 and Figure  8.3 - Figure 
 8.7). The obtained significances are summarised for fatty acids of main interest in 
Table  3.19. 
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Table  3.19. Plasma fatty acids (wt%): differences from baseline at weeks 4, 6, and 8 within each 
group or differences between treatments at the same time point, FO/EPO study. 
  FO/EPO  Placebo  FO/EPO 
  versus baseline  versus baseline  versus placebo 
  Week 4 Week 6 Week 8  Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
GLA TL ↑ ↑ ↑  ns ns ns  ns aaa aa aaa 
 PL ↑ ns ↑  ns ns ns  ns aaa ns aaa 
 CE ↑ ↑ ↑  ns ns ns  ns aaa aa aaa 
 TG ↑ ↑ ↑  ns ns ns  ns aaa a a 
              
DGLA  TL ↑ ↑ ↑  ns ns ns  a aa aa aaa 
 PL ↑ ↑ ↑  ns ns ns  a aa aa aaa 
 CE ↑ ↑ ↑  ns ns ns  a aa aa aaa 
 TG ↑ ↑ ↑  ns ns ns  ns aaa aaa aaa 
              
AA TL ns ns ns  ns ↓ ↓  ns ns ns ns 
 PL ns ns ns  ns ↓ ↓  ns ns ns ns 
 CE ns ns ns  ns ns ns  ns ns ns ns 
 TG ↑ ns ns  ns ns ns  a ns ns ns 
              
EPA TL ↑ ↑ ↑  ns ns ↑  ns aa aa a 
 PL ↑ ↑ ↑  ns ns ns  ns aa aa a 
 CE ns ns ns  ns ns ↑  a aa aaa a 
 TG ↑ ↑ ↑  ns ns ns  ns aa aa aa 
              
DHA TL ↑ ↑ ↑  ns ns ns  ns aaa aaa aaa 
 PL ↑ ↑ ↑  ns ns ns  ns aaa aaa aaa 
 CE ↑ ↑ ↑  ns ns ns  ns aaa aaa aaa 
 TG ↑ ↑ ↑  ns ns ns  ns aaa aaa aaa 
AA, arachidonic acid; CE, cholesterol ester; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; GLA, gamma-linolenic acid; ns, non-significant; PL, phospholipids, TG, triglycerides; TL, total lipids. 
↑   Significantly higher than baseline value (Bonferroni-Holm adjusted significances).   
↓   Significantly lower than baseline value (Bonferroni-Holm adjusted significances). 
a, aa and aaa   Higher than placebo value at the same time point with significances p < 0.05, p < 0.01 and p < 0.001,    
                         respectively. 
 
3.2.6.1 Plasma total lipids 
Baseline values of DGLA, ALA, Σn-3 FA, and Σn-6/Σn-3 FA were significantly 
different between FO/EPO and placebo groups; the other fatty acids, sums and ratios 
of interest differed not significantly between the two groups at study entry (Table 
 3.19, Table  8.24, Table  8.25, and Figure  8.3 - Figure  8.7).  
Most investigated fatty acids, their sums and ratios in plasma TL were not 
significantly affected by placebo treatment. Exceptions were ALA, EPA, AA, adrenic 
acid, n-6 DPA, Σn-6 LCPUFA, and Σn-6/Σn-3 LCPUFA, which were significantly 
higher (ALA, EPA) or lower (AA, adrenic acid, n-6 DPA, Σn-6 LCPUFA, Σn-6/Σn-3 
LCPUFA) at week 4, 6, and/or 8 than at baseline.  
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In the FO/EPO group, the following fatty acids, sums and ratios decreased 
significantly during intervention (week 4, 6 and/or 8) compared to baseline: Mead 
acid, adrenic acid, n-6 DPA, ALA as well as the ratios Σn-6/Σn-3 FA and Σn-6/Σn-3 
LCPUFA. Significant increases compared to baseline were observed for GLA, DGLA, 
EPA, DHA, GLA + DGLA, Σn-3 FA, and Σn-3 LCPUFA throughout FO/EPO 
supplementation. The sum of all n-6 LCPUFA was not affected by FO/EPO intake. 
Proportions of GLA, DGLA, EPA, DHA, GLA + DGLA, Σn-3 FA, and Σn-3 LCPUFA 
were significantly higher at weeks 4, 6, and 8 in the FO/EPO than in the placebo 
group. Mead acid, adrenic acid (only at week 6) as well as the ratios of Σn-6/Σn-3 FA 
and Σn-6/Σn-3 LCPUFA were significantly lower throughout intervention period with 
FO/EPO than with placebo supplementation. 
 
3.2.6.2 Plasma phospholipids 
Baseline values of DGLA, ALA, and GLA + DGLA were significantly higher in the 
FO/EPO than in the placebo group; the other fatty acids, sums and ratios of interest 
differed not significantly between the two groups at study entry (Table  3.19, Table 
 8.26, Table  8.27, and Figure  8.3 - Figure  8.7).  
Most investigated fatty acids, their sums and ratios in plasma PL were not 
significantly affected by placebo treatment. Exceptions were AA, adrenic acid, n-6 
DPA, and Σn-6 LCPUFA, which were significantly lower at weeks 4, 6, and/or 8 
compared to baseline values.  
In the FO/EPO group, the following fatty acids, sums and ratios were significantly 
lower at ≥ 1 time point during intervention compared to baseline: Mead acid, adrenic 
acid, n-6 DPA, ALA, n-3 DPA, Σn-6 FA as well as the ratios Σn-6/Σn-3 FA and Σn-
6/Σn-3 LCPUFA. Increases compared to baseline were observed for GLA (not 
significant at week 6), DGLA, EPA, DHA, GLA + DGLA, Σn-3 FA, and Σn-3 LCPUFA 
throughout FO/EPO supplementation. The sum of all n-6 LCPUFA was not affected 
by FO/EPO intake. 
The proportions of GLA (not significant at week 6), DGLA, EPA, DHA, GLA + DGLA, 
Σn-3 FA, and Σn-3 LCPUFA were significantly higher at weeks 4, 6, and 8 in the 
FO/EPO than in the placebo group. With FO/EPO treatment, Mead acid, LA, adrenic 
acid, n-6 DPA, ALA, Σn-6 FA as well as the ratios Σn-6/Σn-3 FA and Σn-6/Σn-3 
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LCPUFA were significantly lower at ≥ 1 time point of the intervention period 
compared to placebo. 
 
3.2.6.3 Plasma cholesterol esters 
Baseline values of DGLA, ALA, EPA, Σn-3 FA, Σn-3 LCPUFA, and Σn-6/Σn-3 FA 
were significantly different between FO/EPO and placebo groups; the other fatty 
acids, sums and ratios of interest differed not significantly between the two groups at 
study entry (Table  3.19, Table  8.28, Table  8.29, and Figure  8.3 - Figure  8.7).  
Most investigated fatty acids, their sums and ratios in plasma CE were not 
significantly affected by placebo treatment; exceptions were n-6 DPA, EPA, and Σn-
6/Σn-3 LCPUFA, which were significantly higher (EPA) or lower (n-6 DPA, Σn-6/Σn-3 
LCPUFA) at week 8 than at baseline.  
In the FO/EPO group, the following fatty acids, sums and ratios were significantly 
lower at ≥ 1 time point during intervention compared to baseline: Mead acid, n-6 
DPA, ALA as well as the ratios Σn-6/Σn-3 FA and Σn-6/Σn-3 LCPUFA. Significant 
increases compared to baseline were observed for GLA, DGLA, DHA, GLA + DGLA, 
Σn-3 FA, and Σn-3 LCPUFA throughout FO/EPO supplementation. The sum of all n-6 
LCPUFA was not affected by FO/EPO intake. 
The proportions of GLA, DGLA, EPA, DHA, GLA + DGLA, Σn-3 FA, and Σn-3 
LCPUFA were significantly higher at weeks 4, 6, and 8 in the FO/EPO than in the 
placebo group. With FO/EPO treatment, the ratios Σn-6/Σn-3 FA and Σn-6/Σn-3 
LCPUFA were significantly lower throughout intervention compared to placebo. 
 
3.2.6.4 Plasma triglycerides 
Baseline values of ALA, Σn-3 FA, Σn-3 LCPUFA and Σn-6/Σn-3 FA were significantly 
different between FO/EPO and placebo groups; the other fatty acids, sums and ratios 
of interest differed not significantly between the two groups at study entry (Table 
 8.30, Table  8.31, and Figure  8.3 - Figure  8.7).  
Most investigated fatty acids, their sums and ratios in plasma TG were not 
significantly affected by placebo treatment; exceptions were ALA levels, Σn-3 FA, Σn-
6/Σn-3 FA, Σn-6/Σn-3 LCPUFA, which were significantly higher (ALA, Σn-3 FA) or 
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lower (Σn-6/Σn-3 FA, Σn-6/Σn-3 LCPUFA) at ≥ 1 time points during intervention 
compared to baseline.  
In the FO/EPO group, the following fatty acids and ratios were significantly lower 
throughout intervention compared to baseline: Mead acid as well as the ratios Σn-
6/Σn-3 FA and Σn-6/Σn-3 LCPUFA. Significant increases compared to baseline were 
observed for LA, GLA, DGLA, AA, EPA, DHA, GLA + DGLA, Σn-6 FA, Σn-3 FA, and 
Σn-3 LCPUFA at ≥ 1 time points of FO/EPO supplementation (Table  3.19). The sum 
of all n-6 LCPUFA was not affected by FO/EPO intake. 
The proportions of GLA, DGLA, AA, EPA, n-3 DPA, DHA, GLA + DGLA, Σn-3 FA, Σn-
6 LCPUFA, and Σn-3 LCPUFA were significantly higher at ≥ 1 time point during 
intervention in the FO/EPO than in the placebo group. With FO/EPO treatment, Mead 
acid (only significant at week 6) as well as the ratios Σn-6/Σn-3 FA and Σn-6/Σn-3 
LCPUFA were significantly lower during intervention compared to placebo. 
 
3.2.7 Relative changes in fatty acid composition 
Relative changes from baseline in GLA, DGLA, AA, EPA, and DHA levels (wt%/wt%) 
are shown in Figure  8.8 - Figure  8.12. For GLA, percentage changes from baseline 
were significantly different between FO/EPO and placebo groups at weeks 4 and 8 in 
all investigated plasma lipid domains and additionally at week 6 in plasma TG (Figure 
 8.8). In the placebo group, GLA changes from baseline at weeks 4, 6, and 8 were 
between -25.7% and 6.6% in all lipid domains (medians). With FO/EPO 
supplementation, GLA increased in plasma TL by 34.6 – 63.0%, in PL by 16.5 – 
42.5%, in CE by 25.8 – 56.8%, and in TG by 27.4 – 49.7%.  
For DGLA, percentage changes from baseline were significantly different between 
the two intervention groups at week 8 in plasma PL and at weeks 4, 6 (in TL: p = 
0.050), and 8 in plasma TL, CE, and TG (Figure  8.9). The proportion of DGLA 
changed negligible with placebo treatment: median changes were between –7.1% 
and 3.8% in all investigated lipid domains. FO/EPO supplementation increased 
DGLA in plasma TL by 9.5 – 13.3%, in plasma PL by 12.2 – 14.8%, in plasma CE by 
14.0 – 19.9%, and in plasma TG by 29.3 – 33.3%.  
AA changes from baseline at weeks 4, 6, and 8 did not differ between FO/EPO and 
placebo groups in plasma TL, PL, and CE (median changes were between -8.7% 
and 5.9%), but were higher in plasma TG at all time points with FO/EPO 
supplementation than with placebo (Figure  8.10). The active treatment increased AA 
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in plasma TG by 14.8 – 17.3%, whereas median changes were between –7.6% and 
–5.0% with placebo intake.  
Percentage changes from baseline in EPA levels were not significantly different 
between the two groups at weeks 4, 6 or 8 (Figure  8.11). EPA levels increased in 
plasma TL by 5.9 – 21.6% with placebo and by 32.7 – 44.7% with FO/EPO 
supplementation. In plasma PL, median increases were between 5.6 – 23.7% with 
placebo and between 30.3 – 38.3% with FO/EPO treatment. Placebo 
supplementation increased EPA in plasma CE by 7.5 – 21.8% as it did FO/EPO 
treatment by 28.6 – 42.9%. In plasma TG, median EPA increases were 15.2 - 29.4% 
with placebo and 47.0 – 60.7% with the active treatment.  
DHA changes from baseline were significantly higher throughout intervention in the 
FO/EPO than in the placebo group (Figure  8.12). Placebo treatment changed DHA 
levels in plasma TL, PL, and CE by –2.2 to 4.0%, and in plasma TG by 16.8 – 25.2%. 
FO/EPO increased DHA levels in plasma TL by 57.3 – 66.2%, in plasma PL by 45.5 
– 60.3%, in plasma CE by 52.4 – 67.0%, and in plasma TG by 130.8 – 155.8%. 
 
3.2.8 Correlations between relative fatty acid concentrations 
Spearman-Rho correlation coefficients were computed for all subjects (n = 39/40) 
between relative fatty acid levels (wt%) of the various lipid domains. Proportions of 
LA, GLA, ALA, DGLA, AA, EPA, and DHA were significantly correlated between TL, 
CE, PL, and TG, with the exception of LA levels in plasma TG at week 4, which were 
not correlated with LA in TL, PL, or CE (Table  8.32).  
The proportions of LA correlated strongly between TL, CE, and PL at all time points (r 
≥ 0.785). GLA levels showed the strongest correlations between TL and CE (r ≥ 
0.936 at all time points). Correlation coefficients for ALA were ≥ 0.760 between TL – 
CE, TL – PL, TL - TG, and CE - PL. Proportions of DGLA were in general highly 
correlated between TL – CE (r ≥ 0.887), TL – PL (r ≥ 0.954), and CE – PL (r ≥ 0.860). 
AA levels showed strong correlations between TL – CE (r ≥ 0.857), TL – PL (r ≥ 
0.875), and CE – PL (r ≥ 0.839). Correlation coefficients between EPA levels in TL, 
CE or PL were ≥ 0.887 at all time points. The proportions of DHA were highly 
correlated between TL – CE (r ≥ 0.921), TL – PL (r ≥ 0.951), and CE – PL (r ≥ 0.927) 
at all time points. 
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3.2.9 Correlations between percentage fatty acid changes 
Spearman-Rho correlations for the percentage fatty acid changes from baseline 
(wt%/wt%) during FO/EPO supplementation in plasma TL and lipid fractions are 
given in Table  8.33. Percentage fatty acid changes from baseline (calculated for 
GLA, DGLA, AA, EPA, and DHA) at weeks 4, 6, and 8 were significantly correlated 
between TL – CE, TL – PL, and CE - PL. The correlations with fatty acid changes in 
plasma TG were in general not as strong as between the other lipid fractions or not 
significant. Correlations for DGLA, AA, and DHA percentage changes were highest 
between plasma TL and PL (r > 0.81), whereas GLA changes correlated best 
between TL and CE (r > 0.87). Correlation coefficients for EPA changes were 
comparable high between TL – CE and TL – PL (r > 0.87 and r > 0.88 respectively).  
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4 Discussion 
4.1 Method development 
4.1.1 Fatty acids in RBC total lipids 
The described method enabled the analysis of relative concentrations of fatty acids in 
RBC total lipids with satisfactory reproducibility. Even though each lipid fraction 
revealed a distinct and characteristic fatty acid pattern, RBC total lipid fatty acids 
were significantly correlated with fatty acids from RBC PC, RBC PE, and plasma PL. 
In agreement, also Vlaardingerbroek et al. [119] and Harris & von Schacky [33] 
reported strong correlations between RBC and plasma PL LCPUFA. In contrast, a 
study by Leichsenring et al. [120] did not find any relation of RBC DHA (PE, PC, and 
total lipids) values to DHA levels in plasma PL, which might be due to a greater 
heterogeneity of their subjects with respect to age and diet.  
After 8-week supplementation, correlation coefficients between omega-3 index and 
RBC PE, RBC PC, and plasma PL EPA + DHA were higher in the placebo than in the 
DHA group. Furthermore, correlations between omega-3 index from weeks 0 and 8 
were stronger for the placebo group. These findings may indicate that EPA + DHA 
contents in plasma and RBC lipid fractions are not in a steady state after 8 weeks of 
DHA supplementation. Another explanation may be that there are individual 
differences in digestion of the supplemented fatty acids, their absorption, beta-
oxidation or preferential incorporation into the various lipid fractions. 
Our study shows that RBC total lipids are a good biomarker for dietary n-3 LCPUFA 
intake as they reflect increased DHA intake. Furthermore, the fatty acid composition 
and the relative fatty acid changes of RBC total lipids correlate well with that in other 
biomarkers of n-3 fatty acid intake (plasma phospholipids, RBC PC and PE), and the 
analytical procedure required for RBC total fatty acid analyses is less demanding 
than the analyses of fatty acids in isolated RBC lipid fractions. Thus, RBC total lipid 
fatty acid analyses can be used instead of RBC lipid fraction analyses for assessing 
PUFA status. 
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4.1.2 Vitamin A and E in plasma 
The used method enabled the analysis of absolute concentrations of retinol and 
alpha-tocopherol in plasma with good reproducibility. The performed recovery tests 
from added standard substances to plasma were satisfactory, but accuracy of alpha-
tocopherol determination was not acceptable for high levels (bias –13%). One reason 
for the bad accuracy of the method could be that the chosen internal standard 
substance retinyl acetate was not optimal: first, its retention time was so close to that 
of retinol that the peaks could not be completely separated with the mobile phase 
used (Figure  2.4), and furthermore, the extraction behaviour of retinyl acetate (a 
vitamin A analogue) might be comparable with that of retinol, but might rather differ 
from that of alpha-tocopherol. Other explanations might be that the used precipitation 
reagent was not optimal, so that vitamins were partly enclosed in the precipitate, or 
that there were imprecisions when preparing the standard dilutions for the calibration 
curve. 
To improve the method, we tried the synthetic vitamin E analogue tocol as an internal 
standard: its peak can be well separated from the tocopherols (Figure  4.1) and its 
extraction behaviour might be more comparable with that of alpha-tocopherol. To 
optimise the extraction procedure, we used ethanol/BHT (0.0625%) for protein 
precipitation: Göbel et al. [113] tested four precipitation reagents (ethanol, acid 
ethanol, isopropanol and acid isopropanol) for their suitability for increasing vitamin 
yields in pool plasma. While obtained retinol levels showed no differences, highest 
yields of tocopherol were achieved with ethanol used as precipitation reagent. 
Because Göbel et al. reported greater precision when three extraction steps were 
employed, we enhanced the number of extraction steps from two to three and placed 
additionally the tubes after centrifugation on ice to improve phase separation.  
We also changed the preparation of the standard curves: instead of doing a standard 
mixture (containing retinol and alpha-tocopherol) as stock standard and preparing 
from it 7 standard dilutions, we did separate stock standards for each vitamin (equals 
the highest standard of the standard curve). The advantages were as follows: two 
pipette steps and one drying step less per vitamin means less imprecision; 
furthermore, it was now possible to determine the exact concentrations of the two 
stock standards photometrically, and to use these stock standards (with known 
concentrations) directly for preparation of the other 6 standard dilutions.  
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The improved method for quantification of vitamin A and E in plasma showed good 
reproducibilities: intra-assay CV (n = 8) were 1.0% for retinol and 0.9% for alpha-
tocopherol; inter-assay CV (n = 7 during 3 weeks) were 1.5% for retinol and 1.4% for 
alpha-tocopherol. Recoveries from added standard substances to plasma (n = 4) 
were 96% for vitamin A and 102% for vitamin E. The accuracy of the vitamin A and E 
measurements was verified with lyophilised standard reference material 968c 
obtained from the US National Institute of Standards and Technology (level 1, n = 3). 
The results for retinol and alpha-tocopherol were in good agreement with the 
approved values (bias: +1% for retinol and +4% for alpha-tocopherol). 
 
 
 
Figure  4.1. Chromatogram of a standard mixture (containing retinol, tocopherols, and carotenes) with 
tocol as internal standard (IS) using UV-Vis detection, DHAVEG study. 
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4.2 DHAVEG study 
A daily intake of 1.05 g DHA (as triglyceride) from Ulkenia oil markedly increased the 
DHA content of plasma and RBC phospholipids. Previous studies reported a two to 
threefold increase of the DHA content of serum and platelet phospholipids after 
supplementation with 0.75 g, 1.50 g or 1.62 g DHA/d for 6 wk [44,57,121] and a rise 
of DHA levels in plasma PL by 76% and in RBC phosphoglycerides by 58% 
respectively, after 3 months of supplementation with 0.7 g DHA/d [56]. The observed 
increase in EPA in RBC and plasma lipids after DHA supplementation in our study 
appears to reflect retroconversion of DHA, as suggested also by other investigators 
[44,45,54,121]. We found a decrease in the n-6 LCPUFA 20:3n-6, 20:4n-6, and 
22:4n-6, accompanied by a decrease in n-3 DPA, consistent with other findings 
[44,45,57,121]. In contrast, n-3 DPA shows considerable enrichment in serum and 
platelet phospholipids when fish or seal oils (providing EPA, DHA and some n-3 
DPA) are fed [122,123]. Thus, dietary DHA and possibly also n-6 DPA appear to 
partially replace n-3 DPA in circulating and cellular phospholipids in human subjects. 
In contrast to other studies using DHA-rich oils from an algal source, which reported 
significant decreases in n-6 DPA [44,45,121], we observed an increase of n-6 DPA in 
plasma and RBC phospholipids, which is explained by the significant n-6 DPA 
content in the tested oil derived from microalgae Ulkenia sp. (9.7 wt% or 0.22 g/d). 
Sanders et al. [124] also reported an increase of n-6 DPA and DHA levels in plasma 
and RBC lipids after 4-week supplementation with an algal triglyceride providing 1.5 g 
DHA and 0.6 g n-6 DPA per day. 
The omega-3 index rose significantly from 4.8 ± 1.2 wt% to 8.4 ± 1.3 wt% (mean ± 
SD) in the DHA supplemented group. A similar increase (from 4.7 to 9.9 wt%, means) 
of the omega-3 index was reported by Harris & von Schacky [33] after EPA and DHA 
supplementation (1 g/d) for 5 months. At baseline, no one of our subjects reached a 
desirable omega-3 index ≥ 8 wt%, although more than 50% of the subjects reached 
or exceeded recommended intakes for ALA (0.5% of energy) and 26% had a dietary 
LA:ALA ratio below 5:1 as considered desirable [17]. These results suggest that the 
in vivo conversion of ALA to n-3 LCPUFA is not adequate to reach a desirable EPA + 
DHA status even with adequate ALA intake and low dietary LA:ALA ratio. Thus, a 
dietary intake of pre-formed n-3 LCPUFA seems to be necessary to enhance the 
omega-3 index. After 8-week supplementation with microalgae oil, 69% of the 
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subjects had an omega-3 index ≥ 8%, while no subject of the placebo group showed 
an omega-3 index above 8%. 
Relative changes of n-6 DPA, EPA and DHA were greater in plasma PL and RBC PC 
than in RBC total lipids or RBC PE, with strong correlations between RBC PC and 
plasma PL fatty acid changes. RBC PE and plasma PL fatty acid changes were less 
closely related. Plasma PL fatty acids change relatively fast and reflect dietary 
intakes over the past few days [125]. RBC PL are asymmetrically distributed between 
the outer and the inner layer of the membrane [126]: the major part of PE is located 
at the inner layer, whereas PC occurs predominantly on the outer layer and can 
exchange more easily with plasma lipids. Thus, PC reflects more directly the fatty 
acid composition of PL of the plasma [127], whereas the fatty acid composition of PE 
appears to be more independent from the plasma fatty acids and depends on 
selective incorporation of PUFA and LCPUFA into PE [128].  
Relative changes in RBC total lipid n-6 DPA, EPA and DHA were lower than their 
average changes in RBC PE and RBC PC, indicating that these fatty acids were 
preferentially incorporated into PE and PC, which comprise about 23% and 22% of 
total membrane lipids (modified from [129], calculated without cholesterol), but less in 
the other lipids of the RBC membrane like sphingomyeline, phosphatidylserine, 
glycolipids and other lipids, comprising about 23%, 9%, 4%, and 18% of total 
membrane lipids respectively. 
Dietary intake of EPA and DHA combined with the background diet was as expected 
very low in these vegetarian subjects (23 mg/d in both groups, median). The 
observed values are in agreement with a study by Conquer & Holub, who reported 
that vegetarians consume minimal EPA (< 5 mg/d) and varying amounts of DHA 
depending on egg consumption (< 33 mg/d) [20]. For comparison, the dietary intake 
of EPA and DHA combined in the German population has recently been estimated to 
be 141 mg/d among women and 186 mg/d among men (medians) [11]. Reported 
energy intake in the DHA group was significantly lower during intervention compared 
to baseline (7.7 MJ vs. 8.8 MJ, medians), but remained unchanged in the placebo 
group. We observed no changes in body weight over the 8-week study period in the 
DHA group, but a slight weight gain in the placebo group (+ 0.5 kg). An explanation 
for the reduced energy intake without weight loss in the DHA group and the weight 
gain without (recorded) increased energy intake in the placebo group could be that 
energy requirements decreased in both groups during the intervention period, e.g. 
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because of less physical activity related to seasonal influences. The participation in a 
nutritional study and the intake of oil-containing capsules might have caused larger 
reductions in dietary intakes and/or a greater “underreporting” of consumed foods 
than before the intervention in both groups at the days of the dietary record. Since we 
observed a trend towards lower energy intakes in the DHA group relative to placebo, 
the tested microalgae oil might have had a different effect on appetite or regulation of 
food intake than olive oil in the vegetarian subjects studied. 
In the present study, heart rate and diastolic blood pressure were not affected by 
DHA supplementation. Similar results were shown previously with DHA intakes of 0.7 
g and 3.0 g/d [48,57]. Mori et al. [130] reported a decrease of systolic and diastolic 
BP after DHA supplementation in men with otherwise normal BP, whereas 
Grimsgaard et al. [131] did not detect a reduction of BP in comparable subjects. Both 
groups observed a significant influence of DHA on heart rate in healthy men. Very 
clear effects in respect to n-3 LCPUFA on BP control have been observed in 
hypertensive patients [132-135], but these investigators used extremely large 
amounts of omega-3 fatty acids ranging from 3.4 to 15 g per day. In the present 
study, systolic and diastolic BP at baseline were very low (DHA group: 100/65 mm 
Hg; placebo group: 95/70 mm Hg, medians); therefore, a further decrease of BP 
could not be expected and would also be considered undesirable. The observed 
increase of systolic BP in the placebo group and the same trend in the DHA group 
may be caused by a systematic change in BP measurement or by environmental 
influences.  
Sanders & Hinds [136] reported that plasma alpha-tocopherol concentrations fell 
below the normal range during a period of fish oil supplementation (2.1 g DHA and 
0.8 g EPA per day), suggesting that fish oil increases the requirement for 
antioxidants. No significant changes in plasma alpha-tocopherol were evident 
following fish oil treatment (3 g EPA + DHA per day) providing 21 mg/d total 
tocopherol of which 16 mg was alpha-tocopherol [137]. In the present study, the olive 
oil and microalgae oil capsules provided a total of 2.2-2.3 mg mixed natural 
tocopherols per day. No changes of alpha-tocopherol levels and lipid-adjusted alpha-
tocopherol concentrations were observed after intervention in both groups, 
suggesting that 2.3 mg mixed natural tocopherols are sufficient to maintain alpha-
tocopherol levels at a DHA intake of ∼1 g/d. 
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For safety and tolerance evaluation, side effects were reported and several 
haematology and biochemistry parameters were analysed. Self-reported side effects 
were equally distributed between DHA and placebo group. We observed significant 
changes in some blood parameters after DHA supplementation within the normal 
ranges (e.g. alanine aminotransferase and cholinesterase levels), which are 
presumed to be of no clinical relevance. Incidence of liver and cardiac enzymes out 
of the laboratory’s reference range did not differ neither at baseline nor at week 8 
between DHA and placebo groups; within-group incidences did not differ between 
baseline and week 8. Slight increases in the serum activity of liver enzymes during n-
3 LCPUFA supplementation has been noted repeatedly [138,139]; the mechanisms 
remain unclear.  
With the exception of von Willebrand factor (vWF), incidence of haemostatic factors 
out of the laboratory’s reference range did not differ neither at baseline nor at week 8 
between DHA and placebo groups; within-group incidences did not differ between 
baseline and week 8. Concerning vWF, we observed values out of reference range 
less often after DHA supplementation than at baseline (1 vs. 12 subjects), and 
incidence of such values was lower in the DHA than in the placebo group at week 8 
(1 vs. 11 subjects). Other studies supplementing n-3 LCPUFA observed decreased 
[140,141] or unchanged [122,124,142,143] vWF levels. Plasma vWF levels have 
been proposed as risk factor for CHD and stroke, especially in high-risk populations 
with previous cardiovascular events, diabetes or old age [144]. Our results might 
indicate a normalisation of prior abnormal vWF levels with DHA supplementation. 
Further research is needed to clarify the possible beneficial effects of DHA on 
haemostasis and the impact on CHD or stroke risk in normolipidaemic subjects.  
Our results show that a supplementation with ∼1 g DHA/d for 8 weeks significantly 
lowered TG in normolipidaemic (basal TG < 2.5 mM) subjects. Previous studies with 
single-cell oil sources of DHA reported a significant reduction in TG concentrations 
and an increase in HDL cholesterol levels with DHA intakes in the range of 1.6 - 2.4 
g/d in normolipidaemic volunteers [44,49,55], whereas other studies with DHA 
intakes of 0.7 g/d [56] and 0.75 - 1.5 g/d [57] did not find any significant effects on 
plasma TG and lipoproteins. In persons with combined hyperlipidaemia, significant 
reductions in TG and increases in LDL and HDL cholesterol concentrations were 
observed after supplementation with 1.25 g or 2.5 g DHA per day [46]. N-3 LCPUFA 
lower plasma TG concentrations by several mechanisms such as increased hepatic 
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fatty acid oxidation, inhibition of fatty acid and TG synthesis and depressed assembly 
and secretion of VLDL TG [51]. The TG-lowering effect of DHA is greater in subjects 
with higher initial TG concentrations [50]. Considering the normolipidaemic subjects 
in our study, it also seems that DHA lowers plasma TG only in subjects with higher 
basal TG (> ∼1.2 mmol/l). 
HDL cholesterol concentrations increased after 8 weeks of DHA supplementation. 
Plasma TG and HDL cholesterol of all subjects at baseline were slightly inversely 
correlated (r = -0.207, p = 0.033), and absolute changes in TG correlated inversely 
with HDL concentrations after DHA supplementation (r = -0.308, p = 0.025). The 
mechanisms by which DHA supplementation increases HDL cholesterol are not 
known, but may be related to alterations in lipid transfer protein activity [145]. A 
decrease of cholesteryl ester transfer protein (CETP) activity would reduce the 
exchange from HDL cholesterol esters and VLDL triglycerides, resulting in larger, 
more cholesterol-rich HDL cholesterol particles. Indeed, other studies applying 
purified DHA (3.6 g/d and 4.9 g/d respectively) observed a decrease in the 
apoA1:HDL-cholesterol ratio [47,54]. These findings suggest an effect of DHA 
supplementation on HDL particle size with a shift towards the larger, more 
cholesterol-rich HDL-2 particle. Other investigators observed an increased HDL-
2:HDL-3 cholesterol ratio [52,55] or increased HDL-2 cholesterol [53] after DHA 
supplementation.  
In the present study, total and LDL cholesterol levels increased after DHA intake. 
Other studies did not detect any significant changes in total cholesterol after 
supplementation with 0.75 - 4.9 g DHA/d [47,48,52,54,57] or increased total 
cholesterol levels after supplementation with an algal triglyceride providing 1.5 g DHA 
and 0.6 g n-6 DPA per day [124]. Inconsistent effects of DHA on LDL cholesterol 
levels were reported in previous studies: some investigators observed LDL 
cholesterol-raising effects of DHA [46,53,56,124], whereas others found no effects 
[44,47-49,52,54,57]. The repeatedly observed increase in plasma LDL cholesterol 
after DHA / fish oil supplementation must be due to either decreased clearance or 
increased production of LDL. The limited amount of TG available for packaging into 
VLDL after supplementation with n-3 LCPUFA could result in smaller VLDL particles 
that contain less TG. Small VLDL are more readily converted to LDL, which may 
cause increased LDL cholesterol levels [43]. However, previous studies did not find 
increases in smaller VLDL subspecies with n-3 fatty acid supplementation [146,147]. 
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Lu et al. [147] suggested that n-3 fatty acids could enhance the conversion of VLDL 
to LDL via increased inherent susceptibility of VLDL particles to lipolysis and/or 
increased in vivo lipolytic activity.  
Decreased clearance of LDL might be due to decreases in LDL receptor binding 
activity or reduced LDL receptor expression. Animal experiments feeding fish oil with 
DHA to hamsters and primates showed decreased receptor-mediated clearance of 
LDL cholesterol [148,149]. Binding of LDL to the LDL receptor decreased because of 
an altered LDL structure and a reduced affinity of LDL for its receptor. Lindsey et al. 
[150] observed an in vitro depression of LDL receptor activity and expression in 
human hepatoma HepG2 cells after supplementation with 3.6 g EPA/d and 2.9 g 
DHA/d for only 2 weeks. Whether n-3 FA alter LDL receptor activity or expression in 
humans is not known, but LDL kinetic studies showed no decrease in fractional 
catabolic rate relative to a high saturated fat diet [151] or a vegetable diet [152], 
providing no evidence for a change in LDL receptor activity in humans. Further 
research is needed to clarify the reasons for the increase in LDL cholesterol with 
moderate intakes of DHA and the possible consequences for CHD risk in 
normolipidaemic subjects.  
Kinosian et al. [153,154] proposed that changes in total cholesterol:HDL cholesterol 
and LDL:HDL cholesterol ratios are better predictors of risk for CHD than changes in 
total or LDL cholesterol alone. The ratio of TG to HDL cholesterol is additionally 
considered a predictor of risk for myocardial infarction [155]. In our study, the total 
cholesterol:HDL cholesterol ratio as well as the LDL:HDL cholesterol remained 
unchanged in both intervention groups, but the TG:HDL cholesterol ratio was 
significantly lower after DHA supplementation. Stark & Holub [45] also reported a 
significant decrease of TG:HDL cholesterol after supplementation with 2.8 g DHA/d 
over 4 weeks in postmenopausal women. Decreased ratios of total:HDL cholesterol 
[44,47] and LDL:HDL cholesterol [44] or no changes in LDL:HDL or total:HDL 
cholesterol ratios [45,57] were observed with DHA supplementation in other studies. 
In conclusion, DHA-rich oil from microalgae Ulkenia sp. is well tolerated and can be 
considered a suitable vegetarian source of n-3 LCPUFA. Eight-week 
supplementation with this microalgae oil can achieve a desirable omega-3 index ≥ 
8% in subjects with low basal n-3 LCPUFA status. The DHA intake was associated 
with improvements in some CHD risk factors (plasma TG, TG:HDL cholesterol ratio, 
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vWF), but others, notably LDL cholesterol, worsened. Therefore, the overall effects of 
this treatment on CHD risk are unclear and should be further investigated. 
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4.3 FO/EPO study 
The objective of this pilot study was to investigate the effects of a fatty acid mixture 
(providing 419 mg DHA, 337 mg GLA, 72 mg EPA, and 14 mg AA as triglycerides per 
day) on plasma fatty acid composition in healthy, non-pregnant women. Previous 
studies showed that supplementation with DHA alone increased plasma lipid 
concentrations of DHA and (in most studies) EPA, but decreased GLA, DGLA, and 
AA concentrations [44-48,53,54,56,57,121,156]. Supplementation with GLA on the 
other hand increased plasma concentrations of DGLA as well as (in most studies) AA 
and GLA levels, but did not enhance EPA and DHA levels [10,157-161]. We 
hypothesised that the tested n-3 LCPUFA/GLA mixture (FO/EPO) would result in an 
increase of plasma DHA, GLA, and DGLA levels without impairing AA status.  
This pilot study showed that 8-week supplementation with FO/EPO increased the 
proportions of GLA and its elongation product DGLA in plasma total lipids and in all 
measured plasma lipid fractions (CE, PL, and TG) compared to baseline, suggesting 
that some of the GLA is elongated before incorporation into PL, CE or TG. These 
observations are consistent with those of Laidlaw & Holub [123], who found 
significant increases from baseline in the proportions of GLA and DGLA (measured in 
plasma PL) in healthy women given EPA + DHA and GLA in a ratio of 1:1 or 1:0.5 for 
4 weeks; no GLA and DGLA changes could be observed in this study when the ratio 
of n-3 LCPUFA to GLA was 1:0.25. Miles et al. [10] reported increases in the 
proportion of GLA in plasma TG and CE, but not in PL, after supplementation with a 
n-3 LCPUFA/GLA mixture (1:0.625). Other studies supplementing 8 – 28 subjects 
with n-3 LCPUFA and GLA (in a ratio from 1:0.33 to 1:1.14) could not detect any 
changes in absolute GLA and DGLA levels of plasma total lipids or in relative 
concentrations of plasma PL [159,160,162,163]. The effects on GLA and DGLA 
might be influenced by the total GLA amount or by the ratio of n-3 LCPUFA to GLA in 
the used supplement: Laidlaw & Holub [123] observed increasing DGLA values with 
increasing amounts of GLA and constant EPA + DHA dosages. Concerning the 
changes in GLA levels, a reason for the different findings between the studies may 
be the lipid fraction studied: as demonstrated by several investigators [10,164], GLA 
is mainly found in CE and TG, but hardly in PL (< 0.1 wt%), so that changes would be 
more readily detected in these fractions than in plasma PL (depending also on the 
used method for fatty acid analyses and on the number of subjects). 
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In the present study, the proportion of AA increased in plasma TG, whereas AA 
levels did not change in plasma TL, CE, and PL. Other investigators reported 
decreased [123,162] or unchanged [10,159,163] plasma AA levels in TL or PL with n-
3 LCPUFA/GLA mixtures compared to baseline. The inconsistent effects on AA 
levels may relate on the one hand to the lipid fraction studied, on the other hand to 
differences in the GLA, AA, and EPA contents or in the EPA:GLA ratio of the used 
supplements: EPA and DGLA compete with AA for esterification into phospholipids 
and furthermore, the (n-3) fatty acid product of the ∆5-desaturase reaction, EPA, 
attenuates the conversion of (GLA-derived) DGLA to AA [159,165]. In the current 
study, the decrease of AA levels in plasma, which is often observed with n-3 
LCPUFA supplementation, could be prevented in all measured plasma lipid fractions 
as anticipated by adding GLA (and AA) to the supplement (n-3 LCPUFA:GLA = 1: 
∼0.7; EPA:GLA = 1: ∼4.7); thus, the GLA amount in the supplement seems to be 
adequate. 
FO/EPO supplementation increased the proportions of EPA and DHA in all 
investigated plasma lipid fractions (exception: EPA levels in plasma CE were not 
significantly changed from baseline values). Consistent with our results, other studies 
supplementing n-3 LCPUFA combined with GLA also observed increased levels of 
EPA and DHA in plasma TL and PL [10,123,159,160,162,163]. The observed 
increase in plasma EPA levels after FO/EPO supplementation in our study may relate 
to the EPA content of the supplement (∼72 mg/day) and/or could reflect 
retroconversion of DHA, as suggested also by other investigators [44,45,54,121].  
As we observed increases in ALA and EPA levels and decreases in long-chain n-6 
fatty acids (AA, adrenic acid, n-6 DPA) in some plasma lipid fractions with placebo 
treatment, the fatty acid composition of the placebo oil might not have been 
sufficiently comparable to the habitual fatty acid composition of the subjects’ diet. In a 
previous study conducted in November 2003 at our hospital, we determined the 
dietary intake in 23 female omnivores (age: 23.8 ± 3.2 years, height: 1.68 ± 0.06 m, 
BMI: 20.9 ± 1.9 kg/m2, mean ± SD for all). These subjects were well comparable with 
the subjects in the present study (predominantly medicine students with comparable 
age, height and BMI). In this previous study, we evaluated the median EPA intake 
with the normal diet to be 20 mg per day (IQR 10 – 30 mg/d). If we assumed that ALA 
conversion to EPA could be up to 20% in young women [2], the additional ALA 
supply with placebo capsules (about 69 mg/d) would deliver about 14 mg EPA, what 
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accounts for an additional EPA supply of 47% or more in ¾ of the subjects (30 mg 
EPA/d = 100% ⇒ 44 mg EPA/d = 146.7%). This might have caused the observed 
increases in plasma EPA and decreases in plasma long-chain n-6 fatty acids. 
Another possibility might be that the subjects changed their dietary habits during the 
intervention period, because with this study they became aware of the benefits of n-3 
fatty acids. As the subjects did not record their diets before and during the 
intervention period of this study, we cannot prove or disprove one of these 
speculations. For future intervention studies, dietary records might be helpful to 
detect possible changes in the background diet. A possible change in fatty acid 
composition of the placebo oil should be taken into account for the planned main 
study supplementing pregnant and lactating women with the FO/EPO mixture. 
The present pilot study also serves to compare the fatty acid responses in the various 
lipid domains. This information will then be used to decide which lipid domain will be 
investigated in future studies supplementing n-3 and n-6 fatty acids. The proportions 
of GLA, DGLA, EPA, and DHA in all investigated plasma lipids (total lipids and lipid 
fractions) reached their maximum already after 4 - 6 weeks of FO/EPO 
supplementation; therefore, the intervention period of 8 weeks is definitely adequate 
and could possibly be reduced to 6 weeks in future studies. Regarding all subjects at 
study entry (n = 40), GLA was mainly found in cholesterol esters, triglycerides, and 
total lipids (medians: 0.85 wt%, 0.31 wt%, and 0.37 wt% respectively), but hardly in 
phospholipids (< 0.1 wt%) as demonstrated by several investigators [10,164]. DGLA, 
AA, and DHA concentrations, on the other hand, were highest in phospholipids 
(medians: 3.43 wt%, 9.34 wt% and 3.09 wt% respectively) and considerably lower in 
cholesterol esters and triglycerides. Relative GLA changes from baseline (wt%/wt%) 
with FO/EPO supplementation were comparably high in plasma TL, CE, and TG 
(median changes at weeks 4, 6, and 8 ranged between 25 – 63%) and little lower in 
PL (16 – 43%). DGLA, EPA, and DHA changes from baseline were highest in plasma 
TG (29 – 33%, 47 – 61%, 131 – 156% respectively), and for each fatty acid 
comparably high in plasma TL, CE, and PL (about 10 – 20% for DGLA, 29 – 45% for 
EPA, and 45 – 67% for DHA). Percentage changes from baseline in these fatty acids 
of main interest at weeks 4 – 8 were significantly correlated between TL – CE, TL – 
PL, and CE - PL.  
As proportions and changes of the tested n-6 and n-3 fatty acids were correlated 
between TL – CE and TL - PL, fatty acid analyses might be limited to plasma total 
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lipids, provided that the subjects are healthy (no dyslipidaemias), non-pregnant and 
fasting. In our subjects, the proportion of PL, CE, and TG total fatty acids (in % of 
plasma total lipid fatty acids) changed only negligible between weeks 0, 4, 6, and 8 
(PL: 44.7 – 45.0% of TL, CE: 26.0 – 26.7% of TL, TG: 19.5 – 20.0% of TL, means, p 
> 0.05 between the four time points); this finding is probably an important condition 
for the strong correlations between fatty acids of TL and lipid fractions. Plasma total 
lipids as biomarkers for n-6 and n-3 fatty acid status have the following positive 
attributes: all n-6 and n-3 fatty acids are present in adequate amounts in plasma TL, 
fatty acid composition in plasma TL responds to increasing EFA/LCPUFA intakes and 
is correlated with fatty acids in plasma PL, CE, the analyses are less time-consuming 
(no separation of the lipid fractions), and the required sample volume is smaller. A 
disadvantage is that the fatty acid composition in plasma total lipids is influenced by 
fasting or fed state; therefore, it might be problematical in pregnant women, because 
of the observed raise in plasma triglycerides during pregnancy [166], as well as in 
neonates, in whom it is not possible to take fasted blood samples. For these subjects, 
fatty acid analyses in plasma PL and CE might be the best choice as markers for 
fatty acid status. 
For safety and tolerance evaluation, side effects were reported and several 
haematological and biochemical parameters were analysed. The supplementation 
with the FO/EPO mixture did not result in any physiologically relevant changes of 
safety parameters: incidence of liver enzymes and haematological parameters out of 
the laboratory’s reference range did not differ neither at baseline nor at week 8 
between FO/EPO and placebo groups; within-group incidences did not differ between 
baseline and week 8. The observed different changes in cholinesterase levels with 
DHA/EPO or placebo intake might be due to the lower basal cholinesterase levels in 
the placebo group and their normalisation over the intervention period. Self-reported 
side effects were equally distributed between FO/EPO and placebo groups. 
In conclusion, in women of childbearing age the tested fatty acid supplement is well 
tolerated and appears safe. FO/EPO intake resulted in the anticipated increase of 
plasma GLA, DGLA, and DHA levels without impairing AA status. These data provide 
a basis for testing this FO/EPO mixture in pregnant women for its efficacy to optimise 
maternal and neonatal LCPUFA status, and for its effects on infantile development, 
early markers of allergy risk and prevention of obesity, insulin resistance, 
hypertriglyceridaemia or other chronic diseases in later life. 
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4.4 Comparison of the two used supplements 
The fatty acid profiles of plasma and/or RBC lipids followed closely the fatty acid 
composition of the supplements and illustrate the competitive interactions between n-
3 and n-6 metabolic pathways: in the DHAVEG study, main fatty acids in the 
supplement were DHA (∼1050 mg/d as triglyceride) and n-6 docosapentaenoic acid 
(∼222 mg/d as triglyceride). Median percentage changes from baseline in plasma 
phospholipids after 8 weeks of intervention were highest (and significantly different 
from changes with placebo intervention) for these two fatty acids with a +159% 
increase for DHA and +87% increase for n-6 DPA (Figure  4.2, blue bars). Reductions 
in GLA, DGLA, AA levels as well as in n-6 LCPUFA were greater with microalgae oil 
than with placebo intake. 
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Figure  4.2. Percentage changes from baseline in plasma phospholipids after 8 weeks of 
supplementation with microalgae oil, FO/EPO or placebo (%, medians). 
GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; n-6 DPA, n-6 
docosapentaenoic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-3 LCPUFA, sum 
of all long-chain n-3 fatty acids; n-6 LCPUFA, sum of all long-chain n-6 fatty acids; FO/EPO, fish 
oil/evening primrose oil. 
*  p < 0.05 vs. changes with the appropriate placebo (A in DHAVEG study; B in FO/EPO study). 
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In the FO/EPO study, the FO/EPO mixture provided 419 mg DHA and 337 mg GLA 
as triglycerides per day. Percentage changes from baseline values of plasma 
phospholipid fatty acids showed a significantly greater increase with FO/EPO than 
with placebo for GLA (medians: +22% vs. –7%), its elongation product DGLA (+15% 
vs. –4%), and DHA (+45% vs. –1%) (Figure  4.2, green bars).  
In contrast to the supplementation with DHA alone (DHAVEG study), the expected 
dietary DHA-induced decrease of n-6 fatty acids (e.g. GLA, DGLA, AA, Σn-6 
LCPUFA) in plasma phospholipids was attenuated in the FO/EPO study by the 
presence of GLA in the supplement. The combination of DHA and GLA may be of 
added benefit especially in pregnant or lactating women, in whom it is desirable to 
enhance n-3 LCPUFA status without compromising GLA, DGLA, or AA status. 
Further studies should compare the effects of DHA alone and in combination with 
GLA on neonatal and infantile brain development and function. 
Concerning the CHD risk, it is noteworthy that increasing concentrations of DHA in 
serum phospholipids have been inversely correlated with risk of CHD [31]. In this 
regard, Simon et al. [31] reported that a standard deviation increase (+1.22 wt%) in 
plasma PL DHA resulted in an odds ratio of 0.66 for CHD risk (95% confidence 
interval 0.46 - 0.94). In our two studies, 8-week supplementation resulted in absolute 
DHA increases from baseline values ≥ 1.22 wt% in 96% (53/55) of the microalgae oil 
supplemented subjects and in 74% (14/19) of the FO/EPO supplemented subjects.  
The omega-3 index has been also identified as a risk indicator for death from CHD 
and especially SCD [33]. To convert plasma fatty acid data of the FO/EPO study to 
the correspondent omega-3 index, we used the following equation which was 
determined from fatty acid data of the DHAVEG study (Figure  4.3): 
 
Omega-3 index (wt%) = Plasma phospholipid EPA+DHA (wt%) x 0.7612 + 2.1649 
 
In both studies, no subject had a desirable omega-3 index ≥ 8 wt% at baseline. After 
8-week supplementation with microalgae oil, 69% of the subjects reached an omega-
3 index ≥ 8% (median omega-3 index increased from 4.70 wt% at baseline to 8.54 
wt% at week 8), whereas FO/EPO treatment did not result in omega-3 index values ≥ 
8 wt% (median (estimated) omega-3 index increased from 5.02 wt% at baseline to 
6.57 wt% at week 8).  
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Figure  4.3. RBC vs. plasma phospholipid EPA + DHA, DHAVEG study.  
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PL, phospholipids. 
These two parameters were measured in 103 pairs of blood samples (DHAVEG study, week 8, 
Spearman-Rho r = 0.94, p < 0.001). 
 
 
Regarding only the changes in plasma phospholipid DHA or omega-3 index, there 
might be a better reduction of CHD risk with microalgae oil than with the tested 
combination of fish oil and evening primrose oil. But a study by Laidlaw & Holub [123] 
indicated added benefit from combined supplementation of n-3 LCPUFA and GLA on 
reduction of CHD risk. These investigators observed reduced serum TG 
concentrations by 40%, 39%, and 35% with EPA+DHA supplementation alone (4 g) 
or in conjunction with GLA (1 or 2 g), whereas TG concentrations did not change 
significantly when GLA supplementation increased to 4 g/d. Interestingly, the 
combination of EPA+DHA and GLA in the 4:2 and 4:4 groups resulted in a tendency 
of LDL cholesterol to decrease, whereas EPA+DHA alone typically has no effect 
[44,47-49,52,54,57] or a modest elevating effect [46,53,56,124,156] on LDL 
concentrations.  
The international task force for the prevention of CHD uses the variables age, systolic 
blood pressure, cigarette smoking, diabetes, family history of MI, and LDL 
cholesterol, HDL cholesterol, and TG concentrations with the PROCAM risk 
calculator to predict the risk of MI within the next 10 years [167]. Laidlaw & Holub 
[123] reported that on the basis of this risk calculator, the lipid changes observed 
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(before and after supplementation) in the four groups studied yielded estimated 
reductions in the risk of MI over a 10-y period of 37%, 33%, 43%, and 24% (group 
means) in the 4:0, 4:1, 4:2, and 4:4 groups respectively. Thus, the 4:2 group (4 g 
EPA + DHA and 2 g GLA) had the greatest overall reduction in MI risk on the basis of 
the PROCAM risk calculator. Further studies are needed investigating and comparing 
the effects of DHA alone and in combination with GLA on CHD risk. 
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5 Summary 
 
5.1 DHAVEG study 
Background: Low red blood cell (RBC) membrane content of eicosapentaenoic and 
docosahexaenoic acids (EPA + DHA, hereafter called omega-3 index) has recently 
been described as an indicator for increased risk of death from coronary heart 
disease (CHD). Previous studies demonstrated repeatedly beneficial effects of n-3 
long-chain polyunsaturated fatty acids (n-3 LCPUFA) on plasma triglyceride (TG) 
levels, but studies investigating the individual effects of EPA or DHA on plasma TG 
and lipoproteins in humans are rare.  
Objectives: This study aimed to investigate the influence of a vegetarian DHA-rich 
oil from microalgae Ulkenia sp. (almost free of EPA) on plasma and RBC DHA status, 
omega-3 index, and plasma lipids as well as its tolerance and safety in healthy adults 
with low basal DHA status.  
Design: A randomised, double blind, placebo-controlled intervention study with two 
parallel groups was performed. One hundred fourteen vegetarians (87 f, 27 m) aged 
18 to 43 years consumed 2.28 g daily of either microalgae oil providing ∼1 g DHA (as 
triglyceride) or about the same amount of olive oil (as placebo) for 8 weeks. RBC and 
plasma fatty acids, plasma lipids, and safety parameters (blood cell count, liver and 
cardiac enzymes, haemostatic parameters, plasma vitamin E) were measured at 
week 0 and week 8. 
Results: DHA supplementation significantly increased DHA in RBC total lipids (from 
4.4 to 7.9 wt%, means), in RBC phosphatidylethanolamine (from 6.5 to 12.1 wt%), in 
RBC phosphatidylcholine (from 1.4 to 3.8 wt%), and in plasma phospholipids (from 
2.8 to 7.4 wt%), whereas EPA levels rose to a much lesser extent. The mean omega-
3 index rose significantly from 4.8 to 8.4 wt% in the DHA group. After intervention, 
69% of DHA supplemented subjects but no subject of the placebo group reached an 
omega-3 index above the desirable value of 8 wt%. Microalgae oil supplementation 
resulted in significant decreases of 18:2n-6, 18:3n-6, 20:3n-6, 20:4n-6, 22:4n-6 and 
22:5n-3 levels in all measured fractions relative to baseline values.  
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Plasma TG decreased by 20% from 0.96 to 0.77 mmol/l (medians) with DHA 
treatment. Plasma total, LDL and HDL cholesterol increased significantly in the DHA 
group, resulting in lower TG:HDL cholesterol and unchanged LDL:HDL and total 
cholesterol:HDL cholesterol ratios.  
Self-reported side effects were minor und evenly distributed between DHA and 
placebo groups (11% vs. 8%). The intake of DHA-rich microalgae oil did not result in 
any physiologically relevant changes of safety and haemostatic factors with exception 
of von Willebrand factor (vWF) levels. Concerning vWF, we observed values out of 
reference range less often after DHA supplementation than at baseline (1 vs. 12 
subjects), and incidence of such values was lower in the DHA than in the placebo 
group at week 8 (1 vs. 11 subjects). Absolute and lipid-adjusted alpha-tocopherol 
levels did not change with DHA supplementation. 
Conclusions: In healthy adults DHA-rich oil from microalgae Ulkenia sp. is well 
tolerated, appears safe and can be considered a suitable vegetarian source of n-3 
LCPUFA. Eight-week supplementation with the tested oil can achieve a desirable 
omega-3 index ≥ 8% in subjects with low basal n-3 LCPUFA status. The DHA intake 
was associated with improvements in some CHD risk factors (plasma TG, TG:HDL 
cholesterol ratio, vWF), but others, notably LDL cholesterol, worsened. Therefore, the 
overall effects of this treatment on CHD risk are unclear and should be further 
investigated. 
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5.2 FO/EPO study 
Background: Fish oil supplementation can enhance docosahexaenoic acid (DHA) 
blood levels in pregnancy, but this might compromise maternal and neonatal 
arachidonic acid (AA) status, which is also important for infantile development. 
Objectives: This pilot study investigated whether co-administration of fish oil (FO) 
and evening primrose oil (EPO) will enhance n-3 long-chain polyunsaturated fatty 
acid (LCPUFA) status without reduction of AA levels. We also evaluated the effects 
on plasma gamma-linolenic acid (GLA) and dihomo-GLA (DGLA) concentrations, 
since these fatty acids have been shown to be associated with increased birth weight 
(DGLA) and reduced risk of certain aspects of metabolic syndrome (GLA). Tolerance 
and safety of this fatty acid mixture were assessed as well. 
Design: A randomised, double blind, placebo-controlled intervention study with two 
parallel groups was performed. Forty non-pregnant women aged 19 – 36 years 
consumed 3.4 g daily of either a FO/EPO mixture (providing 419 mg DHA, 337 mg 
GLA, and 72 mg eicosapentaenoic acid as triglycerides per day) or a placebo 
(mixture of palm oil, rapeseed oil, and sunflower seed oil) for 8 wk. Fatty acids were 
quantified in plasma total lipids (TL), phospholipids (PL), cholesterol esters (CE), and 
triglycerides (TG) at baseline and after 4, 6 and 8 weeks. Safety parameters (e.g. 
blood cell count, liver enzymes) were measured at weeks 0 and 8.  
Results: Eight-week supplementation with FO/EPO significantly increased plasma 
total lipid DHA (from 2.0 to 3.1 wt%, means), DGLA (from 2.0 to 2.3 wt%), and GLA 
(from 0.36 to 0.52 wt%), whereas AA levels did not change. After 8 weeks, mean 
percentage changes from baseline values of plasma total lipid fatty acids showed a 
significantly greater increase with FO/EPO than with placebo for GLA (+49.9 vs. 
+2.1%), DGLA (+13.8 vs. +0.7%) and DHA (+59.6 vs. +5.5%), while there was no 
difference for AA (-2.2 vs. -5.9%). Results were largely comparable for the other lipid 
fractions (PL, CE, and TG).  
Three subjects each both in the active and in the placebo group reported mild 
adverse effects (skin reactions, gastrointestinal upsets). FO/EPO supplementation 
did not result in any physiologically relevant changes of liver enzymes and full blood 
cell count. 
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Conclusions: In women of childbearing age the tested FO/EPO mixture is well 
tolerated and appears safe. FO/EPO intake resulted in the anticipated increase of 
plasma GLA, DGLA, and DHA levels without impairing AA status. These data provide 
a basis for testing this FO/EPO mixture in pregnant women for its efficacy to optimise 
maternal and neonatal LCPUFA status, and for its effects on infantile development, 
early markers of allergy risk and prevention of obesity, insulin resistance, 
hypertriglyceridaemia or other chronic diseases in later life. 
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5.3 Conclusions from both studies 
In contrast to supplementation with DHA alone (DHAVEG study, microalgae oil), the 
expected dietary DHA-induced decrease of n-6 fatty acids (e.g. GLA, DGLA, AA, Σn-
6 LCPUFA) in plasma lipids is attenuated in the FO/EPO study by the presence of 
GLA in the supplement (fish oil/evening primrose oil mixture). The combination of 
DHA and GLA may be of added benefit especially in pregnant or lactating women, in 
whom it is desirable to enhance n-3 LCPUFA status without compromising GLA, 
DGLA, and AA status. Further studies should compare the effects of DHA alone and 
in combination with GLA on neonatal and infantile brain development and function. 
Increases from baseline in plasma phospholipid DHA, n-3 LCPUFA and (probably) 
omega-3 index are smaller with FO/EPO than with microalgae oil treatment. Further 
studies are needed investigating and comparing the effects of DHA alone and in 
combination with GLA on CHD risk. 
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6 Zusammenfassung 
6.1 DHAVEG-Studie 
Hintergrund: Der Gehalt an Eicosapentaensäure (EPA) und Docosahexaensäure 
(DHA) in der Erythrozytenmembran (von nun an „Omega-3 Index“ genannt) wurde 
kürzlich als Risikoindikator für den Tod durch kardiovaskuläre Erkrankungen (CHD) 
beschrieben. Für den günstigen Effekt von langkettigen n-3 Fettsäuren (n-3 
LCPUFA) wird u.a. ihre Triglyzerid-senkende Wirkung diskutiert. Nur wenige Studien 
untersuchten die individuellen Effekte von EPA oder DHA auf Triglyzerid- (TG) und 
Lipoproteinspiegel im Plasma.  
Ziele: In dieser Studie sollte der Einfluss eines vegetarischen, DHA-reichen 
(praktisch EPA-freien) Öles der Mikroalge Ulkenia sp. auf den DHA-Gehalt von 
Plasma und Erythrozyten (RBC), den Omega-3 Index, Plasmalipide sowie seine 
Verträglichkeit und Unbedenklichkeit bei gesunden Erwachsenen mit niedrigem 
basalen DHA-Status untersucht werden.  
Studiendesign: Es wurde eine randomisierte, doppelt-blinde, Plazebo-kontrollierte 
Interventionsstudie mit zwei parallelen Gruppen durchgeführt. Einhundertvierzehn 
Vegetarier (87 Frauen, 27 Männer) zwischen 18 und 43 Jahren nahmen über 8 
Wochen täglich 2,28 g Mikroalgenöl (entspricht einer täglichen Aufnahme von ∼1 g 
DHA als TG) oder dieselbe Menge Olivenöl (als Plazebo) zu sich. An Woche 0 
(Baseline) und Woche 8 wurden RBC- und Plasmafettsäuren, Plasmalipide und 
verschiedene Sicherheitsparameter (u.a. Blutbild, Leberwerte, Gerinnungsparameter, 
Vitamin E im Plasma) bestimmt.  
Ergebnisse: Die Supplementierung mit DHA erhöhte signifikant den DHA-Gehalt in 
RBC-Gesamtlipiden (von 4,4 auf 7,9 wt%, Mittelwerte), in RBC-Phosphatidyl-
ethanolamin (von 6,5 auf 12,1 wt%), in RBC-Phosphatidylcholin (von 1,4 auf 3,8 
wt%) und in Plasma-Phospholipiden (von 2,8 auf 7,4 wt%), während der EPA-Anstieg 
geringer ausfiel. Der mittlere Omega-3 Index erhöhte sich in der DHA-Gruppe 
signifikant von 4,8 auf 8,4 wt%. Nach 8-wöchiger Intervention erreichten 69% der 
DHA-supplementierten Probanden, aber kein Proband der Plazebo-Gruppe, einen 
wünschenswerten Omega-3 Index größer 8 wt%. Die Supplementierung mit 
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Mikroalgenöl führte zu signifikanten Abnahmen von 18:2n-6, 18:3n-6, 20:3n-6, 20:4n-
6, 22:4n-6 und 22:5n-3 in Plasma und RBC.  
Die DHA-Gabe senkte die Plasma-TG um 20% von 0,96 auf 0,77 mmol/l (Mediane). 
Plasma-Gesamtcholesterol sowie LDL- und HDL-Cholesterol stiegen in der DHA-
Gruppe signifikant an, was zu einem niedrigeren Verhältnis von TG:HDL-Cholesterol 
und unveränderten LDL:HDL- sowie Gesamtcholesterol:HDL-Cholesterol-Ratios 
führte.  
Leichte Nebenwirkungen (Hautreaktionen und gastrointestinale Beschwerden) traten 
gleichhäufig in DHA- und Plazebo-Gruppe auf (11% vs. 8%). Bei der Einnahme von 
DHA-reichem Mikroalgenöl wurden keine physiologisch relevanten Veränderungen 
der Sicherheitsparameter beobachtet. Ausnahme waren die Plasmaspiegel des von 
Willebrand-Faktors (vWF), die nach DHA-Gabe seltener außerhalb des 
Referenzbereiches lagen als zu Studienbeginn (1 vs. 12 Probanden) sowie seltener 
als in der Plazebo-Gruppe zum selben Zeitpunkt (1 vs. 11 Probanden). Die absoluten 
und auf Gesamtlipide bezogenen Alpha-Tocopherolspiegel im Plasma veränderten 
sich nicht durch die DHA-Gabe.  
Schlussfolgerungen: DHA-reiches Öl der Mikroalge Ulkenia sp. ist bei gesunden 
Erwachsenen gut verträglich und anscheinend unbedenklich und kann als geeignete 
vegetarische Quelle für n-3 LCPUFA angesehen werden. Durch 8-wöchige 
Supplementierung des getesteten Öles lässt sich bei Personen mit niedrigem 
basalen n-3 LCPUFA-Status ein wünschenswerter Omega-3 Index ≥ 8% erzielen. 
Die DHA-Aufnahme war mit Verbesserungen einiger CHD-Risikofaktoren verbunden 
(Plasma-TG, TG:HDL-Cholesterol, vWF), aber andere Risikofaktoren, insbesondere 
das LDL-Cholesterol, verschlechterten sich leicht. Deshalb ist der Gesamteffekt 
dieser Intervention auf das CHD-Risiko unklar und sollte weiter untersucht werden. 
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6.2 FO/EPO-Studie 
Hintergrund: Eine Supplementierung mit Fischöl kann den Docosahexaensäure 
(DHA)-Status während der Schwangerschaft erhöhen, aber gleichzeitig zu einer 
Verminderung der maternalen und neonatalen Arachidonsäure (AA)-Konzentra-
tionen führen. Da auch AA für die Entwicklung des fötalen Gehirns und anderer 
Gewebe benötigt wird, ist eine Verschlechterung ihrer Verfügbarkeit nicht 
wünschenswert.  
Ziele: In dieser Pilotstudie sollte untersucht werden, ob eine Supplementierung von 
Fischöl (FO) und Nachtkerzenöl (EPO) die Plasmaspiegel an langkettigen n-3 
Fettsäuren (n-3 LCPUFA) erhöht, ohne den AA-Status zu beeinträchtigen. 
Desweiteren waren die Auswirkungen auf Gamma-Linolensäure (GLA)- und Dihomo-
GLA (DGLA)-Konzentrationen von Interesse, da gezeigt werden konnte, dass diese 
Fettsäuren mit erhöhtem Geburtsgewicht (DGLA) und geringerem Risiko für 
bestimmte Aspekte des metabolischen Syndroms (GLA) assoziiert sind. Auch die 
Verträglichkeit und Unbedenklichkeit dieser Fettsäuremischung sollten beurteilt 
werden.  
Studiendesign: Es wurde eine randomisierte, doppelt-blinde, Plazebo-kontrollierte 
Interventionsstudie mit zwei parallelen Gruppen durchgeführt. Vierzig nicht-
schwangere Frauen zwischen 19 und 36 Jahren nahmen über 8 Wochen täglich 3,4 
g einer FO/EPO-Mischung (entspricht einer täglichen Aufnahme von 419 mg DHA, 
337 mg GLA und 72 mg Eicosapentaensäure) oder ein Plazebo (Mischung aus 
Palmöl, Rapsöl und Sonnenblumenöl) zu sich. Zu Studienbeginn und nach 4, 6 und 8 
Wochen wurden die Fettsäurekonzentrationen in Plasma-Gesamtlipiden (TL), 
Phospholipiden (PL), Cholesterolestern und Triglyzeriden (TG) gemessen. Zusätzlich 
wurden an Woche 0 und Woche 8 verschiedene Sicherheitsparameter (Blutbild, 
Leberwerte) bestimmt.  
Ergebnisse: Die 8-wöchige Supplementierung mit FO/EPO erhöhte in den Plasma-
Gesamtlipiden die Spiegel an DHA (von 2,0 auf 3,1 wt%, Mittelwerte), DGLA (von 2,0 
auf 2,3 wt%) und GLA (von 0,36 auf 0,52 wt%), während sich die AA-Level nicht 
veränderten. Die relativen Veränderungen in den Gesamtlipiden nach 8 Wochen 
Intervention (% der Baselinewerte) von GLA (+49,9 vs. +2,1% mit Plazebo, 
Mittelwerte), DGLA (+13,8 vs. +0,7%) und DHA (+59,6 vs. +5,5%) waren nach 
FO/EPO-Gabe signifikant größer als mit Plazebo, wohingegen sich die 
Veränderungen der AA-Spiegel nicht zwischen den beiden Interventionen 
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unterschieden (-2,2 vs. –5,9%). Die Fettsäureveränderungen in den untersuchten 
Plasma-Lipidfraktionen (PL, CE, TG) waren in Richtung und Ausmaß ähnlich wie in 
den Gesamtlipiden.  
Je drei Probandinnen aus der FO/EPO- sowie der Plazebogruppe berichteten von 
leichten Nebenwirkungen (z.B. Hautreaktionen, leichte gastrointestinale Beschwer-
den). Die FO/EPO-Supplementierung führte zu keinen physiologisch relevanten 
Veränderungen der Leberwerte oder im Blutbild. 
Schlussfolgerungen: Die getestete FO/EPO-Mischung ist bei Frauen im gebär-
fähigen Alter gut verträglich und anscheinend unbedenklich. Das Supplement erhöht 
die Plasmaspiegel von DHA, GLA und DGLA, ohne den AA-Status zu 
beeinträchtigen. In einer weiteren Studie sollten nun die Effekte dieser FO/EPO-
Mischung auf den LCPUFA-Status schwangerer Frauen und ihres Föten sowie die 
Auswirkungen auf Gemütsverfassung und Gehirnleistung der Mutter, auf die geistige 
Entwicklung des Kindes, das Allergierisiko sowie die Prävention von Übergewicht, 
Insulinresistenz, Hypertriglyzeridämie oder anderen chronischen Erkrankungen im 
weiteren Leben untersucht werden. 
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6.3 Schlussfolgerungen aus beiden Studien 
Im Gegensatz zur alleinigen DHA-Gabe in der DHAVEG-Studie (Mikroalgenöl) wird 
die durch Nahrungs-DHA induzierte Abnahme der n-6 Fettsäuren im Plasma 
(insbesondere von GLA, DGLA, AA sowie Σn-6 LCPUFA) durch den GLA-Gehalt im 
Supplement (Mischung aus Fischöl und Nachtkerzenöl, FO/EPO-Studie) verhindert. 
Die Kombination von DHA und GLA könnte von zusätzlichem Nutzen insbesondere 
für schwangere und stillende Frauen sein, bei denen eine Erhöhung des n-3 
LCPUFA-Status ohne Beeinträchtigung der GLA-, DGLA- und AA-Level erwünscht 
ist. Zukünftige Studien sollten die Auswirkungen von DHA alleine sowie in 
Kombination mit GLA auf die neonatale und kindliche Gehirnentwicklung und -
funktion untersuchen und vergleichen. 
Die Erhöhung der DHA- und n-3 LCPUFA-Gehalte in Plasmaphospholipiden sowie 
(vermutlich) auch des Omega-3 Indexes ist mit FO/EPO-Gabe geringer als mit 
Mikroalgenöl-Gabe. Weitere Studien sind notwendig, um die Effekte von DHA alleine 
und in Kombination mit GLA auf das CHD-Risiko zu untersuchen. 
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 A1 
8 Attachment 
8.1 Tables 
Table  8.1. Reproducibility of triglyceride and lipoprotein analyses, DHAVEG study.* 
 Intra-assay  Inter-assay 
 n Mean CV (%)  n Mean CV (%) 
Triglycerides (mg/dl) 
     Level 1 
     Level 2 
 
20 
20 
 
84.9 
143.0 
 
1.6 
1.6 
  
20 
20 
 
84.9 
143.0 
 
1.9 
1.9 
Total cholesterol (mg/dl) 
     Level 1 
     Level 2 
 
20 
20 
 
205 
259 
 
1.3 
1.1 
  
20 
20 
 
205 
259 
 
2.2 
2.5 
HDL cholesterol (mg/dl) 
     Level 1 
     Level 2 
 
21 
21 
 
21.7 
46.0 
 
0.75 
0.85 
  
21 
21 
 
21.7 
46.0 
 
2.1 
1.7 
n, n-fold determination of one sample. 
*  According to manufacturer’s declarations. 
 
Attachment A2 
Table  8.2. Reproducibility of test kits for biochemical parameters, DHAVEG study and FO/EPO study.* 
 Intra-assay  Inter-assay 
 n Mean CV (%)  n Mean CV (%) 
Bilirubin (mg/dl) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
2.1 
2.1 
5.0 
 
1.3 
1.8 
1.2 
 n.s.  
2.1 
2.1 
5.0 
 
1.9 
2.1 
1.6 
Creatinine (mg/dl) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
1.67 
1.95 
3.69 
 
0.7 
0.6 
0.6 
 n.s.  
1.09 
1.92 
3.70 
 
2.3 
1.5 
1.7 
Gamma-GT (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
51.6 
40.6 
185 
 
1.5 
0.5 
0.3 
 n.s.  
53.7 
39.1 
173 
 
1.4 
1.9 
1.8 
ALT (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
48 
61 
131 
 
1.8 
2.9 
1.1 
  
10 
10 
10 
 
40 
55 
124 
 
3.2 
2.1 
0.5 
AST (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
143 
81 
174 
 
0.7 
4.0 
0.8 
  
10 
10 
10 
 
101 
74 
161 
 
2.9 
3.4 
1.9 
Cholinesterase (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
15998 
3358 
4756 
 
0.7 
1.4 
1.1 
  
10 
10 
10 
 
16117 
3402 
4759 
 
1.4 
1.4 
1.7 
Creatinekinase (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
31 
224 
484 
 
2.6 
0.4 
0.5 
  
10 
10 
10 
 
150 
220 
475 
 
2.1 
1.7 
1.7 
LDH (U/l) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
132.3 
144.7 
243.7 
 
1.4 
1.3 
1.0 
 n.s.  
195.9 
160.6 
247.3 
 
2.3 
1.8 
1.3 
Uric acid (mg/dl) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
5.57 
4.67 
10.18 
 
0.5 
0.5 
0.4 
 n.s.  
7.21 
4.86 
9.39 
 
1.7 
1.3 
1.6 
Total protein (g/dl) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
4.4 
5.0 
4.8 
 
0.60 
0.47 
0.70 
 n.s.  
6.4 
5.1 
4.9 
 
0.95 
1.21 
1.22 
CRP (mg/dl) 
     Human serum 
     Precinorm U 
     Precipath U 
 
21 
21 
21 
 
2.3 
5.4 
9.4 
 
1.3 
1.0 
0.6 
  
8 
8 
8 
 
2.2 
4.2 
11.5 
 
6.0 
2.9 
1.3 
Glucose (mg/dl) 
     Human serum 
     Control serum I 
     Control serum II 
 
21 
21 
21 
 
127 
66 
274 
 
1.0 
1.1 
0.8 
 n.s.  
126 
118 
253 
 
1.7 
1.9 
1.9 
n, n-fold determination of one sample; gamma-GT, gamma-glutamyl transpeptidase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive 
protein; n.s., not specified. *  According to manufacturer’s declarations. 
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Table  8.3. Reproducibility of test kits for haemostatic parameters, DHAVEG study.* 
 Intra-assay  Inter-assay 
 n Mean CV (%)  n Mean CV (%) 
Quick’s test (%) 
     Behring Coagulation Timer 
     Bering Fibrintimer A 
 
8 
8 
  
0.7 – 1.2 
1.2 – 6.0 
  
5 
5 
 
 
 
1.5 – 2.2 
0.7 – 3.3 
PTT (sec) 
     Normal plasma 
     Pathological plasma 
     Heparine plasma pool 
 
4 
4 
4 
  
 
0.6 – 2.0 
  
10 
10 
10 
  
 
0.3 – 2.8 
Fibrinogen (mg/dl) 
     Normal plasma 
     Pathological plasma 
n.s.   
1.5 - 5 
3 - 6 
 n.s.   
2.0 - 5 
3 - 6 
D-dimeres (µg/ml) 
     Plasma 
     Low control 
     High control 
 
21 
21 
21 
 
0.19 
0.86 
5.11 
 
7.3 
1.7 
0.8 
 n.s.  
0.30 
0.87 
4.58 
 
6.5 
8.3 
3.2 
Factor VII (%) 
     Normal 
     Low abnormal 
n.s.  
99.4 
47.6 
 
0.8 
1.4 
 n.s.  
99.7 
47.6 
 
2.6 
3.5 
Von Willebrand factor (%) 
     Level 1 
     Level 2 
     Level 3 
n.s.  
33.7 
80.8 
101.5 
 
2.2 
1.3 
1.4 
 n.s.   
? 
? 
? 
PAI-1 (AU/ml) 
     Level 1 
     Level 2 
 
9 
9 
 
12 
23 
 
2.4 
0.4 
  
10 
10 
 
12 
23 
 
7.6 
1,6 
PFA-ADP   ?    ? 
PFA-EPI   ?    ? 
n, n-fold determination of one sample; PTT, partial thromboplastin time; PAI-1, plasminogen activator 
inhibitor-1 activity; PFA-ADP, platelet function analysis with adenosine diphosphate; PFA-EPI, platelet 
function analysis with epinephrine; n.s., not specified; ?, no informations available. 
*  According to manufacturer’s declarations. 
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Table  8.4. Reproducibility of fatty acid analysis in plasma PL, DHAVEG study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 11) 
 mg/l  CV (%) wt%  CV (%)  mg/l CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 4.84 1.98 0.45 1.66  6.71 4.74 0.44 3.47 
15:0 IS  IS   IS  IS  
16:0 327.15 1.63 30.23  0.43  437.57 2.19 28.82 2.12 
17:0 4.23   2.02 0.39 0.64  4.69 6.36 0.31 3.81 
18:0 147.82  1.94 13.66  0.83  190.92  2.59 12.57 2.53 
20:0 7.44 1.81 0.69 0.83  6.77 11.04 0.45 10.44 
22:0 20.18 1.47 1.86 0.69  19.00 15.07 1.25 14.74 
24:0 16.37 1.58 1.51 1.36  15.47 12.00 1.02 12.00 
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t 1.15 5.50 0.11 5.08  0.78 16.71 0.05 15.45 
18:1t 2.91 3.66 0.27 3.32  2.59 18.59 0.17 16.55 
18:2tt 0.94 3.94 0.09 3.52  0.65 12.61 0.04 13.27 
22:1t 1.02 9.64 0.09 9.79  n.d.  n.d.  
MUFA          
14:1n-5 n.d.  n.d.   n.d.  n.d.  
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 7.13 1.57 0.66 0.73  20.49 5.58 1.35 2.85 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 17.04 1.61 1.57 0.42  22.17 5.56 1.46 2.75 
18:1n-9 112.05 1.44 10.35 0.57  177.37 5.50 11.67 2.92 
20:1n-9 1.81 3.44 0.17 2.75  2.39 8.37 0.16 5.49 
22:1n-9 2.70 9.92 0.25 9.33  2.61 34.48 0.17 33.04 
24:1n-9 33.65 1.96 3.11 1.61  30.06 15.79 1.98 14.83 
PUFA          
20:3n-9 1.29 23.62 0.12 23.73  3.85 11.01 0.25 8.25 
18:2n-6 211.35 1.52 19.53 0.64  270.19 4.70 17.78 1.79 
18:3n-6 0.91 8.16 0.08 8.12  2.15 7.97 0.14 5.17 
20:2n-6 5.16 7.11 0.48 6.80  7.47 9.43 0.49 6.87 
20:3n-6 29.11 1.58 2.69 0.83  69.84 5.12 4.60 2.10 
20:4n-6 72.26 1.76 6.68 0.39  127.79  7.19 8.41 5.47 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 2.58 1.85 0.24 1.33  9.23 6.22 0.61 3.82 
22:5n-6 2.61 3.82 0.24 4.19  7.29 6.15 0.48 3.72 
18:3n-3 1.39 2.15 0.13 1.76  4.02 4.27 0.26 2.01 
18:4n-3 0.47 7.88 0.04 7.64  0.21 22.49 0.01 22.19 
20:3n-3 0.65 22.83 0.06 22.83  2.39 15.59 0.16 13.94 
20:5n-3 5.96 3.02 0.55 2.29  7.57 6.74 0.50 3.92 
22:5n-3 5.36 2.93 0.50 2.74  11.60 7.46 0.76 6.72 
22:6n-3 23.42 4.31 2.16 4.11  53.18 5.13 3.50 2.95 
CV, coefficient of variation; IS, internal standard; n.d., not detected, PL, phospholipids. 
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Table  8.5. Reproducibility of fatty acid analysis in RBC PC and PE, DHAVEG study (mean, CV). 
 Intra-assay (n = 7*)  Inter-assay (n = 14) 
 RBC PC RBC PE  RBC PC RBC PE 
 wt% CV (%) wt% CV (%)  wt% CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 0.60 2.96 0.26 5.98  0.74 3.95 0.23 11.29 
15:0 n.d.  n.d.   n.d.  n.d.  
16:0 37.42 0.86 17.36 2.71  37.62 1.30 17.36 1.56 
17:0 0.38 1.34 0.28 3.74  0.33 3.49 0.23 4.64 
18:0 8.76 1.17 8.02 1.10  8.78 2.17 7.47 1.75 
20:0 n.d.  n.d.   n.d.  n.d.  
22:0 n.d.  n.d.   n.d.  n.d.  
24:0 0.06 22.1 n.d.   0.22 35.11 n.d.  
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t 0.07 33.63 0.44 3.92  0.11 8.48 0.10 14.87 
18:1t 0.13 12.08 0.18 4.82  0.08 21.70 0.13 13.85 
18:2tt 0.06 10.41 n.d.   0.05 9.22 0.05 9.18 
22:1t n.d.  n.d.   n.d.  n.d.  
MUFA          
14:1n-5 n.d.  n.d.   n.d.  n.d.  
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 0.68 2.28 0.37 5.32  1.33 2.26 0.52 3.42 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 1.64 0.86 0.78 2.22  2.08 1.64 1.27 7.93 
18:1n-9 15.63 1.32 16.48 3.18  15.29 1.61 16.58 1.20 
20:1n-9 0.19 3.25 0.34 1.80  0.18 4.40 0.37 2.66 
22:1n-9 n.d.  n.d.   0.24 3.83 n.d.  
24:1n-9 0.232 22.14 n.d.   0.23 41.38 n.d.  
PUFA          
20:3n-9 0.09 3.30 0.09 4.84  0.15 3.78 0.14 4.35 
18:2n-6 19.53 0.92 5.64 2.68  18.54 0.94 5.02 1.30 
18:3n-6 0.07 3.49 n.d.   0.08 5.64 0.09 5.30 
20:2n-6 0.32 2.04 0.22 2.93  0.48 4.36 0.20 3.21 
20:3n-6 2.87 1.49 1.24 0.71  3.67 2.14 1.79 1.26 
20:4n-6 7.54 2.27 25.93 2.00  5.62 3.28 23.55  1.25 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 0.32 9.49 7.99 2.77  0.34 6.11 7.43 1.80 
22:5n-6 0.14 7.31 0.99 3.28  0.23 8.82 1.16 2.44 
18:3n-3 0.14 6.18 0.16 5.38  0.26 2.84 0.17 6.76 
18:4n-3 n.d.  n.d.   n.d.  n.d.  
20:5n-3 0.45 2.07 1.26 1.85  0.30 3.99 0.83 1.48 
22:5n-3 0.31 4.14 4.25 3.15  0.42 9.74 4.66 2.19 
22:6n-3 1.57 3.71 7.50 3.32  1.85 6.02 9.71 1.84 
*  One sample was lost; n.d., not detected; PC, phosphatidylcholine, PE, phosphatidylethanolamine. 
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Table  8.6. Reproducibility of fatty acid analysis in RBC total lipids, DHAVEG study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 19) 
 wt% CV (%)  wt% CV (%) 
Saturated fatty acids      
14:0 0.36 1.40  0.37 2.14 
15:0 0.21 0.58  0.21 3.14 
16:0 22.24 0.29  22.26 0.88 
17:0 0.32 1.10  0.32 2.52 
18:0 13.80 0.19  13.64 0.80 
20:0 0.36 2.31  0.37 4.08 
22:0 1.33 1.31  1.35 2.64 
24:0 4.45 2.08  4.61 5.93 
Trans fatty acids      
14:1t n.d.   n.d.  
16:1t n.d.   n.d.  
18:1t 0.19 7.98  0.17 5.41 
18:2tt n.d.   n.d.  
22:1t n.d.   n.d.  
MUFA      
14:1n-5 n.d.   n.d.  
15:1n-5 n.d.   n.d.  
16:1n-7 0.45 1.00  0.46 1.42 
17:1n-7 n.d.   n.d.  
18:1n-7 1.49 1.13  1.48 5.46 
18:1n-9 11.55 0.20  11.44 0.94 
20:1n-9 0.21 1.50  0.20 2.11 
22:1n-9 0.17 34.69  0.19 34.03 
24:1n-9 3.96 1.55  4.17 4.31 
PUFA      
20:3n-9 0.10 2.33  0.10 3.79 
18:2n-6 9.20 0.65  9.23 1.17 
18:3n-6 0.07 2.74  0.06 7.96 
20:2n-6 0.23 1.16  0.25 4.32 
20:3n-6 2.05 1.32  2.05 0.86 
20:4n-6 15.29 0.22  15.07 0.82 
22:2n-6 n.d.   n.d.  
22:4n-6 3.77 0.44  3.82 1.04 
22:5n-6 0.71 1.74  0.76 2.31 
18:3n-3 0.09 2.51  0.09 3.23 
18:4n-3 n.d.   n.d.  
20:3n-3 0.17 6.41  0.15 10.43 
20:5n-3 0.49 0.93  0.49 1.99 
22:5n-3 2.82 0.48  2.80 1.78 
22:6n-3 3.79 0.54  3.76 2.06 
n.d., not detected. 
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Table  8.7. Reproducibility of fatty acid analysis in plasma phospholipids, FO/EPO study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 11) 
 mg/l  CV (%) wt%  CV (%)  mg/l CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 9.52 0.94 0.54 0.74  9.43 3.37 0.52 3.65 
15:0 IS  IS   IS  IS  
16:0 611.67 1.00 34.75 0.40  620.63 2.17 34.41 1.43 
17:0 6.14 1.78 0.35 1.61  6.21 2.11 0.34 2.42 
18:0 154.98 1.34 8.80 0.72  159.99 2.42 8.87 1.16 
20:0 8.25 4.81 0.47 4.83  9.10 4.50 0.50 4.37 
22:0 24.47 1.39 1.39 1.35  25.60 10.78 1.42 10.46 
24:0 13.59 1.55 0.77 1.61  15.27 4.12 0.85 3.40 
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t 1.98 5.07 0.11 5.15  1.66 17.54 0.09 18.74 
18:1t 1.75 8.53 0.10 8.51  2.40 11.06 0.13 10.27 
18:2tt 0.81 11.71 0.05 11.42  0.84 8.06 0.05 7.53 
22:1t 4.37 2.43 0.25 2.17  4.63 5.76 0.26 4.61 
MUFA          
14:1n-5 n.d.  n.d.   n.d.  n.d.  
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 32.26 0.96 1.83 0.77  32.53 3.08 1.80 1.44 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 32.62 1.15 1.85 0.57  33.32 3.32 1.85 1.12 
18:1n-9 195.64 0.90 11.11 0.40  200.06 3.05 11.09 0.52 
20:1n-9 2.11 2.68 0.12 2.13  2.24 4.68 0.12 4.62 
22:1n-9 3.72 28.11 0.21 27.35  4.96 41.79 0.27 41.60 
24:1n-9 36.98 0.80 2.10 0.63  39.22 3.45 2.17 2.69 
PUFA          
20:3n-9 5.73 1.09 0.33 1.27  6.02 2.79 0.33 2.02 
18:2n-6 246.23 0.70 13.99 0.35  250.87 3.22 13.90 0.71 
18:3n-6 1.94 2.46 0.11 2.78  1.98 4.55 0.11 2.85 
20:2n-6 7.61 0.52 0.43 0.69  7.87 3.17 0.44 1.72 
20:3n-6 77.27 0.74 4.39 0.69  79.37 3.52 4.40 1.29 
20:4n-6 178.25 1.21 10.13 1.12  184.12 3.80 10.20 1.53 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 9.57 0.88 0.54 1.15  9.96 4.36 0.55 2.52 
22:5n-6 10.23 1.49 0.58 1.44  10.16 3.39 0.56 2.26 
18:3n-3 3.11 0.96 0.18 1.15  3.15 4.07 0.17 2.50 
18:4n-3 0.68 11.17 0.04 11.68  0.70 10.92 0.04 10.92 
20:3n-3 2.31 3.67 0.13 3.34  2.30 9.30 0.13 9.19 
20:5n-3 11.70 1.27 0.66 1.71  11.88 3.92 0.66 1.73 
22:5n-3 15.38 1.39 0.87 1.76  16.09 4.66 0.89 2.81 
22:6n-3 49.59 1.62 2.82 1.85  51.51 4.91 2.85 2.97 
IS, internal standard; n.d., not detected. 
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Table  8.8. Reproducibility of fatty acid analysis in plasma CE, FO/EPO study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 10) 
 mg/l  CV (%) wt%  CV (%)  mg/l CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 12.01 1.09 1.11 0.86  12.18 3.02 1.15 4.02 
15:0 IS  IS   IS  IS  
16:0 136.00 1.04 12.62 0.23  135.16 2.23 12.72 1.89 
17:0 0.92 6.15 0.09 5.49  1.14 6.63 0.11 7.35 
18:0 6.68 1.75 0.62 1.24  6.92 4.27 0.65 4.96 
20:0 1.06 2.85 0.10 3.43  0.93 14.34 0.09 14.86 
22:0 n.d.  n.d.   n.d.  n.d.  
24:0 n.d.  n.d.   n.d.  n.d.  
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t n.d.  n.d.   n.d.  n.d.  
18:1t n.d.  n.d.   n.d.  n.d.  
18:2tt n.d.  n.d.   n.d.  n.d.  
22:1t 1.21 7.82 0.11 7.08  1.16 9.78 0.11 8.12 
MUFA          
14:1n-5 0.82 5.83 0.08 6.26  0.88 7.28 0.08 7.29 
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 111.46 1.17 10.34 0.41  110.40 2.86 10.39 1.83 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 15.77 1.16 1.46 0.35  16.38 4.27 1.54 2.51 
18:1n-9 241.77 1.25 22.43 0.16  238.52 3.17 22.43 0.49 
20:1n-9 n.d.  n.d.   n.d.  n.d.  
22:1n-9 1.06 15.56 0.10 16.26  1.26 38.92 0.12 38.84 
24:1n-9 n.d.  n.d.   n.d.  n.d.  
PUFA          
20:3n-9 1.29 3.61 0.12 3.79  1.34 22.84 0.13 23.82 
18:2n-6 417.23 1.22 38.70 0.08  409.68 3.37 38.53 0.43 
18:3n-6 14.50 1.17 1.35 0.33  14.42 3.53 1.36 2.23 
20:2n-6 n.d.  n.d.   n.d.  n.d.  
20:3n-6 10.46 1.49 0.97 0.41  10.13 4.90 0.95 2.88 
20:4n-6 82.07 1.37 7.61 0.38  79.75 3.97 7.50 1.37 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 n.d.  n.d.   n.d.  n.d.  
22:5n-6 0.58 6.37 0.05 5.57  0.56 9.26 0.05 7.58 
18:3n-3 7.59 1.54 0.70 0.58  7.40 3.88 0.70 1.45 
18:4n-3 0.65 5.12 0.06 4.90  0.63 20.19 0.06 19.50 
20:3n-3 0.52 10.53 0.05 9.81  0.47 12.77 0.04 11.92 
20:5n-3 7.87 1.56 0.73 0.62  7.46 5.18 0.70 4.18 
22:5n-3 n.d.  n.d.   n.d.  n.d.  
22:6n-3 4.97 2.21 0.46 1.59  4.80 5.66 0.45 4.41 
CE, cholesterol esters; CV, coefficient of variation; IS, internal standard; n.d., not detected. 
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Table  8.9. Reproducibility of fatty acid analysis in plasma triglycerides, FO/EPO study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 10) 
 mg/l  CV (%) wt%  CV (%)  mg/l CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 25.90 1.21 2.79 1.02  26.32 3.02 2.95 4.40 
15:0 IS  IS   IS  IS  
16:0 305.63 1.04 32.92 0.37  303.36 2.65 33.94 0.85 
17:0 2.50 2.83 0.27 2.20  2.62 3.54 0.29 3.44 
18:0 21.64 1.59 2.33 1.29  20.72 5.31 2.32 3.70 
20:0 1.46 7.77 0.16 7.59  1.16 13.60 0.13 12.72 
22:0 0.82 5.22 0.09 4.36  0.32 11.13 0.04 10.41 
24:0 n.d.  n.d.   n.d.  n.d.  
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t 0.72 6.64 0.08 6.89  0.74 8.95 0.08 8.40 
18:1t 3.25 3.07 0.35 2.30  3.27 17.37 0.37 15.24 
18:2tt 0.81 10.44 0.09 10.38  0.69 8.20 0.08 8.20 
22:1t 0.80 4.99 0.09 4.62  0.76 9.05 0.09 7.31 
MUFA          
14:1n-5 2.65 1.07 0.29 1.09  2.78 7.02 0.31 8.46 
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 82.78 1.21 8.91 0.31  81.89 3.00 9.16 2.98 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 41.39 1.42 4.46 0.37  38.50 3.59 4.31 1.28 
18:1n-9 278.87 1.42 30.03 0.30  263.09 3.42 29.43 1.02 
20:1n-9 4.40 1.57 0.47 0.72  3.94 6.57 0.44 5.11 
22:1n-9 1.29 8.23 0.14 8.02  1.43 25.61 0.16 25.84 
24:1n-9 n.d.  n.d.   n.d.  n.d.  
PUFA          
20:3n-9 3.34 0.91 0.36 0.95  3.10 7.36 0.35 6.16 
18:2n-6 95.60 1.38 10.30 0.28  89.97 2.87 10.07 0.45 
18:3n-6 2.40 1.88 0.26 1.24  2.31 3.47 0.26 2.38 
20:2n-6 2.45 1.05 0.26 0.58  2.28 6.63 0.26 5.52 
20:3n-6 4.81 1.37 0.52 0.74  4.24 4.88 0.48 3.38 
20:4n-6 17.60 1.35 1.90 0.22  15.91 4.07 1.78 2.56 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 2.68 3.29 0.29 2.36  2.48 5.30 0.28 4.44 
22:5n-6 3.57 2.20 0.38 1.24  3.16 5.37 0.35 4.01 
18:3n-3 6.81 1.76 0.73 1.16  6.40 2.84 0.72 2.92 
18:4n-3 n.d.  n.d.   n.d.  n.d.  
20:3n-3 0.80 4.99 0.09 5.00  0.71 8.44 0.08 6.54 
20:5n-3 1.97 3.16 0.21 2.90  1.66 4.14 0.19 3.70 
22:5n-3 2.54 2.06 0.27 2.02  2.14 5.23 0.24 4.06 
22:6n-3 8.69 1.82 0.94 1.44  7.45 5.13 0.83 3.91 
CV, coefficient of variation; IS, internal standard; n.d., not detected. 
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Table  8.10. Reproducibility of fatty acid analysis in plasma total lipids, FO/EPO study (mean, CV). 
 Intra-assay (n = 8)  Inter-assay (n = 10) 
 mg/l  CV (%) wt%  CV (%)  mg/l CV (%) wt% CV (%) 
Saturated fatty acids          
14:0 50.70 1.20 1.26 0.56  51.65 2.69 1.27 2.86 
15:0 IS  IS   IS  IS  
16:0 1134.12 1.17 28.11 0.61  1140.11 2.06 27.95 1.13 
17:0 10.56 2.56 0.26 2.13  10.48 3.08 0.26 2.03 
18:0 206.16 2.20 5.11 1.78  205.02 3.41 5.03 2.58 
20:0 9.32 6.07 0.23 6.13  11.82 5.16 0.29 4.59 
22:0 27.84 2.93 0.69 2.60  26.72 15.69 0.66 15.51 
24:0 15.06 3.08 0.37 2.45  15.95 4.94 0.39 3.97 
Trans fatty acids          
14:1t n.d.  n.d.   n.d.  n.d.  
16:1t 2.96 4.09 0.07 3.08  2.75 9.81 0.07 9.85 
18:1t 5.48 2.59 0.14 2.69  6.24 4.98 0.15 4.76 
18:2tt 1.92 7.72 0.05 7.73  1.87 4.13 0.05 4.26 
22:1t 7.36 3.07 0.18 2.76  7.18 5.50 0.18 3.63 
MUFA          
14:1n-5 4.16 2.06 0.10 2.47  4.33 3.67 0.11 4.52 
15:1n-5 n.d.  n.d.   n.d.  n.d.  
16:1n-7 235.78 1.33 5.84 1.07  241.01 3.09 5.91 1.98 
17:1n-7 n.d.  n.d.   n.d.  n.d.  
18:1n-7 97.16 1.22 2.41 0.68  97.87 2.81 2.40 0.86 
18:1n-9 753.10 1.48 18.66 1.20  772.53 3.57 18.94 1.75 
20:1n-9 7.02 3.09 0.17 3.42  7.42 4.68 0.18 3.41 
22:1n-9 5.20 68.11 0.13 66.65  5.33 32.00 0.13 31.93 
24:1n-9 42.40 2.87 1.05 2.50  42.27 5.06 1.04 4.48 
PUFA          
20:3n-9 11.40 1.64 0.28 1.13  11.57 5.38 0.28 3.43 
18:2n-6 787.38 1.31 19.51 0.98  800.91 3.35 19.63 1.22 
18:3n-6 19.34 1.85 0.48 1.55  19.94 3.55 0.49 1.96 
20:2n-6 11.92 1.60 0.30 1.43  12.00 4.49 0.29 2.36 
20:3n-6 104.38 2.06 2.59 1.76  103.07 4.06 2.53 3.12 
20:4n-6 308.30 1.43 7.64 0.90  307.09 3.32 7.53 1.68 
22:2n-6 n.d.  n.d.   n.d.  n.d.  
22:4n-6 14.40 1.97 0.36 1.50  14.30 4.48 0.35 3.06 
22:5n-6 17.16 2.04 0.43 1.86  16.21 5.23 0.40 4.67 
18:3n-3 19.28 1.17 0.48 0.98  19.41 3.16 0.48 0.88 
18:4n-3 2.02 8.40 0.05 8.96  2.16 18.89 0.05 18.62 
20:3n-3 3.98 5.45 0.10 4.93  3.82 9.75 0.09 9.03 
20:5n-3 24.36 1.71 0.60 1.09  23.74 3.85 0.58 2.81 
22:5n-3 21.36 2.16 0.53 1.84  20.90 4.24 0.51 3.29 
22:6n-3 73.60 2.21 1.82 1.90  73.60 3.81 1.80 2.57 
CV, coefficient of variation; IS, internal standard; n.d., not detected.
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Table  8.11. BMI, blood pressure and heart rate at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 54 - 55)*  Placebo group (n = 53)   
 Week 0 Week 8  Week 0 Week 8  P† 
Weight (kg)§ 60.8 (56.2 – 67.3) 60.9 (54.8 – 67.7)  60.2 (53.7 – 69.0) 60.7 (54.0 – 70.4)1  0.072 
BMI (kg/m2) 21.23 ± 1.69 21.23 ± 1.75  21.18 ± 1.94 21.36 ± 1.901  0.056 
Systolic BP (mm Hg)§ 100 (90 – 100) 100 (94 – 110)  95 (90 – 100) 100 (95 – 105)1  0.675 
Diastolic BP (mm Hg)§ 65 (60 – 70) 70 (60 – 70)  70 (60 – 70) 70 (65 – 70)  0.700 
Heart rate (beats/min)§ 68 (63 – 72) 68 (64 – 72)  68 (64 – 72) 68 (64 – 72)  0.664 
BMI, body mass index; BP, blood pressure; IQR, interquartile range. 
*  For one subject, blood pressure and heart rate values are missing; §  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.12. Plasma triglycerides and lipoproteins at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 53)  Placebo group (n = 53)   
 Week 0 Week 8  Week 0 Week 8  P† 
Triglycerides (mmol/l)§ 0.96 (0.75 – 1.21) 0.77 (0.63 – 1.05)1,a  1.04 (0.68 – 1.30) 0.91 (0.71 – 1.34)  0.033 
Total cholesterol (mmol/l)§ 4.47 (3.89 – 5.18) 4.73 (4.02 – 5.39)1  4.71 (4.05 – 5.30) 4.68 (4.03 – 5.13)  0.004 
LDL cholesterol (mmol/l)§ 2.43 (1.86 – 2.96) 2.74 (2.19 – 3.07)1  2.64 (2.03 – 3.10) 2.48 (1.95 – 3.07)  0.003 
HDL cholesterol (mmol/l) 1.65 ± 0.47 1.77 ± 0.471  1.67 ± 0.44 1.66 ± 0.43  0.002 
LDL:HDL cholesterol 1.58 ± 0.54 1.64 ± 0.60  1.64 ± 0.65 1.65 ± 0.69  0.441 
Total:HDL cholesterol 2.92 ± 0.70 2.87 ± 0.68  2.95 ± 0.76 2.97 ± 0.82  0.486 
TG:HDL chosterol§ 0.57 (0.43 – 0.91) 0.43 (0.35 – 0.64)1,a  0.63 (0.36 – 0.87) 0.57 (0.43 – 0.86)  0.021 
IQR, interquartile range; TG, triglycerides. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0. 
a  p < 0.05 vs. placebo at the same time point. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.13. Vitamin A and E levels at weeks 0 and 8, DHAVEG study (mean ± SD). 
 DHA group (n = 55)  Placebo group (n = 53)   
 Week 0 Week 8  Week 0 Week 8  P† 
Retinol (µmol/l) 1.78 ± 0.44 1.81 ± 0.42  1.81 ± 0.43 1.74 ± 0.43  0.020 
alpha-Tocopherol (µmol/l) 20.80 ± 3.99 20.32 ± 3.79  21.22 ± 4.17 21.11 ± 4.02  0.450 
alpha-Tocopherol/ 
(Cholesterol+TG) (µmol/mmol) 3.67 ± 0.58 3.60 ± 0.59  3.72 ± 0.54 3.72 ± 0.55  0.736 
TG, triglycerides. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.14. Plasma haemostatic factors at weeks 0 and 8, DHAVEG study (median with IQR). 
  DHA group   Placebo group   
 n* Week 0 Week 8  n* Week 0 Week 8  P† 
PTT (sec) 53 32.0 (31.0 – 34.0) 32.0 (29.5 – 35.0)  52 31.5 (30.0 – 34.7) 31.5 (29.0 – 34.0)1  0.212 
Fibrinogen (mg/dl) 53 233 (209 – 264) 258 (230 – 301)1  51 230 (203 – 292) 268 (226 – 327)1  0.608 
D-dimers (µg/ml) 55 0.2 (0.1 – 0.3) 0.2 (0.1 – 0.3)  53 0.2 (0.1 – 0.3) 0.2 (0.1 – 0.3)  0.838 
Factor VII (%) 55 103.0 (94.0 – 120.0) 104.0 (90.0 – 119.0)  53 105.0 (88.0 – 130.5) 107.0 (88.5 – 122.0)  0.330 
Von Willebrand factor (%) 55 91.0 (75.0 – 119.0) 89.0 (71.0 – 105.0)1  53 92.0 (65.5 – 116.0) 96.0 (67.0 – 109.5)  0.033 
PAI-1 (AU/ml) 55 2.75 (0.00 – 6.08) 3.57 (1.31 – 6.15)  53 2.25 (0.00 – 6.39) 5.42 (1.90 – 8.32)1  0.083 
PFA-ADP 43 82.0 (70.0 – 101.0) 92.0 (81.0 – 105.0)1  40 85.0 (74.0 – 96.8) 88.0 (74.0 – 109.5)  0.728 
PFA-EPI 42 117.5 (104.0 – 134.0) 128.0 (108.8 – 147.0)  34 116.0 (101.0 – 139.0) 129.5 (105.8 – 149.5)  0.761 
IQR, interquartile range; PTT, partial thromboplastin time; PAI-1, plasminogen activator inhibitor-1 activity; PFA-ADP, platelet function analysis with adenosine 
diphosphate; PFA-EPI, platelet function analysis with epinephrine. 
*  Some samples are missing because of technical problems during measurement or coagulation of the blood samples. 
1  p < 0.05 vs. week 0. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
 
   
Table  8.15. Biochemical parameters and full blood cell count at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 54 - 55)*  Placebo group (n = 51 - 53)*   
 Week 0 Week 8  Week 0 Week 8  P† 
Creatinine (mg/dl)§ 0.8 (0.8 – 0.9) 0.9 (0.8 – 0.9)  0.8 (0.8 – 0.9) 0.8 (0.8 – 0.9)  0.184 
Bilirubin (mg/dl)§ 0.7 (0.5 – 1.0)a 0.8 (0.5 – 1.0)  0.6 (0.4 – 0.8) 0.6 (0.4 – 0.8)  0.328 
GGT (U/l)§ 15.0 (12.0 – 20.0) 15.0 (12.0 – 20.0)  14.0 (13.0 – 20.0) 15.0 (12.0 – 18.5)  0.069 
ALT (U/l)§ 13.0 (10.0 – 18.0) 16.0 (12.0 – 20.0)1  14.0 (10.5 – 19.0) 13.0 (11.0 – 19.0)  0.031 
AST (U/l)§  20.0 (18.0 – 25.0) 21.0 (18.0 – 26.0)  21.0 (18.5 – 26.5) 21.0 (19.0 – 24.0)  0.267 
CHE (kU/l)§ 7.5 (6.6 – 8.6) 7.2 (6.5 – 8.0)1  6.9 (5.9 – 8.1) 6.9 (6.2 – 7.7)  <0.001 
CK (U/l)§ 79.0 (57.0 – 104.0) 80.0 (64.0 – 102.0)  84.0 (66.0 – 102.5) 77.0 (64.0 – 117.0)  0.567 
LDH (U/l § 144.0 (135.5 – 154.3) 146.5 (131.8 – 158.0)  147.0 (128.5 – 165.5) 140.0 (128.0 – 165.5)  0.566 
Uric acid (mg/dl) 4.56 ± 1.15 4.55 ± 0.95  4.95 ± 1.20 4.73 ± 1.231  0.140 
Total protein (g/dl) 7.60 ± 0.45 7.44 ± 0.531  7.69 ± 0.45 7.43 ± 0.421  0.308 
CRP (mg/dl)§ 0.20 (0.10 – 0.30) 0.20 (0.05 – 0.30)  0.20 (0.10 – 0.30) 0.20 (0.10 – 0.40)  0.326 
Glucose (mg/dl)§ 93.3 ± 7.5 92.2 ± 7.6  95.9 ± 6.1 94.6 ± 7.8  0.926 
Blood cell count        
     Leucocytes (G/l)§ 5.80 (4.90 – 6.60) 5.60 (4.40 – 7.00)  5.60 (4.95 – 6.60) 5.50 (4.85 – 6.15)1  0.397 
     Erythrocytes (T/l)§ 4.40 (4.30 – 4.70) 4.30 (4.10 – 4.70)  4.40 (4.30 – 4.80) 4.30 (4.05 – 4.45)1  0.028 
     Haemoglobin (g/dl)§ 13.7 (12.9 – 14.5) 13.4 (12.8 – 14.5)1  13.7 (12.7 – 14.5) 13.2 (12.6 – 13.9)1  0.255 
     Haematocrit (%) 40.0 ± 3.1 39.5 ± 3.6  40.1 ± 3.4 38.5 ± 3.31  0.044 
     MCV (fl) 88.9 ± 4.5 89.3 ± 4.5  89.4 ± 4.7 89.8 ± 4.7  0.821 
     MCH (pg)§ 30.6 (29.4 – 32.0) 30.9 (29.8 – 32.0)  30.6 (29.6 – 31.5) 30.9 (30.2 – 32.3)1  0.194 
     MCHC (%)§ 34.7 (33.0 – 35.3) 34.5 (33.6 – 35.4)  34.1 (33.0 – 35.1) 34.7 (33.5 – 35.6)  0.439 
     Platelets (G/l) 233.3 ± 57.0 236.7 ± 60.6  238.9 ± 53.3 239.3 ± 59.2  0.775 
GGT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHE, cholinesterase; CK, creatinekinase; LDH, lactate 
dehydrogenase; CRP, C-reactive protein; MCV, mean cellular volume; MCH, mean cellular haemoglobin; MCHC, mean cellular haemoglobin concentration. 
*  Some samples are missing because of technical problems measurement; §  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0; a p < 0.05 vs. placebo at the same time point. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.16. Relative fatty acid composition (wt%) in plasma phospholipids at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 55)  Placebo group (n = 53) 
 Week 0 Week 8  Week 0 Week 8 
16:0§ 27.95 (26.98 – 29.66) 28.15 (27.38 – 29.91)a  27.95 (26.40 – 29.20) 27.40 (26.38 – 29.58) 
18:0§ 12.03 (10.99 – 13.00) 12.08 (10.82 – 13.18)  12.40 (11.43 – 13.10) 12.23 (11.33 – 12.93) 
18:1n-9 10.35 ± 1.42 9.07 ± 1.181,a  10.33 ± 1.62 10.48 ± 1.43 
20:3n-9§ 0.14 (0.10 – 0.21) 0.08 (0.05 – 0.11)1,a  0.14 (0.10 – 0.20) 0.14 (0.12 – 0.18) 
18:2n-6 22.01 ± 2.80 20.63 ± 2.821,a  23.04 ± 3.23 22.91 ± 2.90 
18:3n-6§ 0.10 (0.07– 0.12) 0.06 (0.04 – 0.08) 1,a  0.10 (0.08 – 0.13) 0.08 (0.07 – 0.12) 
20:3n-6 3.49 ± 0.72 2.59 ± 0.601,a  3.31 ± 0.87 3.34 ± 0.88 
20:4n-6 8.93 ± 1.40 8.07 ± 1.421,a  8.92 ± 1.66 8.99 ± 1.76 
22:4n-6§ 0.42 (0.35 – 0.50) 0.23 (0.20 – 0.28)1,a  0.40 (0.35 – 0.48) 0.40 (0.34 – 0.46) 
22:5n-6§ 0.34 (0.29 – 0.45) 0.66 (0.56 – 0.73)1,a  0.31 (0.24 – 0.45) 0.32 (0.24 – 0.44) 
18:3n-3§ 0.19 (0.14 – 0.24) 0.16 (0.11 – 0.21)  0.17 (0.14 – 0.24) 0.18 (0.13 – 0.26) 
20:5n-3§ 0.54 (0.42 – 0.64) 0.75 (0.62 – 0.87)1,a  0.52 (0.41 – 0.73) 0.48 (0.39 – 0.66) 1 
22:5n-3 0.90 ± 0.27 0.55 ± 0.181,a  0.85 ± 0.26 0.85 ± 0.27 
22:6n-3 2.84 ± 0.89 7.36 ± 1.611,a  2.56 ± 0.74 2.52 ± 0.68 
EPA + DHA 3.42 ± 0.91 8.13 ± 1.671,a  3.13 ± 0.78 3.04 ± 0.69 
∑n-6 FA 35.74 ± 2.15 32.62 ± 2.291,a  36.49 ± 2.47 36.46 ± 2.27 
∑n-3 FA§ 4.61 (4.06 – 5.23) 8.84 (8.00 – 9.89)1,a  4.20 (3.75 – 4.85) 4.26 (3.79 – 4.70) 
∑n-6/∑n-3 FA§ 7.83 (6.87 – 8.91) 3.80 (3.11 – 4.15)1,a  8.55 (7.17 – 9.93) 8.32 (7.58 – 9.99) 
∑n-6 LCPUFA 13.61 ± 1.74 11.92 ± 1.711,a  13.35 ± 2.13 13.44 ± 1.98 
∑n-3 LCPUFA 4.48 ± 0.94a 8.82 ± 1.661,a  4.13 ± 0.78 4.03 ± 0.71 
∑n-6/∑n-3 LCPUFA§ 3.23 (2.82 – 3.64) 1.34 (1.18 – 1.56)1,a  3.31 (2.92 – 3.76) 3.29 (2.99 – 3.80) 
IQR, interquartile range; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ∑n-6 FA, sum of n-6 fatty acids; ∑n-3 FA, sum of n-3 fatty acids; ∑n-6/∑n-3 
FA, ratio of n-6 to n-3 fatty acids; ∑n-6 LCPUFA, sum of all long-chain n-6 fatty acids; ∑n-3 LCPUFA, sum of all long-chain n-3 fatty acids; ∑n-6/∑n-3 LCPUFA, 
ratio of n-6 to n-3 long-chain polyunsaturated fatty acids. 
§  Median with IQR in parentheses; 1  p < 0.05 vs. week 0; a p < 0.05 vs. placebo at the same time point. 
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Table  8.17. Relative fatty acid composition (wt%) in RBC phosphatidylcholine at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 55)  Placebo group (n = 52)* 
 Week 0 Week 8  Week 0 Week 8 
16:0§ 35.59 (34.44 – 37.13) 36.26 (34.76 – 37.21)1  35.20 (34.26 – 37.35) 35.03 (34.20 – 36.68)1 
18:0§ 10.07 (8.71 – 10.90) 10.27 (9.25 – 10.99)1  10.13 (9.11 – 10.87) 10.33 (9.04 – 10.97) 
18:1n-9 15.92 ± 1.48 15.45 ± 1.261,a  15.99 ± 1.28 16.16 ± 1.30 
20:3n-9§ 0.08 (0.05 – 0.11) 0.04 (0.03 – 0.07)1,a  0.08 (0.06 – 0.11) 0.08 (0.06 – 0.11) 
18:2n-6 21.09 ± 2.34 20.16 ± 2.341,a  21.58 ± 2.21 21.43 ± 2.34 
18:3n-6§ 0.07 (0.06 – 0.09) 0.04 (0.03 – 0.05)1,a  0.07 (0.06 – 0.09) 0.06 (0.05 – 0.08) 
20:3n-6 2.50 ± 0.52 1.96 ± 0.441,a  2.45 ± 0.65 2.45 ± 0.65 
20:4n-6 6.00 ± 1.10 5.49 ± 1.001,a  5.97 ± 1.00 6.02 ± 1.09 
22:4n-6§ 0.31 (0.26 – 0.37) 0.22 (0.20 – 0.27)1,a  0.31 (0.25 – 0.34) 0.33 (0.26 – 0.35)1 
22:5n-6§ 0.16 (0.12 – 0.20) 0.33 (0.27 – 0.38)1,a  0.13 (0.11 – 0.21) 0.14 (0.11 – 0.21) 
18:3n-3§ 0.19 (0.15 – 0.24) 0.16 (0.12 – 0.20) 1  0.18 (0.14 – 0.22) 0.18 (0.15 – 0.24) 
20:5n-3§ 0.31 (0.24 – 0.41) 0.43 (0.35 – 0.53)1,a  0.30 (0.23 – 0.41) 0.28 (0.22 – 0.36) 
22:5n-3 0.52 ± 0.16 0.37 ± 0.101,a  0.51 ± 0.14 0.51 ± 0.14 
22:6n-3 1.38 ± 0.51 3.78 ± 0.951,a  1.25 ± 0.41 1.23 ± 0.43 
EPA + DHA§ 1.58 (1.35 – 2.13) 4.10 (3.57 – 4.99)1,a  1.58 (1.22 – 1.91) 1.46 (1.23 – 1.90) 
∑n-6 FA§ 30.56 (29.00 – 32.19) 28.36 (27.57 – 29.69)1,a  30.91 (29.73 – 32.19) 30.33 (29.62 – 32.00) 
∑n-3 FA 2.56 ± 0.62 4.88 ± 1.021,a  2.41 ± 0.48 2.36 ± 0.47 
∑n-6/∑n-3 FA§ 12.73 (10.11 – 14.23) 5.84 (5.10 – 6.71)1,a  13.17 (11.38 – 15.36) 13.09 (11.17 – 14.71) 
∑n-6 LCPUFA§ 9.28 (8.26 – 10.52) 8.22 (7.20 – 9.43)1,a  9.02 (8.09 – 10.43) 9.27 (8.38 – 10.04) 
∑n-3 LCPUFA 2.37 ± 0.60 4.71 ± 1.021,a  2.20 ± 0.45 2.17 ± 0.45 
∑n-6/∑n-3 LCPUFA§ 4.23 (3.68 – 4.76) 1.82 (1.54 – 2.06)1,a  4.20 (3.85 – 4.77) 4.26 (3.95 – 4.91) 
Abbreviations see Table  8.16. 
*  One sample was lost during preparation. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0; a p < 0.05 vs. placebo at the same time point. 
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Table  8.18. Relative fatty acid composition (wt%) in RBC phosphatidylethanolamine at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 55)  Placebo group (n = 52)* 
 Week 0 Week 8  Week 0 Week 8 
16:0 15.97 ± 1.21 16.54 ± 1.211,a  15.94 ± 1.27 15.79 ± 1.20 
18:0 7.61 ± 0.71 7.61 ± 0.67  7.56 ± 0.47 7.71 ± 0.441 
18:1n-9 16.36 ± 1.56 16.12 ± 1.531  16.70 ± 1.67 16.72 ± 1.61 
20:3n-9 0.10 ± 0.04 0.08 ± 0.031,a  0.10 ± 0.03 0.11 ± 0.041 
18:2n-6 6.55 ± 1.27 5.82 ± 1.161,a  6.87 ± 1.19 6.88 ± 1.36 
18:3n-6 0.11 ± 0.02 0.09 ± 0.021,a  0.11 ± 0.02 0.11 ± 0.02 
20:3n-6§ 1.63 (1.41 – 1.87) 1.48 (1.29 – 1.62)1,a  1.57 (1.40 – 1.82) 1.60 (1.43 – 1.87) 
20:4n-6 25.56 ± 1.84 23.77 ± 1.891,a  25.49 ± 1.68 25.60 ± 1.65 
22:4n-6 8.52 ± 1.40 6.57 ± 1.261,a  8.45 ± 1.23 8.48 ± 1.20 
22:5n-6 1.15 ± 0.30 1.67 ± 0.28  1.07 ± 0.33 1.07 ± 0.32 
18:3n-3§ 0.13 (0.11 – 0.16) 0.11 (0.08 – 0.14)1,a  0.13 (0.11 – 0.17) 0.14 (0.11 – 0.18) 
20:5n-3§ 0.71 (0.55 – 0.88) 0.81 (0.67 – 0.96)1  0.70 (0.59 – 0.89) 0.73 (0.60 – 0.89) 
22:5n-3 5.12 ± 1.11 3.65 ± 0.851,a  5.13 ± 1.02 5.15 ± 1.04 
22:6n-3§ 6.06 (4.83 – 8.13) 12.49 (10.97 – 13.39)1,a  5.72 (4.48 – 7.85) 5.32 (4.37 – 7.56)1 
EPA + DHA§ 7.03 (5.43 – 9.16) 13.45 (11.61 – 14.40)1,a  6.48 (5.22 – 8.62) 6.20 (5.00 – 8.56)1 
∑n-6 FA 43.94 ± 2.85 39.76 ± 2.651,a  44.04 ± 2.25 44.21 ± 1.93 
∑n-3 FA 12.79 ± 2.30 16.93 ± 2.201,a  12.37 ± 1.92 12.20 ± 1.98 
∑n-6/∑n-3 FA§ 3.44 (3.03 – 4.12) 2.36 (2.08 – 2.70)1,a  3.58 (3.12 – 4.15) 3.73 (3.18 – 4.08)1 
∑n-6 LCPUFA§ 38.35 (34.84 – 39.25) 33.88 (32.01 – 35.72)1,a  37.51 (36.34 – 38.34) 37.52 (35.91 – 38.64) 
∑n-3 LCPUFA§ 12.77 (11.04 – 14.13) 17.06 (15.41 – 18.27)1,a  12.15 (10.61 – 13.84) 11.77 (10.78 – 13.65)1 
∑n-6/∑n-3 LCPUFA§ 2.94 (2.62 – 3.57) 1.98 (1.79 – 2.31)1,a  3.06 (2.71 – 3.52) 3.21 (2.79 – 3.49)1 
Abbreviations see Table  8.16. 
*  One sample was lost during preparation. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0; a p < 0.05 vs. placebo at the same time point. 
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Table  8.19. Relative fatty acid composition (wt%) in RBC total lipids at weeks 0 and 8, DHAVEG study (mean ± SD or median with IQR). 
 DHA group (n = 52)*  Placebo group (n = 51)* 
 Week 0 Week 8  Week 0 Week 8 
16:0§ 21.41 (20.88 – 21.94) 21.79 (21.14 – 22.26)1,a  21.25 (20.73 – 22.03) 20.98 (20.62 – 21.95)1 
18:0 13.89 ± 0.67 13.99 ± 0.631  13.88 ± 0.69 14.04 ± 0.681 
18:1n-9§ 12.02 (11.63 – 12.90) 11.85 (11.42 – 12.40)1,a  12.32 (11.86 – 13.02) 12.51 (11.88 – 13.20) 
20:3n-9§ 0.07 (0.06 – 0.09) 0.05 (0.04 – 0.07)1,a  0.08 (0.05 – 0.09) 0.07 (0.06 – 0.09) 
18:2n-6 10.18 ± 1.36 9.66 ± 1.421,a  10.55 ± 1.18 10.56 ± 1.37 
18:3n-6§ 0.04 (0.03 – 0.05) 0.03 (0.02 – 0.03)1,a  0.04 (0.03 – 0.05) 0.04 (0.03 – 0.05) 
20:3n-6§ 1.82 (1.61 – 2.14) 1.53 (1.38 – 1.74)1,a  1.75 (1.54 – 2.15) 1.82 (1.53 – 2.08) 
20:4n-6§ 14.04 (13.27 – 14.67) 12.75 (12.19 – 13.26)1,a  14.09 (13.50 – 14.64) 14.26 (13.59 – 14.54) 
22:4n-6 3.36 ± 0.60 2.58 ± 0.541,a  3.31 ± 0.54 3.32 ± 0.51 
22:5n-6 0.78 ± 0.20 1.07 ± 0.171,a  0.72 ± 0.19 0.72 ± 0.19 
18:3n-3§ 0.12 (0.10 – 0.14) 0.11 (0.09 – 0.13)1,a  0.12 (0.11 – 0.15) 0.12 (0.10 – 0.15) 
20:5n-3§ 0.39 (0.32 – 0.49) 0.46 (0.37 – 0.53)1,a  0.38 (0.30 – 0.49) 0.39 (0.30 – 0.46) 
22:5n-3 2.29 ± 0.47 1.66 ± 0.371,a  2.32 ± 0.45 2.31 ± 0.43 
22:6n-3§ 4.26 (3.56 – 5.11) 8.03 (7.41 – 8.53)1,a  3.94 (3.42 – 5.14) 3.85 (3.21 – 4.88)1 
EPA + DHA 4.84 ± 1.16 8.38 ± 1.311,a  4.58 ± 1.03 4.43 ± 0.951 
∑n-6 FA 30.61 ± 1.64 27.98 ± 1.671,a  30.85 ± 1.45 30.91 ± 1.52 
∑n-3 FA 7.40 ± 1.17 10.28 ± 1.221,a  7.18 ± 0.99 7.02 ± 0.891 
∑n-6/∑n-3 FA§ 4.24 (3.60 – 4.85) 2.69 (2.42 – 3.03)1,a  4.35 (3.75 – 4.88) 4.39 (3.89 – 4.95)1 
∑n-6 LCPUFA§ 20.58 (19.70 – 21.34) 18.23 (17.49 – 18.93)1,a  20.51 (19.63 – 21.04) 20.44 (19.41 – 21.09) 
∑n-3 LCPUFA 7.27 ± 1.16 10.17 ± 1.221,a  7.04 ± 0.99 6.89 ± 0.881 
∑n-6/∑n-3 LCPUFA§ 2.85 (2.51 – 3.33) 1.78 (1.63 – 1.99)1,a  2.97 (2.57 – 3.27) 3.03 (2.65 – 3.29)1 
Abbreviations see Table  8.16. 
*  Some samples were lost during preparation. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0; a p < 0.05 vs. placebo at the same time point. 
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Table  8.20. Spearman-Rho correlations between RBC total lipid fatty acids (wt%) and fatty acids from RBC PE, RBC PC                                                               
and plasma PL at week 0 and week 8 in all subjects, DHAVEG study (n = 103). 
  RBC PE  RBC PC  Plasma PL 
  Week 0 Week 8  Week 0 Week 8  Week 0 Week 8 
16:0  0.491* 0.521*  0.785* 0.705*  0.745* 0.753* 
18:1n-9  0.711* 0.664*  0.782* 0.704*  0.528* 0.515* 
18:2n-6  0.896* 0.887*  0.858* 0.930*  0.759* 0.802* 
20:3n-6  0.798* 0.791*  0.777* 0.757*  0.790* 0.781* 
20:4n-6  0.700* 0.826*  0.615* 0.700*  0.581* 0.661* 
22:4n-6  0.946* 0.965*  0.668* 0.821*  0.604* 0.758* 
22:5n-6  0.973* 0.969*  0.905* 0.910*  0.899* 0.895* 
18:3n-3  0.612* 0.672*  0.815* 0.827*  0.747* 0.743* 
20:5n-3  0.939* 0.913*  0.857* 0.856*  0.830* 0.817* 
22:5n-3  0.947* 0.961*  0.691* 0.755*  0.762* 0.851* 
22:6n-3  0.954* 0.971*  0.921* 0.955*  0.921* 0.944* 
EPA + DHA  0.956* 0.972*  0.900* 0.959*  0.911* 0.944* 
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine;  
PL, phospholipids; RBC, red blood cells. 
*  Significant correlations between RBC total lipid fatty acids and fatty acids of the other lipid fractions  (p < 0.001). 
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Table  8.21. Spearman-Rho correlations between percentage fatty acid changes from baseline in RBC total lipids or plasma phospholipids and percentage fatty 
acid changes in the other lipid fractions after 8-week supplementation with DHA, DHAVEG study (n = 52 – 55). 
 RBC TL – Plasma PL RBC TL – RBC PC RBC TL – RBC PE Plasma PL – RBC PC Plasma PL – RBC PE 
18:2n-6 0.746* 0.797* 0.666* 0.768* 0.595* 
20:4n-6 0.580* 0.636* 0.628* 0.770* ns 
22:5n-6 0.750* 0.849* 0.965* 0.863* 0.705* 
18:3n-3 0.823* 0.791* 0.531* 0.738* 0.278* 
20:5n-3 0.849* 0.902* 0.754* 0.949* 0.525* 
22:5n-3 0.603* 0.487* 0.834* 0.658* 0.412* 
22:6n-3 0.814* 0.897* 0.941* 0.885* 0.720* 
EPA + DHA 0.794* 0.898* 0.933* 0.861* 0.682* 
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ns, non-significant; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PL, phospholipids;  
RBC, red blood cells. 
*  Significant correlations between RBC total lipid fatty acids and fatty acids of the other lipid fractions  (p < 0.05). 
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Table  8.22. BMI, blood pressure and heart rate at weeks 0 and 8, FO/EPO study (mean ± SD or median with IQR). 
 FO/EPO group (n = 19)  Placebo group (n = 20)   
 Week 0 Week 8  Week 0 Week 8  P† 
Weight (kg) 60.9 ± 7.0 61.0 ± 7.0  62.3 ± 6.5 62.0 ± 6.4  0.136 
BMI (kg/m2) 21.7 ± 1.9 21.7 ± 1.8  21.9 ± 2.0 21.9 ± 2.0  0.438 
Systolic BP (mm Hg) 118 ± 13 120 ± 11  119 ± 11 120 ± 12  0.755 
Diastolic BP (mm Hg)§ 74 (67 – 78) 69 (67 – 77)1  71 (67 – 79) 73 (69 – 81)  0.126 
Heart rate (beats/min) 74 ± 11 74 ± 10  74 ± 14 75 ± 14  0.710 
BMI, body mass index; BP, blood pressure; IQR, interquartile range. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.23. Liver enzymes and full blood cell count at weeks 0 and 8, FO/EPO study (mean ± SD or median with IQR). 
 FO/EPO group (n = 19)  Placebo group (n = 20)   
 Week 0 Week 8  Week 0 Week 8  P† 
GGT (U/l)§ 14.0 (11.0 – 18.0) 12.0 (11.0 – 17.0)  12.0 (10.0 – 16.8) 12.5 (11.0 – 16.5)  0.216 
ALT (U/l)§ 21.0 (14.0 – 26.0) 19.0 (12.0 – 23.0)  18.0 (14.0 – 21.8) 17.5 (14.0 – 19.8)  0.872 
AST (U/l)§ 19.0 (18.0 – 29.0) 20.0 (19.0 – 22.0)  20.0 (17.0 – 23.5) 21.0 (18.3 – 23.0)  0.228 
CHE (kU/l) 6.4 ± 1.6 6.3 ± 1.6  5.5 ± 1.2 5.8 ± 1.11  0.001 
Blood cell count        
     Leucocytes (G/l)§  5.6 (5.0 – 6.3) 5.7 (5.2 – 6.8)  5.9 (5.4 – 6.7) 5.9 (5.3 – 6.7)  0.851 
     Erythrocytes (T/l)§ 4.6 (4.4 – 4.8) 4.4 (4.2 – 4.8)  4.5 (4.3 – 4.8) 4.6 (4.3 – 4.9)  0.050 
     Haemoglobin (g/dl) 13.6 ± 0.7 13.4 ± 0.9  13.6 ± 0.9 13.9 ± 0.9  0.033 
     Haematocrit (%) 41.9 ± 2.5 40.0 ± 2.61  41.3 ± 2.4 41.7 ± 2.8  0.010 
     MCV (fl) 90.9 ± 4.6 88.7 ± 5.71  91.7 ± 2.9 90.8 ± 3.6  0.145 
     MCH (pg) 29.7 ± 1.7 29.8 ± 1.8  30.0 ± 1.0 30.2 ± 1.1  0.744 
     MCHC (%)§ 32.5 (32.2. – 32.7) 33.6 (32.6 – 34.3)1  32.7 (32.3. – 33.2) 33.3 (32.5 – 34.0)1  0.263 
     Platelets (G/l) 300 ± 59a 289 ± 71a  257 ± 50 246 ± 56  0.862 
IQR, interquartile range; GGT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHE, cholinesterase; MCV, 
mean cellular volume; MCH, mean cellular haemoglobin; MCHC, mean cellular haemoglobin concentration. 
§  Median with IQR in parentheses. 
1  p < 0.05 vs. week 0; a  p < 0.05 vs. placebo at the same time point. 
†  Analyses of group differences in absolute changes from baseline (week 8 – week 0). 
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Table  8.24. Relative fatty acid composition (wt%) of plasma total lipids at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
20:3n-9  ln 
* 
-1.95 ± 0.33 
0.142 
-2.34 ± 0.421,a 
0.096 
-2.34 ± 0.391,a 
0.096 
-2.29 ± 0.081,a 
0.101 
 
-1.93 ± 0.39 
0.144 
-2.03 ± 0.37 
0.131 
-1.98 ± 0.41 
0.138 
-2.03 ± 0.39 
0.131 
18:2n-6 ln 
* 
3.24 ± 0.10 
25.46 
3.25 ± 0.10 
25.88 
3.26 ± 0.11 
26.06 
3.22 ± 0.13 
25.00 
 
3.28 ± 0.13 
26.46 
3.28 ± 0.11 
26.57 
3.29 ± 0.11 
26.88 
3.30 ± 0.13 
27.08 
18:3n-6  ln 
* 
-1.05 ± 0.23 
0.351 
-0.658 ± 0.2441,a 
0.518 
-0.798 ± 0.2351,a 
0.450 
-0.686 ± 0.2281,a 
0.504 
 
-1.09 ± 0.48 
0.338 
-1.17 ± 0.28 
0.310 
-1.08 ± 0.33 
0.341 
-1.169 ± 0.329 
0.311 
20:3n-6 - 2.00 ± 0.30a 2.25 ± 0.491,a 2.20 ± 0.411,a 2.27 ± 0.451,a  1.76 ± 0.35 1.76 ± 0.36 1.78 ± 0.37 1.73 ± 0.35 
20:4n-6  1/x 
* 
0.156 ± 0.034 
6.42 
0.155 ± 0.027 
6.44 
0.155 ± 0.035 
6.45 
0.161 ± 0.037 
6.20 
 
0.145 ± 0.020 
6.90 
0.148 ± 0.024 
6.74 
0.153 ± 0.0221 
6.52 
0.154 ± 0.0191 
6.49 
22:4n-6 - 0.228 ± 0.061 0.194 ± 0.0481 0.179 ± 0.0431,a 0.190 ± 0.0571  0.231 ± 0.042 0.212 ± 0.0341 0.206 ± 0.0371 0.194 ± 0.0381 
22:5n-6 - 0.267 ± 0.092 0.219 ± 0.0731 0.207 ± 0.0741 0.208 ± 0.0791  0.246 ± 0.068 0.237 ± 0.060 0.236 ± 0.057 0.218 ± 0.0521 
18:3n-3 ln 
* 
-0.609 ± 0.310a 
0.503 
-0.726 ± 0.309 
0.484 
-0.751 ± 0.403 
0.472 
-0.802 ± 0.2071 
0.440 
 
-0.852 ± 0.302 
0.427 
-0.687 ± 0.285 
0.503 
-0.721 ± 0.248 
0.486 
-0.639 ± 0.3021 
0.528 
20:5n-3§ - 0.510 
(0.388 – 0.684) 
0.6791,a 
(0.524 – 0.783) 
0.6441,a 
(0.598 – 0.747) 
0.6861,a 
(0.548 – 0.811) 
 
0.472 
(0.329 – 0.521) 
0.459 
(0.377 – 0.551) 
0.444 
(0.349 – 0.671) 
0.5051 
(0.428 – 0.599) 
22:5n-3 - 0.392 ± 0.105 0.356 ± 0.072 0.350 ± 0.089 0.357 ± 0.081  0.355 ± 0.089 0.362 ± 0.075 0.350 ± 0.086 0.375 ± 0.092 
22:6n-3 - 2.04 ± 0.43 3.12 ± 0.481,a 3.25 ± 0.481,a 3.14 ± 0.421,a  1.87 ± 0.42 1.98 ± 0.60 1.92 ± 0.51 1.97 ± 0.61 
IQR, interquartile range; T, transformation of the data; -, no transformation; ln, natural logarithm; 1/x, reciprocal value. 
*  Back transformed mean.   
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.25. Fatty acid sums (wt%) and ratios in plasma total lipids at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
GLA + DGLA - 2.36 ± 0.35 2.78 ± 0.551,a 2.66 ± 0.451,a 2.78 ± 0.491,a  2.13 ± 0.41 2.08 ± 0.38 2.14 ± 0.40 2.06 ± 0.37 
∑n-6 FA - 35.40 ± 2.63 36.10 ± 2.68 36.31 ± 2.74 35.14 ± 3. 56  36.57 ± 3.47 36.48 ± 2.86 36.53 ± 2.86 36.57 ± 3.36 
∑n-3 FA ln 
* 
1.30 ± 0.22a 
3.65 
1.56 ± 0.141,a 
4.75 
1.58 ± 0.141,a 
4.85 
1.56 ± 0.121,a 
4.74 
 1.16 ± 0.14 
3.20 
1.24 ± 0.21 
3.44 
1.20 ± 0.20 
3.33 
1.25 ± 0.23 
3.50 
∑n-6/∑n-3 FA - 9.94 ± 0.51
a 7.65 ± 0.261,a 7.55 ± 0.271,a 7.46 ± 0.241,a  11.57 ± 0.48 10.86 ± 0.53 11.21 ± 0.58 10.77 ± 0.6 0 
∑n-6 LCPUFA 1/x 
* 
0.108 ± 0.017 
9.23 
0.107 ± 0.014 
9.38 
0.107 ± 0.018 
9.35 
0.109 ± 0.018 
9.20 
 0.107 ± 0.013 
9.38 
0.108 ± 0.013 
9.24 
0.111 ± 0.013 
9.01 
0.113 ± 0.0111 
8.88 
∑n-3 LCPUFA ln 
* 
1.11 ± 0.24 
3.03 
1.43 ± 0.161,a 
4.19 
1.46 ± 0.141,a 
4.30 
1.44 ± 0.131,a 
4.23 
 0.99 ± 0.17 
2.70 
1.05 ± 0.24 
2.87 
1.02 ± 0.23 
2.78 
1.06 ± 0.25 
2.90 
∑n-6/∑n-3 
LCPUFA§ 
- 3.24 
(2.28 – 3.88) 
2.161,a 
1.99 – 2.54) 
2.081,a 
(1.85 – 2.54) 
2.081,a 
(1.94 – 2.43) 
 3.53 
(3.19 – 3.89) 
3.27 
(3.04 – 3.71) 
3.38 
(2.72 – 3.84) 
3.271 
(2.48 – 3.85) 
IQR, interquartile range; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; ∑n-6 FA, sum of n-6 fatty acids; ∑n-3 FA, sum of n-3 fatty acids; ∑n-
6/∑n-3 FA, ratio of n-6 to n-3 fatty acids; ∑n-6 LCPUFA, sum of all long-chain n-6 fatty acids; ∑n-3 LCPUFA, sum of all long-chain n-3 fatty acids; ∑n-6/∑n-3 
LCPUFA, ratio of n-6 to n-3 long-chain polyunsaturated fatty acids; T, transformation of the data; -, no transformation; ln, natural logarithm; 1/x, reciprocal value. 
*  Back transformed mean. 
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.26. Relative fatty acid composition (wt%) of plasma phospholipids at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
20:3n-9  ln 
* 
-1.72 ± 0.29 
0.179 
-2.13 ± 0.401,a 
0.119 
-2.17 ± 0.291,a 
0.114 
-2.08 ± 0.351,a 
0.125 
 
-1.76 ± 0.40 
0.172 
-1.82 ± 0.34 
0.163 
-1.78 ± 0.43 
0.169 
-1.81 ± 0.41 
0.164 
18:2n-6 - 18.73 ± 1.87 18.08 ± 2.28 18.04 ± 2.51a 17.46 ± 2.29a  19.38 ± 2.42 19.49 ± 2.31 19.87 ± 2.37 20.02 ± 1.9 4 
18:3n-6  1/x 
* 
11.19 ± 3.08 
0.089 
8.51 ± 2.491,a 
0.117 
10.32 ± 3.16 
0.097 
8.49 ± 2.051,a 
0.118 
 
11.52 ± 4.40 
0.087 
12.24 ± 3.45 
0.082 
11.34 ± 3.45 
0.088 
12.68 ± 3.75 
0.079 
20:3n-6 - 3.50 ± 0.57a 3.89 ± 0.941,a 3.77 ± 0.731,a 3.98 ± 0.911,a  3.04 ± 0.59 3.09 ± 0.72 3.09 ± 0.70 2.98 ± 0.63 
20:4n-6  ln 
* 
2.20 ± 0.18 
9.03 
2.15 ± 0.16 
8.63 
2.16 ± 0.22 
8.68 
2.14 ± 0.20 
8.49 
 
2.26 ± 0.11 
9.55 
2.24 ± 0.13 
9.39 
2.19 ± 0.121 
8.97 
2.18 ± 0.101 
8.85 
22:4n-6 - 0.369 ± 0.085 0.302 ± 0.0771,a 0.277 ± 0.0651,a 0.298 ± 0.0921  0.384 ± 0.077 0.348 ± 0.0551 0.339 ± 0.0601 0.317 ± 0.0601 
22:5n-6 - 0.400 ± 0.138 0.312 ± 0.1101 0.291 ± 0.0971,a 0.300 ± 0.1111  0.377 ± 0.094 0.358 ± 0.081 0.354 ± 0.079 0.328 ± 0.0701 
18:3n-3 ln 
* 
-1.53 ± 0.39a 
0.216 
-1.68 ± 0.36 
0.186 
-1.81 ± 0.44 
0.164 
-1.79 ± 0.281,a 
0.168 
 
-1.81 ± 0.43 
0.163 
-1.62 ± 0.35 
0.198 
-1.65 ± 0.37 
0.191 
-1.56 ± 0.33 
0.210 
20:5n-3§ - 0.591 
(0.460 – 0.792) 
0.7241,a 
(0.607 – 0.907) 
0.7441,a 
(0.661 – 0.849) 
0.7671,a 
(0.653 – 0.953) 
 
0.572 
(0.388 – 0.620) 
0.559 
(0.463 – 0.650) 
0.538 
(0.423 – 0.774) 
0.561 
(0.516 – 0.732) 
22:5n-3 - 0.668 ± 0.157 0.590 ± 0.1061 0.576 ± 0.1331 0.600 ± 0.1331  0.606 ± 0.153 0.620 ± 0.130 0.603 ± 0.135 0.663 ± 0.141 
22:6n-3§ - 3.09 
(3.01 – 3.56) 
4.991,a 
(4.39 – 5.40) 
5.101,a 
(4.67 – 5.45) 
5.031,a 
(4.63 – 5.41) 
 
3.21 
(2.59 – 3.60) 
3.04 
(2.60 – 3.96) 
3.20 
(2.60 – 3.83) 
3.14 
(2.37 – 4.15) 
IQR, interquartile range; T, transformation of the data; -, no transformation; ln, natural logarithm; 1/x, reciprocal value. 
*  Back transformed mean. 
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.27. Fatty acid sums (wt%) and ratios in plasma phospholipids at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
GLA + DGLA - 3.59 ± 0.58a 4.02 ± 0.941,a 3.88 ± 0.731,a 4.11 ± 0.90 1,a  3.14  ± 0.61 3.18 ± 0.72 3.19 ± 0.69 3.07 ± 0.63 
∑n-6 FA§ - 32.63  
(31.56 – 33.84) 
31.35a 
(30.74 – 33.98) 
31.36a 
(30.79 – 33.28) 
31.881,a 
(29.99 – 32.56) 
 
33.33 
(31.66 – 35.07) 
33.76 
(32.13 – 34.42) 
33.57 
(31.85 – 34.45) 
33.33 
(31.88 – 34.21) 
∑n-3 FA ln 
* 
1.61 ± 0.19 
5.00 
1.88 ± 0.131,a 
6.54 
1.90 ± 0.141,a 
6.67 
1.89 ± 0.111,a 
6.65 
 
1.50 ± 0.16 
4.49 
1.57 ± 0.23 
4.79 
1.53 ± 0.22 
4.62 
1.56 ± 0.24 
4.77 
∑n-6/∑n-3 FA - 6.66 ± 0.29 4.92 ± 0.201,a 4.82 ± 0.201,a 4.72 ± 9.141,a  7.51 ± 0.30 7.12 ± 0.35 7.38 ± 0.41 7.15 ± 0.41 
∑n-6 LCPUFA§ - 13.61 
(12.33 – 15.70) 
13.28 
(12.56 – 15.06) 
13.51 
(12.10 – 14.19) 
13.60 
(11.87 – 15.08) 
 13.55 
(13.08 – 14.41) 
14.28 
(12.25 – 14.98) 
13.001 
(12.43 – 14.08) 
12.631 
(12.09 – 13.53) 
∑n-3 LCPUFA 2ln 
* 
0.435 ± 0.11 
4.69 
0.607 ± 0.081,a 
6.26 
0.620 ± 0.081,a 
6.41 
0.620 ± 0.061,a 
6.42 
 0.366 ± 0.12 
4.23 
0.402 ± 0.15 
4.46 
0.376 ± 0.17 
4.29 
0.395 ± 0.17 
4.41 
∑n-6/∑n-3 
LCPUFA 
1/√ 
* 
0.593 ± 0.020 
2.85 
0.685 ± 0.0151,a 
2.13 
0.696 ± 0.0151,a 
2.07 
0.694 ± 0.0141,a 
2.08 
 0.559 ± 0.009 
3.20 
0.581 ± 0.013 
2.97 
0.580 ± 0.014 
2.97 
0.596 ± 0.017 
2.81 
Abbreviations see Table  8.25. IQR, interquartile range; T, transformation of the data; -, no transformation; ln, natural logarithm; 2ln, double natural logarithm; √, 
square root. 
*  Back transformed mean. 
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.28. Relative fatty acid composition (wt%) of plasma cholesterol esters at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
20:3n-9  ln 
* 
-2.59 ± 0.39 
0.075 
-2.91 ± 0.541 
0.054 
-2.90 ± 0.571 
0.055 
-2.82 ± 0.531 
0.060 
 
-2.67 ± 0.42 
0.069 
-2.68 ± 0.46 
0.069 
-2.67 ± 0.53 
0.070 
-2.62 ± 0.53 
0.073 
18:2n-6 - 48.45 ± 3.20 48.82 ± 4.23 48.47 ± 3.84 47.76 ± 4.25  50.16 ± 3.93 49.82 ± 3.35 49.69 ± 3.48 49.71 ± 3.82 
18:3n-6  ln 
* 
-0.113 ± 0.214 
0.893 
0.219 ± 0.2631,a 
1.245 
0.078 ± 0.2541,a 
1.081 
0.223 ± 0.2191,a 
1.250 
 
-0.198 ± 0.444 
0.820 
-0.246 ± 0.277 
0.782 
-0.188 ± 0.338 
0.829 
-0.256 ± 0.305 
0.774 
20:3n-6 x2 
* 
0.783 ± 0.238a 
0.885 
1.03 ± 0.391,a 
1.014 
1.11 ± 0.461,a 
1.054 
1.12 ± 0.421,a 
1.056 
 
0.621 ± 0.254 
0.788 
0.650 ± 0.309 
0.806 
0.638 ± 0.261 
0.799 
0.599 ± 0.248 
0.774 
20:4n-6  ln 
* 
1.90 ± 0.22 
6.69 
1.92 ± 0.20 
6.85 
1.94 ± 0.25 
6.99 
1.91 ± 0.25 
6.77 
 
1.94 ± 0.15 
6.98 
1.94 ± 0.17 
6.98 
1.91 ± 0.16 
6.74 
1.89 ± 0.14 
6.63 
22:4n-6           
22:5n-6 - 0.040 ± 0.017 0.032 ± 0.0131 0.032 ± 0.0161 0.030 ± 0.0141  0.037 ± 0.013 0.034 ± 0.011 0.036 ± 0.012 0.032 ± 0.0081 
18:3n-3 - 0.693 ± 0.168a 0.592 ± 0.1591 0.526 ± 0.1581 0.539 ± 0.1231  0.553 ± 0.173 0.564 ± 0.127 0.580 ± 0.139 0.625 ± 0.172 
20:5n-3 ln 
* 
-0.421 ± 0.483a 
0.656 
-0.233 ± 0.316a 
0.792 
-0.229 ± 0.167a 
0.795 
-0.203 ± 0.300a 
0.816 
 
-0.722 ± 0.373 
0.486 
-0.587 ± 0.385 
0.556 
-0.618 ± 0.381 
0.539 
-0.457 ± 0.4091 
0.633 
22:5n-3           
22:6n-3 - 0.620 ± 0.096 0.938 ± 0.1781,a 1.02 ± 0.191,a 0.979 ± 0.1801,a  0.581 ± 0.159 0.616 ± 0.186 0.614 ± 0.184 0.604 ± 0.198 
T, transformation of the data; -, no transformation; ln, natural logarithm; x2, squared. 
*  Back transformed mean. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.29. Fatty acid sums (wt%) and ratios in plasma cholesterol esters at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
GLA + DGLA 2ln 
* 
1.05 ± 0.06 
1.75 
1.13 ± 0.071,a 
2.22 
1.11 ± 0.071,a 
2.08 
1.14 ± 0.061,a 
2.26 
 
1.02 ± 0.11 
1.59 
1.01 ± 0.08 
1.55 
1.02 ± 0.08 
1.60 
1.00 ± 0.08 
1.52 
∑n-6 FA x
2 
* 
3275 ± 304 
57.23 
3397 ± 429 
58.28 
3363 ± 371 
57.99 
3281 ± 463 
57.28 
 
3490 ± 427 
59.08 
3440 ± 335 
58.65 
3404 ± 366 
58.34 
3384 ± 436 
58.18 
∑n-3 FA§ - 1.98
a 
(1.74 – 2.32) 
2.441,a 
(2.16 – 2.73) 
2.471,a 
(2.35 – 2.67) 
2.411,a 
(2.21 – 2.65) 
 
1.73 
(1.56 – 2.00) 
1.70 
(1.62 – 2.09) 
1.84 
(1.42 – 2.12) 
2.03 
(1.57 – 2.18) 
∑n-6/∑n-3 FA - 28.29 ± 1.55a 24.12 ± 0.831,a 24.00 ± 0.751,a 23.75 ± 0.981,a  35.63 ± 2.18 32.99 ± 1.68 33.18 ± 1.94 30.96 ± 1.8 4 
∑n-6 LCPUFA ln 
* 
2.04 ± 0.20 
7.66 
2.07 ± 0.18 
7.93 
2.09 ± 0.23 
8.11 
2.07 ± 0.23 
7.92 
 2.06 ± 0.15 
7.84 
2.06 ± 0.16 
7.86 
2.03 ± 0.15 
7.61 
2.01 ± 0.13 
7.48 
∑n-3 LCPUFA 1/x 
* 
0.771 ± 0.194a 
1.30 
0.571 ± 0.1211,a 
1.75 
0.544 ± 0.0971,a 
1.84 
0.550 ± 0.1011,a 
1.82 
 0.919 ± 0.242 
1.09 
0.850 ± 0.222 
1.18 
0.870 ± 0.263 
1.15 
0.820 ± 0.242 
1.22 
∑n-6/∑n-3 
LCPUFA 
√ 
* 
2.42 ± 0.11 
5.88 
2.12 ± 0.061,a 
4.50 
2.10 ± 0.061,a 
4.42 
2.09 ± 0.081,a 
4.38 
 2.66 ± 0.06 
7.06 
2.55 ± 0.06 
6.51 
2.54 ± 0.08 
6.44 
2.44 ± 0.071 
5.95 
Abbreviations see Table  8.25. IQR, interquartile range; T, transformation of the data; -, no transformation; 2ln, double natural logarithm (10*x); x2, squared; ln, 
natural logarithm; 1/x, reciprocal value; √, square root. 
*  Back transformed mean. 
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.30. Relative fatty acid composition (wt%) of plasma triglycerides at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD or median with IQR). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
20:3n-9  ln 
* 
-1.67 ± 0.38 
0.189 
-1.91 ± 0.461 
0.148 
-1.85 ± 0.401,a 
0.156 
-1.85 ± 0.361 
0.157 
 
-1.56 ± 0.33 
0.210 
-1.64 ± 0.43 
0.193 
-1.57 ± 0.44 
0.208 
-1.65 ± 0.38 
0.192 
18:2n-6 ln 
* 
2.53 ± 0.19 
12.49 
2.61 ± 0.22 
13.57 
2.68 ± 0.201 
14.58 
2.53 ± 0.19 
12.57 
 
2.59 ± 0.29 
13.36 
2.57 ± 0.23 
13.09 
2.60 ± 0.24 
13.51 
2.65 ± 0.28 
14.12 
18:3n-6  1/√ 
* 
1.95 ± 0.40 
0.263 
1.58 ± 0.281,a 
0.402 
1.62 ± 0.251,a 
0.381 
1.66 ± 0.341,a 
0.361 
 
1.85 ± 0.51 
0.293 
2.06 ± 0.38 
0.236 
1.92 ± 0.43 
0.271 
2.01 ± 0.50 
0.248 
20:3n-6 - 0.301 ± 0.79 0.400 ± 0.1101,a 0.376 ± 0.0771,a 0.378 ± 0.1171,a  0.278 ± 0.076 0.268 ± 0.092 0.274 ± 0.060 0.256 ± 0.059 
20:4n-6  ln 
* 
0.151 ± 0.401 
1.16 
0.341 ± 0.2871,a 
1.41 
0.273 ± 0.337 
1.31 
0.248 ± 0.376 
1.28 
 
0.113 ± 0.259 
1.12 
0.098 ± 0.260 
1.10 
0.096 ± 0.322 
1.10 
0.046 ± 0.279 
1.05 
22:4n-6 ln 
* 
-1.78 ± 0.36 
0.169 
-1.73 ± 0.31 
0.177 
-1.79 ± 0.31 
0.166 
-1.80 ± 0.36 
0.165 
 
-1.82 ± 0.26 
0.162 
-1.87 ± 0.20 
0.153 
-1.92 ± 0.24 
0.147 
-1.96 ± 0.24 
0.141 
22:5n-6 √ 
* 
0.444 ± 0.096 
0.197 
0.440 ± 0.097 
0.194 
0.429 ± 0.092 
0.184 
0.424 ± 0.101 
0.180 
 
0.415 ± 0.077 
0.173 
0.412 ± 0.086 
0.170 
0.418 ± 0.066 
0.175 
0.392 ± 0.076 
0.154 
18:3n-3 1/x 
* 
1.19 ± 0.40a 
0.837 
1.30 ± 0.42 
0.768 
1.31 ± 0.63 
0.762 
1.42 ± 0.40 
0.706 
 
1.52 ± 0.55 
0.658 
1.19 ± 0.351 
0.837 
1.26 ± 0.331 
0.791 
1.19 ± 0.491 
0.844 
20:5n-3 ln 
* 
-2.06 ± 0.51 
0.128 
-1.65 ± 0.261,a 
0.191 
-1.70 ± 0.251,a 
0.183 
-1.70 ± 0.331,a 
0.183 
 
-2.40 ± 0.56 
0.091 
-2.15 ± 0.51 
0.117 
-2.22 ± 0.59 
0.109 
-2.18 ± 0.56 
0.113 
22:5n-3 ln 
* 
-1.60 ± 0.40 
0.202 
-1.54 ± 0.36 
0.215 
-1.49 ± 0.37a 
0.225 
-1.50 ± 0.32 
0.222 
 
-1.80 ± 0.44 
0.166 
-1.73 ± 0.27 
0.177 
-1.76 ± 0.43 
0.172 
-1.68 ± 0.51 
0.187 
22:6n-3§ - 0.612 
(0.421 – 0.761) 
1.491,a 
(1.12 – 2.04) 
1.421,a 
(1.11 – 1.79) 
1.381,a 
(1.08 – 1.76) 
 
0.520 
(0.301 – 0.607) 
0.473 
(0.327 – 0.747) 
0.574 
(0.373 – 0.683) 
0.527 
(0.322 – 0.698) 
IQR, interquartile range; T, transformation of the data; ln, natural logarithm; √, square root; 1/x, reciprocal value. 
*  Back transformed mean. 
§  Median with IQR in parentheses. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.31. Fatty acid sums (wt%) and ratios in plasma triglycerides at weeks 0, 4, 6 and 8, FO/EPO study (mean ± SD). 
  FO/EPO (n = 19)  Placebo (n = 20) 
 T Week 0 Week 4 Week 6 Week 8  Week 0 Week 4 Week 6 Week 8 
GLA + DGLA ln 
* 
-0.555 ± 0.303 
0.574 
-0.214 ± 0.2861,a 
0.808 
-0.260 ± 0.1641,a 
0.771 
-0.281 ± 0.3001,a 
0.755 
 
-0.508 ± 0.349 
0.602 
-0.667 ± 0.272 
0.513 
-0.560 ± 0.251 
0.571 
-0.632 ± 0.361 
0.532 
∑n-6 FA - 15.16 ± 2.79 16.80 ± 3.63 17.62 ± 3.201 15.50 ± 2.62  16.24 ± 4.18 15.65 ± 3.33 16.17 ± 3.2 6 16.78 ± 3.86 
∑n-3 FA 1/x 
* 
0.509 ± 0.140a 
1.96 
0.366 ± 0.0991,a 
2.73 
0.355 ± 0.1031,a 
2.82 
0.383 ± 0.0841,a 
2.61 
 
0.645 ± 0.165 
1.55 
0.548 ± 0.152 
1.82 
0.564 ± 0.131 
1.77 
0.561 ± 0.2241 
1.78 
∑n-6/∑n-3 FA - 7.72 ± 0.64
a 6.05 ± 0.411,a 6.12 ± 0.381,a 5.82 ± 0.271,a  10.44 ± 0.80 8.39 ± 0.521 9.19 ± 0.69 8.99 ± 0.59 
∑n-6 LCPUFA 2ln 
* 
-0.410 ± 0.473 
1.94 
-0.189 ± 0.326a 
2.29 
-0.249 ± 0.316a 
2.18 
-0.301 ± 0.438a 
2.10 
 -0.455 ± 0.342 
1.89 
-0.490 ± 0.344 
1.85 
-0.468 ± 0.322 
1.87 
-0.623 ± 0.529 
1.71 
∑n-3 LCPUFA ln 
* 
0.031 ± 0.395a 
1.03 
0.628 ± 0.3551,a 
1.87 
0.646 ± 0.2771,a 
1.91 
0.608 ± 0.2741,a 
1.84 
 -0.231 ± 0.280 
0.79 
-0.102 ± 0.437 
0.90 
-0.104 ± 0.335 
0.90 
-0.106 ± 0.429 
0.90 
∑n-6/∑n-3 
LCPUFA 
√ 
* 
1.45 ± 0.08 
2.11 
1.15 ± 0.051,a 
1.32 
1.11 ± 0.051,a 
1.23 
1.11 ± 0.041,a 
1.24 
 1.58 ± 0.04 
2.48 
1.47 ± 0.05 
2.17 
1.48 ± 0.05 
2.18 
1.44 ± 0.051 
2.07 
Abbreviations see Table  8.25. T, transformation of the data; ln, natural logarithm; 1/x, reciprocal value; 2ln, double natural logarithm; √, square root. 
*  Back transformed mean. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances). 
a  p < 0.05 vs. placebo at the same time point. 
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Table  8.32. Spearman-Rho correlations between fatty acids (wt%) of plasma TL, PL, CE, and TG, 
FO/EPO study (n = 39/40). 
 TL – CE TL - PL CE - PL TL - TG CE - TG PL - TG 
LA       
   week 0 0.890* 0.850* 0.843* 0.731* 0.642* 0.677* 
   week 4 0.842* 0.864* 0.785* ns ns ns 
   week 6 0.891* 0.817* 0.835* 0.575* 0.502* 0.359* 
   week 8 0.903* 0.845* 0.825* 0.689* 0.602* 0.462* 
GLA       
   week 0 0.941* 0.905* 0.886* 0.801* 0.648* 0.774* 
   week 4 0.937* 0.856* 0.742* 0.784* 0.585* 0.727* 
   week 6 0.941* 0.732* 0.648* 0.718* 0.495* 0.686* 
   week 8 0.936* 0.871* 0.794* 0.704* 0.479* 0.768* 
ALA       
   week 0 0.880* 0.896* 0.846* 0.822* 0.546* 0.645* 
   week 4 0.871* 0.818* 0.763* 0.868* 0.616* 0.659* 
   week 6 0.796* 0.772* 0.760* 0.930* 0.645* 0.597* 
   week 8 0.810* 0.789* 0.806* 0.869* 0.542* 0.514* 
DGLA       
   week 0 0.887* 0.954* 0.871* 0.663* 0.569* 0.694* 
   week 4 0.962* 0.959* 0.947* 0.843* 0.790* 0.803* 
   week 6 0.901* 0.958* 0.860* 0.731* 0.676* 0.722* 
   week 8 0.923* 0.972* 0.911* 0.707* 0.713* 0.682* 
AA       
   week 0 0.936* 0.940* 0.907* 0.805* 0.717* 0.722* 
   week 4 0.892* 0.893* 0.891* 0.477* 0.497* 0.376* 
   week 6 0.863* 0.926* 0.839* 0.784* 0.634* 0.621* 
   week 8 0.857* 0.875* 0.915* 0.702* 0.687* 0.623* 
EPA       
   week 0 0.924* 0.955* 0.887* 0.739* 0.563* 0.735* 
   week 4 0.955* 0.974* 0.948* 0.814* 0.762* 0.767* 
   week 6 0.912* 0.974* 0.905* 0.825* 0.751* 0.797* 
   week 8 0.936* 0.968* 0.929* 0.871* 0.778* 0.828* 
DHA       
   week 0 0.930* 0.960* 0.927* 0.755* 0.642* 0.682* 
   week 4 0.940* 0.960* 0.959* 0.902* 0.801* 0.810* 
   week 6 0.921* 0.958* 0.929* 0.927* 0.829* 0.852* 
   week 8 0.954* 0.951* 0.973* 0.921* 0.848* 0.867* 
AA, arachidonic acid; ALA, alpha-linolenic acid; CE, cholesterol ester; DGLA, dihomo-gamma-linolenic 
acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; LA, 
linoleic acid; PL, phospholipids, TG, triglycerides; TL, total lipids. 
*  p < 0.05; ns, non-significant. 
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Table  8.33. Spearman-Rho correlations between plasma TL, PL, CE, and TG fatty acid changes from  
baseline with FO/EPO supplementation, FO/EPO study (wt%/wt%, n = 19). 
 TL – CE TL - PL CE - PL TL - TG CE - TG PL - TG 
GLA       
   week 4 - 0 0.914* 0.682* 0.547* ns ns 0.481* 
   week 6 - 0 0.942* 0.882* 0.732* 0.542* ns 0.761* 
   week 8 - 0 0.879* 0.937* 0.809* 0.647* ns 0.640* 
DGLA       
   week 4 - 0 0.689* 0.877* 0.611* 0.637* ns 0.672* 
   week 6 - 0 0.561* 0.911* 0.544* 0.589* ns 0.712* 
   week 8 - 0 0.868* 0.865* 0.730* 0.658* 0.630* 0.730* 
AA       
   week 4 - 0 0.805* 0.947* 0.840* ns ns ns 
   week 6 - 0 0.805* 0.867* 0.847* ns ns ns 
   week 8 - 0 0.758* 0.816* 0.898* 0.479* ns ns 
EPA       
   week 4 - 0 0.968* 0.977* 0.933* 0.660* 0.540* 0.709* 
   week 6 - 0 0.879* 0.921* 0.907* 0.639* 0.474* 0.554* 
   week 8 - 0 0.921* 0.888* 0.835* ns ns 0.521* 
DHA       
   week 4 - 0 0.846* 0.895* 0.904* 0.858* 0.663* 0.702* 
   week 6 - 0 0.905* 0.947* 0.821* 0.740* 0.725* 0.588* 
   week 8 - 0 0.853* 0.911* 0.889* 0.851* 0.649* 0.761* 
AA, arachidonic acid; ALA, alpha-linolenic acid; CE, cholesterol ester; DGLA, dihomo-gamma-linolenic 
acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; LA, 
linoleic acid; PL, phospholipids, TG, triglycerides; TL, total lipids. 
*  p < 0.05; ns, non-significant. 
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Figure  8.1. Seven-point standard curves for retinol and alpha-tocopherol, DHAVEG study. 
 
    
 
Figure  8.2. Correlations between EPA + DHA in RBC total lipids (wt%) vs. EPA + DHA in RBC PE, PC and plasma PL (Spearman-Rho correlation),                                  
DHAVEG study.  
 and dashed line, placebo group; • and solid line, DHA group. 
• n = 52 
r = 0.957 
p < 0.001 
• n = 52 
r = 0.893 
p  < 0.001 
• n = 52 
r = 0.909 
p < 0.001 
 
• n = 52 
r = 0.870 
p < 0.001 
• n = 52 
r = 0.804 
p < 0.001 
 
• n = 52 
r = 0.732 
p < 0.001 
 
 n = 51 
r = 0.911 
p < 0.001 
 
 n = 51 
r = 0.949 
p < 0.001 
 n = 51 
r = 0.867 
p < 0.001 
 
 n = 51 
r = 0.890 
p < 0.001 
 
 n = 51 
r = 0.885 
p < 0.001 
 n = 51 
r = 0.943 
p < 0.001 
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Figure  8.3. GLA (wt%) in plasma TL, PL, CE, and TG at weeks 0, 4, 6 and 8, FO/EPO study  
(placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; GLA, gamma-linolenic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances);  
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.4. DGLA (wt%) in plasma TL, PL, CE, and TG at weeks 0, 4, 6 and 8, FO/EPO study  
(placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; DGLA, dihomo-gamma-linolenic acid; PL, phospholipids; TG, triglycerides; TL, 
total lipids. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances);  
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.5. Arachidonic acid (wt%) in plasma TL, PL, CE, and TG at weeks 0, 4, 6 and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; PL, phospholipids; TG, triglycerides; TL, total lipids. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances); 
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.6. EPA (wt%) in plasma TL, PL, CE, and TG at weeks 0, 4, 6 and 8, FO/EPO study  
(placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; EPA, eicosapentaenoic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances);  
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.7. DHA (wt%) in plasma TL, PL, CE, and TG at weeks 0, 4, 6 and 8, FO/EPO study  
(placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; DHA, docosahexaenoic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
1  Significantly different from baseline (Bonferroni-Holm adjusted significances);  
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.8. Percentage changes from baseline in relative GLA levels at weeks 4, 6, and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; GLA, gamma-linolenic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.9. Percentage changes from baseline in relative DGLA levels at weeks 4, 6, and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; DGLA, dihomo-gamma-linolenic acid; PL, phospholipids; TG, triglycerides; TL, 
total lipids. 
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.10. Percentage changes from baseline in relative AA levels at weeks 4, 6, and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; AA, arachidonic acid; PL, phospholipids; TG, triglycerides; TL, total lipids. 
a  p < 0.05 vs. placebo at the same time point. 
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Figure  8.11. Percentage changes from baseline in relative EPA levels at weeks 4, 6, and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; EPA, eicosapentaenoic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
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Figure  8.12. Percentage changes from baseline in relative DHA levels at weeks 4, 6, and 8, FO/EPO 
study (placebo: n = 20; FO/EPO: n = 19). 
 
Bottom and top edges are located at 25th and 75th percentiles, centre horizontal line is drawn at the 
median, whiskers mark the data points nearest to the 1.5 interquartile ranges, outliers are shown as 
points together with subject code. 
CE, cholesterol esters; DHA, docosahexaenoic acid; PL, phospholipids; TG, triglycerides; TL, total 
lipids. 
a  p < 0.05 vs. placebo at the same time point. 
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